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Abbreviation 
AM  adrenomedullin 
AR  adrenergic receptor 
CCR2  chemokine C-C motif receptor 2 
CCR5  chemokine C-C motif receptor 5 
CGRP  calcitonin generelated peptide 
CMC  critical micelle concentration 
CNS  central nervous system 
CX3C   chemokine C-X3-C motif receptor 
DCM  dichloromethane 
DDM  dodecyl-β-d-maltoside 
DHPC  1,2-Diheptanoyl-sn-Glycero-3-Phosphocholine 
DIEA  diisopropylethylamine 
DMF  dimethyl formamide 
DPC  dodecylphosphocholine 
Doxyl   (4,4-dimethyl-3-oxazolidine-N-oxyl) 
DTT   1,4-dithiothreitol 
ECL  extracellular loop 
EDTA  ethylenediamine tetraacetic acid 
ELISA  enzyme linked immunostaining assay 
ESI-MS electrospray ionization mass spectroscopy 
Fmoc  9-fluorenylmethoxycarbonyl 
GABA  gamma amino butyric acid 
GdnHCL guanidinium hydrochloride 
GPCR  G-protein coupled receptor 
GST  glutathione S transferase 
HATU 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HBTU 2-(1H-benzotriazol-1-yL)-1,1,3,3-tetramethyluronium-
hexafluorophosphat) 
HEPES 2-(4-(2-hydroxyethyl)- 1-piperazinyl)-ethanesulfonic acid 
HOBT  N-hydroxybenzotriazole 
HSQC  heteronuclear single-quantum correlation 
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ICL  intracellular loop 
IPTG  isopropyl β-D-1-thiogaloctopyranoside 
KD  dissociation constant 
KSI  ketosteroidisomerase 
LDAO  Lauryldimethylamine-oxide 
LMPG  1-Myristoyl-2-Hydroxy-sn-Glycero-3-[Phospho- rac-(1-glycerol)] 
LPPG  1-Palmitoyl-2-Hydroxy-sn-Glycero-3-[Phospho- rac-(1-glycerol)] 
MALDI-TOF  matrix-assisted Laser desorption ionization-time of flight 
MBP  maltose binding protein 
MCP-1 monocyte chemoattractant protein 1 
NOE  nuclear Overhauser effect 
NOESY nuclear Overhauser enhancement spectroscopy 
NPY  neuropeptide (h, human; p, porcine) 
N-Y4  N-terminal domain of Y4 receptor 
Ni-NTA nickel-nitrilotriacetic acid 
OGP  octyl gluco pyranoside 
PAM  peptidylglycine α-amidating monooxygenase 
PP  pancreatic polypeptide (a, avian; b, bovine; h, human) 
PYY  peptide YY  
RP-HPLC reverse phase-high performance liquid chromatography 
RT  room temperature 
RU  response units; arbitrary unit in SPR 
SDS  sodium dodecyl sulfate 
SPPS  solid phase peptide synthesis 
SPR  surface plasmon resonance 
TEV   tobacco etch virus 
TFA  trifluoroacetic acid  
TOCSY total correlation spectroscopy 
TROSY  transverse relaxation optimized spectroscopy 
TM  transmembrane 
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Summary  
During my Ph.D. study I have investigated two principal aspects of GPCR 
structural biology in two stages: In the first stage I have focused my attention on 
structural studies of N termini of all the Y receptors and their interactions with natural 
ligands from neurohormone Y family, mainly by using NMR as well as by other 
biochemical and biophysical methods; in the second stage I extended my work on the 
N terminus of the Y4 receptor to a longer construct which comprises the N terminus, 
the first transmembrane domain, the first intracellular loop, the second 
transmembrane  domain and the first extracellular loop. This fragment is much longer 
and thus more native-like. With this construct I hope to more accurately shed light on 
the structure and function of the entire Y4 receptor.  
In the first stage we (the work of N terminus of Y2 receptor was conducted by my 
colleague Reto Walser) have expressed and purified by recombinant methods all the 
four N terminal domains from Y receptors. In case of N-Y2 and N-Y5, a soluble 
ubiquitin fusion protein was used to facilitate overexpression and purification and the 
target peptides were liberated later with help of the yeast ubiquitin hydrolase. In case 
of N-Y1 and N-Y4, unspecific cleavages were observed when the soluble fusion 
method was employed. To avoid unspecific cleavage, we produced the target protein 
in inclusion bodies by utilizing ketosteroidisomerase as fusion partner. Since there are 
a number of methionine residues in the target sequence, the classical chemical 
cleavage method (CNBr) could not be applied, and enzymatic cleavage is the only 
option. Extensive detergent screening indicated that sarcosyl could be used for that 
purpose, an anionic detergent, which can solubilize inclusion bodies and maintain the 
activity of the used TEV protease. In general, milligram quantities of labeled purified 
peptides can be obtained by either the soluble or insoluble fusion method from 1L of 
culture, which is sufficient for the following NMR studies. The interactions between 
the N termini of Y receptors and the neuropeptides of the NPY family are studied by 
chemical shift mapping methods using 15N labeled neuropeptides and surface-
plasmon resoance spectroscopy (BIA Core). The chemical shift mapping data 
demonstrated weak binding between the peptides corresponding to the N termini and 
the neuropeptides. This result is consistent with a model for binding of peptides from 
the NPY family to their GPCRs that postulates membrane association prior to 
receptor binding. The neuropeptide residues with large chemical shift changes display 
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surprising conservation in sequence despite much variability for other residues of the 
N termini. Two regions in the neuropeptides, which are mostly affected by the N 
termini, are the hinge region and the α helix in the C terminus. Chemical shift 
mapping of the neuropeptides upon addition of N-Y1 and N-Y4 demonstrate high 
similarity, which is consistent with their common origin as detected in phylogenetic 
studies.  BIA Core measurements suggested that there is a specific binding between 
N-Y4 and PP and the binding affinity is around 50µM. Further mutagenesis 
experiments pinpointed that the positively charged residues from N-Y4 and that 
negatively charged residues from PP are responsible for this binding. The presence of 
specific binding between N-Y4 and PP indicates that the N terminal domain from the 
Y4 receptor might not only transiently bind PP and thus help transferring the ligand 
into the real binding pocket but may also provide specificity for various ligands. 
Moreover, binding of the N termini to DPC micelles results in larger changes of 
structure and dynamics, once more highlighting the significance of membrane 
association during ligand recognition and binding. Importantly in case of N-Y4, α 
helices have been observed in both the N and C terminal parts in presence of DPC 
micelles, whereas the peptide is completely unstructured in the absence of the DPC 
micelles. The structure of N-Y4 does not depend on the presence of the first 
tramsmembrane domain, instead the membrane surface alone is sufficient to induce 
secondary structure. 
In the second stage on basis of structure and functional studies of N-Y4, I have 
extended my research to a longer construct, which contains more domains from the 
entire receptor, thus better mimicking the native properties in principle. For the 
expression of this protein, a direct expression without fusion to another protein was 
used. The non-fusion method bypasses the chemical or enzymatic cleavage of fusion 
proteins, hence simplifying the whole purification and increasing the final yield. After 
systematic optimization of cell strains, induction temperature and inducer 
concentration, optimal conditions were found when using the BL21-AI strain and 
0.2% arabinose at 20oC for induction. Under such conditions around 6 mg labeled 
protein can be purified from 1L of culture as fast as within 3 days. Sample purity and 
homogeneity are critical for a perfect NMR spectrum, and during the purification of 
this hydrophobic protein two steps are found indispensable: (1) the presence of 
multiple cysteine residues lead to aggregation even in 1mM merceptoethanol, 
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therefore addition of high concentration of reducing agents was required: 100mM 
DTT and 250mM merceptoethanol is essential to remove all aggregates and facilitates 
the subsequent HPLC purification; (2) HPLC is necessary to remove non-proteineous 
contaminants, which are invisible on SDS-PAGE. Membrane proteins can only exert 
their functions when they are appropriately integrated in the membrane, therefore 
detergent-formed micelles are employed here as a membrane-mimetic. Failure to find 
proper detergent micelles encouraged me to explore mixtures of detergents, and 1% 
DPC/6% LPPG proves to be the best for mimicking membrane environment for this 
protein. With 2H, 13C and 15N labeled protein, the backbone can be assigned almost 
completely. The CD spectrum and the chemical shift of α and β carbons indicate a 
predominant alpha helical conformation. The sidechain assignment and tertiary 
structure calculation is undergoing presently. 
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Zusammenfassung  
Während meiner Doktorarbeit habe ich zwei wichtige Aspekte der GPCR 
Strukturbiologie untersucht: In der ersten Phase habe ich meine Aufmerksamkeit auf 
strukturelle Studien von N-Termini aller Y-Rezeptoren und deren Wechselwirkungen 
mit natürlichen Liganden der Neuropeptid Y Familie gerichtet; insbesondere durch 
Nutzung der NMR Spektroskopie sowie anderer biochemischer und biophysikalischer 
Methoden. In der zweiten Phase habe ich meine Arbeit auf ein längeres Konstrukt 
gerichtet, das neben dem N-Terminus des Y4-Rezeptors die erste Transmembran-
Domäne, den ersten intrazellulären Loop, die zweite Transmembran-Domäne und die 
erste extrazelluläre Schleife enthält. Dieses Fragment ist wesentlich länger und damit 
dem Gesamtrezeptor ähnlicher. Mit diesem Konstrukt hoffe ich, dass ich genauere 
Aussagen über die Struktur und Funktion des gesamten Y4-Rezeptor machen kann.  
Anfänglich (die Arbeit über den N-Terminus des Y2-Rezeptor wurde von meinem 
Kollegen Reto Walser durchgeführt) habe ich alle vier N-terminalen Domänen der Y-
Rezeptoren mittels rekombinanter Methoden exprimiert und aufgereinigt. Im Falle 
des N-Y2 und N-Y5 wurde ein lösliches Ubiquitin-Fusionsprotein eingesetzt, dass die 
Überexpression und Aufreinigung erleichtert. Die Ziel-Peptide wurden später mit 
Hilfe der Ubiquitinhydrolyase abgespalten. Im Falle des N-Y1 und N-Y4 wurden 
unspezifische Spaltungen beobachtet, als die lösliche Fusionsprotein-Methode benutzt 
wurden. Um die unspezifische Spaltung zu vermeiden, haben wir das Zielprotein in 
“Einschlusskörpern” produziert durch Einsatz der Ketosteroidisomerase als 
Fusionspartner. Weil es mehrere Methionine in der Zielsequenz gibt, konnte die 
klassische chemische Spaltungsmethode (CNBr) nicht angewandt werden, und die 
enzymatische Spaltung war die einzige Option. Umfangreiches Detergenzien-
Screening zeigte, dass Sarcosyl, ein anionisches Detergenz, verwendet werden kann. 
Dieses vermag die  “Einschlusskörper” zu solubilisieren, und erhält die Aktivität der 
verwendeten TEV Protease. In der Regel können Milligramm-Mengen von 
markiertem Peptide entweder mit der löslichen oder der unlöslichen Fusionsmethode 
aus einem Liter Kultur gereinigt werden. Die Menge ist ausreichend für die folgenden 
NMR-Studien. Die Wechselwirkungen zwischen den N-Termini der Y-Rezeptoren 
und den Neuropeptiden der NPY-Familie wurden durch ‘chemical shift mapping’ 
unter Einsatz von 15N markierten Neuropeptiden und ‘surface plasmon resoance’- 
Spektroskopie (BIA-Core) untersucht. Die ‘chemical shift mapping’ Daten zeigen 
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schwache Bindung zwischen den N-Termini und den Neuropeptiden. Dieses Ergebnis 
steht im Einklang mit einem Modell für die Bindung zwischen Peptiden aus der NPY 
Familie und ihren GPCRs, das die Membranassoziation als ein der Rezeptorbindung 
vorgelagerten Schritt postuliert. Die Neuropeptid-Reste mit großen ‘chemical shift’ 
Änderungen zeigten überraschende Sequenzkonservation trotz erheblicher Variabilität 
bei anderen Resten im N Terminus. Zwei Regionen in den Neuropeptiden, die vor 
allem Kontakte mit den N-Termini machen, sind die Scharnier-Region und die C-
terminale α-Helix. Resultate der ‘Chemical shift mapping’ Experimente der 
Neuropeptide nach Zusatz von N-Y1 und N-Y4 zeigen grosse Ähnlichkeit, was im 
Einklang mit ihrer gemeinsamen Herkunft, die in phylogenetischen Studien erkundet 
wurde, steht. BIA-Core-Messungen legen nahe, dass es eine spezifische Bindung 
zwischen N-Y4 und dem pankreatischen Polypeptid (PP) gibt, und die Affinität ist 
rund 50 µM. Weitere Mutagenese Experimente ermittelten, dass die positiv geladenen 
Reste aus N-Y4 und die negativ geladenen Reste aus PP für diese Bindung 
verantwortlich sind. Das Vorhandensein von spezifischer Bindung zwischen N-Y4 
und PP weist darauf hin, dass die N-terminale Domäne des Y4-Rezeptor nicht nur 
vorübergehend PP bindet und dabei hilft, den Liganden in die wahre Bindetasche zu 
übertragen, sondern auch zur Spezifität der Lingandenerkennung beiträgt. Darüber 
hinaus resultiert die Bindung zwischen N-Termini und DPC Mizellen in größeren 
Veränderungen von Struktur und Dynamik; dies weist noch einmal auf die Bedeutung 
der Membranassoziation bei der Ligandenerkennung und – bindung hin. Im Fall von 
N-Y4 wurden in Anwesenheit von DPC Mizellen α-Helices in den N- und C-
terminalen Segmenten beobachtet, während das Peptid in Abwesenheit der DPC 
Mizellen völlig unstrukturiert ist. Diese Struktur von N-Y4 hängt nicht von der 
Anwesenheit der ersten Transmembran-Domäne ab, stattdessen ist die Membran-
Oberfläche allein ausreichend, um die Sekundärstruktur zu induzieren.  
In der zweiten Phase, auf der Grundlage von strukturellen und funktionellen 
Studien von N-Y4 habe ich mein Augenmerk auf ein längeres Konstrukt erweitert, 
das mehrere Domänen aus dem Gesamt-Rezeptor enthält, daher prinzipiell besser die 
nativen Eigenschaften imitiert. Für die Expression dieses Proteins wurde eine direkte 
Expression ohne Fusion zu einem anderen Protein verwendet. Die Nicht-
Fusionsmethode umgeht die chemische oder enzymatische Spaltung des 
Fusionsproteins, daher vereinfacht sie die gesamte Reinigung und erhöht die 
endgültige Ausbeute. Nach der systematischen Optimierung der Zellstämme, 
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Induktionstemperatur und Induktor-Konzentration, wurden optimalen Bedingungen 
gefunden bei der Verwendung des BL21-AI Stamm und 0,2% Arabinose bei 20oC für 
die Induktion. Unter diesen Bedingungen kann etwa 6 mg gereinigtes und markiertes 
Protein aus einem Liter Kultur innerhalb von 3 Tagen hergestellt werden. 
Probenreinheit und Homogenität sind entscheidend für ein befriedigendes NMR-
Spektrum. Während der Reinigung von diesem hydrophoben Protein sind zwei 
Schritte unverzichtbar: (1) das Vorhandensein von mehreren Cystein-Resten führt zur 
Aggregation, auch in 1 mM Merceptoethanol; daher war der Zusatz von hohen 
Konzentrationen an Reduktionsmittel erforderlich: 100 mM DTT und 250 mM 
Merceptoethanol ist von wesentlicher Bedeutung, um alle Aggregate zu reduzieren 
und die spätere Reinigung via HPLC zu erleichtern; (2) HPLC ist notwendig zur 
Beseitigung von nicht-Protein Kontaminationen, die nicht sichtbar auf dem SDS-
PAGE sind. Membranproteine können nur dann ihre Funktionen ausüben, wenn sie 
richtig in die Membran integriert sind, daher werden Detergenz-Mizellen hier als 
Membran-Mimetika verwendet. Da anfänglich keine geeigenten Detergenzien 
gefunden werden konnten, habe ich Detergenz Mischungen auszuprobiert; und 1% 
DPC / 6% LPPG erweist sich als die beste Mischung, um die Membran-Umgebung 
für dieses Protein zu imitieren. Mit 2H, 13C und 15N markiertem Protein konnte das 
Rückgrat fast komplett zugeordnet werden. Das CD-Spektrum und die chemischen 
Verschiebungen der α-und β-Kohlenstoffe deuten auf ein predominant α –helicale 
Struktur hin. Die Seitenketten-Zuordnung und Berechnung der Tertiärstruktur erfolgt 
derzeit. 
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Chapter 1 
  
Introduction 
Membrane proteins (MPs), also known as integral membrane proteins (IMPs), are 
the most abundant proteins in various prokaryotic and eukaryotic organisms and can 
account for 20-30% of the total genome1; 2. The overall topology of membrane 
proteins comprises only the alpha helical proteins and the beta barrel classes, the great 
majority of membrane proteins belongs to the helical bundle class3; 4, while those with 
beta barrel conformation mainly exist as outer membrane proteins (Omps) in Gram-
negative bacteria5. In my thesis unless otherwise mentioned, MPs mean helical bundle 
integral membrane proteins. 
In addition to their great number, membrane proteins also establish the link across 
the membrane, implicated in perception and signal transduction, import and export of 
essential substances. Hence enormous efforts have been dedicated to this protein 
class. Although in recent years significant progress has been made and the growth of 
structure determinations of membrane proteins is growing exponentially, in 
comparison to their soluble counterpart, it is still lagging behind as shown in Figure 
16. 
 
Figure 1. Progress of structural studies of membrane and soluble proteins 
 
1.1 G-Protein Coupled Receptors 
 
G-protein coupled receptors (GPCRs) constitute the largest integral membrane 
protein family7and are one of the largest protein families in the human genome, 
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accounting for 2% of the total genome8. Perhaps more than any other kind of proteins, 
GPCRs have evolved to recognize a plethora of ligands including ions, organic 
odorants, amines, peptides, proteins, lipids, nucleotide and even photons can mediate 
their signal transduction via these proteins. Furthermore GPCRs play critical roles in 
molecular recognition and signal transduction, which are involved in virtually all 
biological processes, so members of the GPCR family are amongst the most pursued 
pharmaceutical targets9. Around 30% of all marketed prescription drugs act on 
GPCRs and around 30% of all targets investigated so far in pharmaceutical companies 
are focused on GPCRs. This makes this class of proteins the historically most 
successful therapeutic target family10. In spite of the diversity in sequence and 
function, all members from this superfamily share a common scaffold as shown in 
Figure 2, which constitutes a 7 transmembrane (TM) helix domain as the core unit 
(thus GPCRs are also named as 7 TM or heptahelical proteins). 7 TM domains are 
connected by 3 extracellular loops (ECLs) and 3 intracellular loops (ICLs) of variable 
length; the N terminus and C terminus are always located extracellularly and 
intracellularly, respectively. Associated with the receptor is a so-called G-protein 
complex, which consists of β, γ and a GDP-bound α subunit. Upon activation from 
the extracellular space, mainly transmembrane helices III and VI of the receptor 
undergo a conformational changes leading to exchange of the bound GDP by GTP in 
the catalytic unit of the G-protein. This destabilizes the G-protein, which dissociates 
from the receptor into activated β/γ and GTP-bound α units, which can have further 
downstream impact, e.g. on adenylylcyclase or phospholipase C and associated 
effects on cAMP or Ca2+ levels in the cell. 
 
 
Figure 2. Schematic representation of GPCRs 
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1.1.1 Classification of GPCRs 
The GPCR superfamily is historically classified into three main families: 1, 2 and 
3, respectively. Rhodopsin belongs to family 1 and is the most intensively studied 
GPCR, so family 1 is also called the rhodopsin-like family. The other two main 
subfamilies are the secretin-like receptor family 2 and the metabotropic glutamate-
like receptor family 311, as is shown in Figure 3 (refer to www.gpcr.org). The 
superfamily of GPCRs can also be classified into to five groups based on 
phylogenetic analysis, named rhodopsin, glutamate, adhesion, taste2 and secretin, 
respectively12; 13. In my thesis the historical nomenclature will be used.   
 
 
Figure 3. Classification of GPCRs 
 
Family 1 comprises almost 90% of all GPCRs and is by far the largest and best-
studied subfamily. Family 1 can be subdivided into receptors for odorants (family 1a), 
receptors for important neurotransmitters (family 1b), such as dopamine or serotonin 
as well as neuropeptides, and receptors for glycoprotein hormones (family 1c). 
Receptors of family 1 are characterized by several highly conserved amino acids 
(some of them are indicated in the diagram by blue letters) and a disulphide bridge, 
that connects the first and second extracellular loops (ECLs). Most of these receptors 
also have a palmitoylated cysteine in the carboxy-terminal tail, which serves as a 
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membrane anchor. The crystal structure of rhodopsin has indicated that some of the 
transmembrane domains of family 1 receptors are ‘tilted’ and ‘kinked’ due to the 
presence of certain amino acids such as proline that distort the transmembrane helices.  
Family 2 GPCRs have been found in all animal species investigated so far, 
including mammals, Caenorhabditis elegans and Drosophila melanogaster, but not in 
plants, fungi or prokaryotes. Many members of GPCR family 2 contain two additional 
structural features in addition to the classical 7 TM region: i) a mucin-like region rich 
in serine and threonine residues; ii) a conserved cysteine-rich proteolysis domain14. 
Their morphology is similar to some family 1 receptors, but the palmitoylation site is 
missing and the conserved residues and motifs are different from the conserved 
residues in the family 1 receptors. Little is known about the orientation of the TM 
domains and their general structure, but given the divergence in amino-acid sequence, 
they are likely to be different from family 1 receptors. Ligands for family 2 GPCRs 
include hormones, such as glucagon, secretin and parathyroid hormone.  
Family 3 is a relatively smaller subfamily and contains the metabotropic 
glutamate, the Ca2+-sensing and the GABAB (γ-aminobutyric acid, type B) receptors. 
A long amino terminus and a long carboxy tail characterize these receptors. The 
ligand-binding domain is located in the amino terminus and is thought to resemble a 
Venus fly trap, which can open and close with the agonist bound inside. Except for 
two cysteines in ECL1 and ECL2 that form a putative disulfide bridge, the family 3 
receptors do not have any of the features that characterize family 1 and 2 receptors. A 
unique characteristic of these receptors is that the third intracellular loop is short and 
highly conserved. At present, little is known about the orientation of the TM domains 
and the general structure.  
 
1.1.2 Current State of Structural Studies of GPCRs 
 
There are two major obstacles against high throughput elucidation of membrane 
protein structures: i) extremely low expression levels in native environment; ii) the 
chemical inhomogeneity of native membranes and the instability in in-vitro 
membrane mimetics. Concerning the recombinant production of membrane proteins 
of sufficient quantity enormous efforts have been invested on various expression 
system such as E.coli, yeast, insect cells, mammlian cells and cell free system15; 16; 17; 
18; 19; 20. Although significant challenges still remain for several GPCRs milligram 
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quantity can be achieved. Taking advantage of the extensive stacks of specialized 
membranes and membrane insertion machineries in the photoreceptor cells, Eroglu et 
al. have even tried transgenic flies for expression of the drosophila melanogaster 
metabotropic glutamate receptor, and discovered that amazingly the expression level 
in such a system is apparently better than in conventionally used systems such as 
yeast or sf9 cells21. So far only 5 out of around 1000 known GPCRs have resulted in 
high-resolution structures and they come from two subfamilies: bovine rhodopsin 
(Figure 4a)22; bovine opsin (Figure 4b)23; squid rhodopsin (Figure 4c)24and the human 
β-2 adrenergic receptor (Figure 4d)25; 26or the turkey β-1 adrenergic receptor (Figure 
4e)27. The available structures confirmed a common architecture of the 7 TM bundle, 
and the differences among different GPCRs are mainly present in flexible loop 
regions and the amino or carboxyl terminal domains. Each new GPCR structure 
revealed the presence of surprising new features. For example, in squid rhodopsin, 
TM helices V and VI are surprisingly long and deeply penetrate into the cytosol, and 
a second cytosolic helix is present24. The major obstacles to obtaining structures of 
other GPCRs include protein production and purification, and protein stability and 
homogeneity. In terms of production, it is now possible to generate sufficient 
quantities (tens of milligrams) of several GPCRs for crystal screening using bacterial, 
yeast, insect cell, and mammalian cell expression systems, but for each GPCR a 
thorough optimization of all parameters are necessary for obtaining milligram yields. 
The availability of robotic systems for preparing setups of 100 nl volumes (or smaller) 
has enabled large parameter screens with relatively small amounts of protein. As 
such, protein production is no longer the major limitation for crystallography efforts. 
Perhaps a greater problem is the stability of purified GPCRs in detergents compatible 
with crystallography. For example, the β2 adrenergic receptor (β2AR) and many other 
GPCRs are not stable in the detergents used to obtain rhodopsin crystals; and 
rhodopsin crystals have not been obtained in dodecylmaltoside, a detergent in which 
the β2AR is relatively stable. GPCRs tend to be more stable in non-ionic detergents 
with relatively long alkyl chains. Another problem is the potential for both structural 
and conformational heterogeneity in GPCRs. Structural heterogeneity means 
heterogeneity in posttranslational modifications such as glycosylation, 
phosphorylation and palmitoylation. These sources of heterogeneity can often be 
eliminated by site directed mutagenesis of the protein, or enzymatic removal of sugars 
and phosphates. This source of heterogeneity is minimized if the GPCR can be 
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expressed in bacteria. The conformational heterogeneity comes from the inherent 
flexibility of GPCRs, which is presumably important for the function of signal 
transduction or substance transportation. In addition the loops and the amino and 
carboxyl termini are intrinsically dynamic due to the lack of interactions with the 
membrane. The conformational heterogeneity can be mitigated by modification of the 
sequence or addition of ligands or antibodies as was done for crystallizing the β2 
adrenergic receptor.   
   
                     a                                             b                                            c 
                                  
                                       d                                                           e 
Figure 4. Available high-resolution structures of GPCRs. (a) bovine rhodopsin; (b) bovine opsin; 
(c) squid rhodopsin; (d) human β-2 adrenergic receptor; (e) turkey β-1 adrenergic receptor 
All the high-resolution structures from whole GPCRs were solved by X-ray 
crystallography, and the application of NMR for membrane proteins requires 
recombinant production of labeled protein, which imposes limitation on the selection 
of the expression organism. Nevertheless, the expression in E. coli of the human 
vasopression V2 receptor for subsequent NMR studies has been described28. In the 
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[15N,1H]-TROSY spectrum 230 complete spin systems out of expected 349 were 
successfully identified, which offers an alternative technique for this fascinating 
protein family. Quite recently Gautier and coworkers have made another big step in 
the structural study of a multispan seven-helical membrane protein receptor, sensory 
rhodopsin pSRII from Natronomonas pharaonis, using high-resolution solution NMR 
methods. In this work near-complete backbone assignment (>98%) of the 241-residue 
chain has been achieved after careful detergent screening, which finally demonstrated 
DHPC is the best membrane model29. Recently Werner and coworkers have 
successfully expressed rhodopsin in HEK293 cells in 13C and 15N labeled form30. 
Though this labeling method only covers 49% of all amino acids based on the 
sequence, it provides a exciting possibility to extend the labeling technique to wide 
range of organisms, thus promoting the applicability of NMR techniques to more 
interesting proteins, such like post-translation modified proteins, membrane proteins 
that can only be expressed in mammalian cells 
 
1.1.3 Oligomerization of GPCRs 
The presence and functional significance of GPCR oligomers has been debated for 
long time, however the pro-evidence keeps accumulating. The concept that GPCRs 
might dimerize was first provoked by the seminal experiment from Roberto Maggio 
and Jurgen Wess in which truncated GPCRs (containing transmembrane regions 1–5) 
from m2 and m3 muscarinic receptor were coexpressed with gene fragments encoding 
the C-terminal regions of the receptor (containing TM 6–7) and functional receptor 
activity similar to wt-receptor was recovered when corresponding N- and C-terminus 
were coexpressed31 . This approach was further refined when a2/m3 and m3/a2 
chimeras were generated in which TM 6 and 7 were exchanged between the a2 
adrenergic receptor and m3-muscarinic receptors. Transfection of COS-7 cells with 
either of the two chimeric constructs alone did not result in any detectable binding 
activity for the muscarinic ligand N-[3H]methylscopolamine or the adrenergic ligand 
[3H]rauwolscine. However, cotransfection with alpha 2/m3 and m3/alpha 2 resulted in 
the appearance of specific binding sites (30-35 fmol/mg of membrane protein) for 
both radioligands. These sites displayed ligand-binding properties similar to those of 
the two wild-type receptors, which indicates the dimerization might exit on molecular 
level31. Michel Bouvier, Terry Hebert and coworkers also used epitope-tagged 
receptors and Western blotting techniques to monitor homodimerisation of the β2-
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adrenergic receptor and to identify a peptide sequence corresponding to TM6 that 
could disrupt receptor dimerization and reduce stimulation of adenylyl cyclase32. A 
clearcut example of a receptor heterodimer that is essential for functional activity 
comes from the interaction between the GABABR1 and GABABR2 gene products 33. 
Fiona Marshall and co-workers showed that GABABR1 is normally poorly expressed 
on the cell surface, but following expression of GABABR2 there is a marked 
expression of heterodimers on the cell surface and ten-fold increase of the agonist 
potency. Furthermore taking the C-terminal domain of the GABABR1 receptor at bait 
against a human brain cDNA library using the yeast two-hybrid system identified the 
GABABR2 receptor as the major hit. More recently, fluorescence and 
bioluminescence resonance energy studies have provided convincing evidence that 
both homodimers and heterodimers exist in living cells34. Perhaps the most visually 
impressive evidence for dimerisation has come from atomic force microscopy images 
of rhodopsin homodimers in native retinal discs shown in Figure 535.    
 
 
Figure 5. Organisation and topography of the cytoplasmic surface of rhodopsin. (a) Topograph 
obtained using atomic-force microscopy showing the paracrystalline arrangement of rhodopsin 
dimers in a native disk membrane. (b) Magnification of a region of the topograph shown in (a) 
showing rows of rhodopsin dimers. Individual dimers (dashed elipse) and monomers (arrow 
heads) can also be observed. Scale bars (a) 50nm and (b) 15 nm. 
 
Additionally dimerization of GPCRs can play regulatory roles. George and 
coworkers have found that µ-opiloid and δ-opioid receptors could be visualized 
following electrophoresis as monomers, homodimers, homotetramers, and higher 
molecular mass oligomers36. However when µ-opiloid and δ-opioid receptors were 
coexpressed, the highly selective synthetic agonists for each had reduced potency and 
altered rank order, whereas endomorphin-1 and Leu-enkephalin had enhanced 
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affinity, suggesting the formation of a novel binding pocket. In contrast to the 
individually expressed µ-opiloid and δ-opioid receptors, the coexpressed receptors 
showed insensitivity to pertussis toxin and continued signal transduction, likely due to 
interaction with a different subtype of a G protein. Gomez et al. have also observed 
that µ-opiloid and δ-opioid receptor complexes exist in live cells and native 
membranes and that the occupancy of δ-opioid receptors (by antagonists) is sufficient 
to enhance µ-opioid receptor binding and signaling activity37. 
 
1.1.4 Posttranslational Modifications of GPCRs 
Posttranslational modification is the chemical modification of target proteins after 
ribosome translation and is usually the last step for the protein synthesis. 
Posttranslational modification is a highly effective method found within nature to 
fine-tune protein activity in a highly sophisticated manner, which of course also adds 
an additional level of complexity in the topographical organization. Among the 
available modifications, phosphorylation, glycosylation and palmitoylation have been 
previously described to play a role in the regulation of GPCR biology. 
The phosophorylation of GPCRs are realized by two kinds of kinases: GPCR 
kinases (GRKs) or second messenger-dependent kinases, such as protein kinase A or 
protein kinase C. GPCR phosphorylation by second messenger-dependent kinases 
typically results in diminished receptor-G protein coupling, whereas phosphorylation 
by GRKs results in both reduced receptor-G protein coupling and enhanced binding 
of additional proteins (arrestins) 38. Phosphorylation of GPCRs plays important roles 
such like desensitization, trafficking, and signaling. Among them phosphorylation-
dependent desensitization has drawn enormous attention, since it is an important 
feature of agonist-stimulated GPCRs that the responsiveness to repeated stimulation 
with agonists is decreasingly waning. Now the canonical view regarding the 
desensitization process is as follows: when GPCRs are stimulated with agonists, they 
activate heterotrimeric guanine nucleotide-binding proteins (G proteins), leading to 
the production of signaling second messengers, such as adenosine 3',5'-
monophosphate, inositol phosphates, and others. Activated receptors are rapidly 
phosphorylated on serine and threonine residues by G protein-coupled receptor 
kinases. Phosphorylated receptors bind the multifunctional adaptor proteins beta-
arrestin1 and beta-arrestin2 with high affinity. Beta-arrestin binding blocks further G 
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protein coupling, leading to "desensitization" of G protein-dependent signaling 
pathways39. The phosphorylation sites have been mainly mapped to the carboxy tail. 
Glycosylation is another important posttranslational modification of GPCRs 
where polysaccharides are attached to protein side chains via enzymatic processes. 
Two kinds of glycosylation are found in nature: N-linked glycosylation, in which the 
polysaccharides are coupled to the amide group of asparagines and Asn-X-Ser/Thr (X 
indicates any residue except Proline), is the common motif recognized by the 
polysaccharides transferases, and O-linked glycosylation in which the hydroxyl 
groups of serine or threonine are coupled with the polysaccharides. Though N-linked 
glycosylation is assumed to be an almost universal modification of GPCRs, quite few 
examples for O-linked glycosylation are available, amongst which are PGE2 and 
PGD2 prostaglandin receptors40 and octopus opsin41. Though a common N-
glycosylation motif is present for all members, the influence of such modifications on 
GPCRs varies from case to case and even in an unpredictable manner. Consequently, 
it has been reported that oligosaccharide moieties are important for V2 vasopressin 
receptor expression and/or stability but not for ligand binding42. Similarly, glycan 
chains are essential for correct folding/trafficking of vasoactive intestinal peptide-1 
receptor, the thyroid stimulating hormone receptor43 and follicle stimulating hormone 
receptor44. For some GPCRs including the somatostatin receptor45, rhodopsin46, the 
β2-adrenergic receptor47 and the gastrin-releasing peptide receptor48, glycosylation is 
important for high affinity ligand binding and/or receptor-G-protein coupling. For 
many GPCRs, however, no functions have been observed related to N-linked 
glycosylation, and this groups includes the histamine H2 receptor49, the A2a adenosine 
receptor50 and the AT2 angiotensin receptor51. The amino terminus is the fragment 
where most of the glycosylations have been observed. In fact, in the N-terminal 
domains from Y receptors there are potential N-linked and/or O-linked glycosylation 
motifs. The group of Markus Aebi has developed tools to transfer the machinery for 
N-linked glycosylation encoded in Campylobacter jejuni to Escherichia coli. The 
eukaryotic primary consensus sequence for N-glycosylation is N terminally extended 
to D/E-Y-N-X-S/T (Y, X not equal P) for recognition by the bacterial 
oligosaccharyltransferase (OST)52. In collaboration with the group of Aebi (ETHZ 
Microbiology) I have also tested in vitro N-glycosylation for the N terminus of the Y2 
receptor. Unfortunately, the poor yield of the in vitro glycosylation product did not 
allow us to investigate the effect of glycosylation on structure and function of this 
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domain.  
Palmitic acid is a 16-carbon saturated fatty acid. When it is attached to the 
sulfhydryl group of cysteine by forming a thioester bond, the process is termed as 
palmtoylation. In many cases, palmitoylation appears to play an important role in the 
expression of functional GPCRs on the cell surface. For example, mutation of the 
palmitoylated cysteines within bovine opsin led to significant intracellular retention of 
the mutants when expressed in COS cells53. Receptor intracellular trapping upon 
mutating the palmitoylation sites has also been reported for the canine H2 histamine 
receptor54and the CCR5 chemokine receptor55. Accelerated degradation has been 
shown to occur in the palmitoylation mutants of the human A1 adenosine receptor. 
FLAG-tagged versions of the wild-type and palmitoylation-deficient mutants of this 
receptor have drastically different half-lives. Approximately 60% of the non-
palmitoylated receptor mutant was cleaved into two smaller polypeptides with a half-
time of 0.8 hours56, which strongly suggests that palmitoylated cysteines are 
important to allow normal processing of GPCRs. Rhodopsin is the first GPCR, in 
which palmytoylation has been observed and the location is mapped to the cysteine in 
the carboxyl terminus57. Considering the presence of cysteine at similar positions in 
many GPCRs, it is apparent that cysteine residues proximal to the cytosolic end of the 
seventh membrane span may represent general targets for palmitoylation. Supporting 
this assumption it is the fact that the palmytoylation site is located in the cytosolic tail 
in case of β2 adrenergic receptor58. However, please note that GPCR palmitoylation 
is not limited to the C-termini of the proteins. Indeed, there is an increasing body of 
evidence that points to the presence of palmitoylated cysteines in the intracellular 
loops connecting the transmembrane spans. For instance, mutation of all the cysteines 
in the carboxyl tail of the rat µ-opioid receptor failed to affect palmitate incorporation, 
indicating that the palmitoylation site(s) resided outside this receptor domain59. 
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1.2 Neuropeptide Y Receptors (Y Receptors) 
 
Y receptors are members of the rhodopsin-like GPCR family 1, which are featured 
by a binding pocket located either within the 7TM bundle (indicated as orange in 
Figure 1a) or at the extracellular loops; there is a conserved disulfide bond connecting 
extracellular loop 1 and 2; there are conserved residues in 7TM domains.  Y receptors 
exert their functions via interaction with neurohormone Y (NPY) peptides and the 
binding is assumed to involve residues from the extracellular loops and possibly the N 
terminal domain60. 
 
1.2.1 Evolution and Members of Y Receptors 
 
Y receptors currently encompass five cloned members in mammals, Y1, Y2, Y4, 
Y5 and y661 and they have different binding affinity against different ligands shown 
in Table 1. The y6 receptor is designated in a lower case due to the fact that y6 is a 
truncated version of Y receptors in mammals and no physiological function has been 
associated with it so far62. In my research I only focused on Y1, Y2, Y4 and Y5 
receptors. The genes for Y1, Y2 and Y5 are clustered together on homo-sapiens 
chromosome 4 (Hsa4), the Y4 gene is located on Hsa10 and the y6 gene is on Hsa5. 
These three chromosomes share members of numerous other gene families, 
supporting the idea that they all arose from a common ancestral chromosome through 
duplications that took place in an early ancestor63. The phylogenetic analyses show 
that Y1, Y2 and Y5 subfamilies are very distantly related, thus the ancestral 
chromosome carried a representative for each of these three subfamilies before the 
chromosome duplications. After the duplications, some genes were lost, but 
interestingly the gene losses seem to differ between the vertebrate lineages. For 
instance, mammals have lost Y7 and teleost fishes seem to have lost Y1, Y5 and Y664. 
Even though all the Y receptors evolve from the same ancestor, they differ from each 
other more than any other G protein coupled receptors with only 27-31% overall 
identity (shown in Figure 6). It is even more surprising in consideration of the fact 
that Y1, Y2 and Y5 receptors bind to not only one but two endogenous ligands, 
Neuropeptide Y (NPY) and peptide YY (PYY)65. While the Y4 subtype is clearly 
more similar to Y1 with 43% overall identity, Y4 is considered as the pancreatic 
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polypeptide (PP) preferring receptor66 even though Y5 also has slightly lower affinity 
to PP67 
 
Table 1. Inhibition constant (nM) of neuropeptide at Y receptors 
 Y1 Y2 Y4 Y5 Type[a] Reference 
NPY 0.81 0.02 1.90 0.19 Ki 68 
PP > 1000.00 > 2000.00 0.04 58.00 IC50 67 
PYY 1.10 0.01 1.06 0.62 Ki 68 
[a] Type of inhibitory constant quoted. Ki=inhibition constant, IC50=concentration at which 50% inhibition occurs.  
 
1.2.2 Physiological Functions of Y Receptors 
The Y1 receptor is the first neurohormone binding receptor to be cloned and 
widely expressed in the central nervous system including the major nuclei in the 
hypothalamus. It is thought to be responsible for the regulation of food intake and 
energy homeostasis. Intracerebroventricular injection of the Y1/Y5 preferring ligand 
Leu31/Pro34 NPY into rodents strongly stimulates feeding behavior. Interestingly, Y1 
receptor knockout models do not display any major abnormalities in regard to food 
intake or bodyweight, although there are subtle changes observed in all Y1 receptor 
knockout mice lines analyzed. Many physiological functions of NPY are mediated via 
the Y1 receptor, for example the vasocontraction function of NPY is completely 
abolished in Y1 knockout mice69. Recently, the Y1 receptor was also observed to be 
involved in the regulation of voluntary alcohol consumption70, and it plays an 
important role in autoimmune and inflammatory processes71. 
The Y2 receptor is widely expressed in the central nervous system (CNS) with 
particularly high levels found in an area of the arcuate nucleus with a permeable 
blood brain barrier. This makes the Y2 receptor accessible to circulating factors and 
an ideal candidate for mediating peripheral signals on the regulation of energy 
homeostasis. The assumption has recently been confirmed by the discovery of the 
endogenous Y2 agonist PYY(3-36) that is released from the gastrointestinal tract 
postprandially72. Similar to the Y1 receptor the Y2 receptor is also directly related to 
some functions from NPY73. For instance, in pig spleen, a Y2-specific agonist evoked 
potent vasoconstriction that could be inhibited by a Y2-selective antagonist, 
BIIE0246. In addition, the Y2 is involved in NPY-induced angiogenesis and circadian 
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rhythms74. Knockout studies of the Y2 receptor have shown that this receptor may be 
involved in the feeding response to NPY as well as in bone formation75. 
The Y4 receptor, also known as the PP preferring receptor, is mainly expressed in 
peripheral tissues including colon, intestine, prostate and pancreas. Unlike other Y 
receptors, the Y4 receptor demonstrates poor sequence conservation, which means 
that the Y4 is one of the fastest evolving GPCRs known. The Y4 knockout mice show 
reduced food intake and significantly reduced body weight76. Plasma levels for PP are 
strongly elevated and white adipose tissue mass is reduced in male knockout mice. 
The increases in plasma PP levels in these animals are the most likely explanation for 
the reduced food intake and body weight seen in these mice. Centrally located Y4 
receptors may be involved in the regulation of reproduction as the Y1 antagonist/Y4 
agonist 1229U91 induced release of the luteinizing hormone when injected into the 
spinal cord77. 
The Y5 receptor is expressed in the human hypothalamus, with the highest density 
being found in the arcuate nucleus. With the administration of an antagonist, the Y5 
receptor has been proved to be involved in the regulation of NPY-mediated food 
intake78, however similar to Y1 receptor, the knockout mice can eat and grow 
normally, which does not confirm this point79.Furthermore, it has been shown that the 
Y5 selective agonist [D-Trp32]NPY inhibited neuronal activity in the suprachiasmatic 
nucleus without generating a phase-shift indicating that Y5 may also be indirectly 
involved in regulation of circadian rhythms77. 
In addition to the regulation of food uptake, recently Y receptors have been found 
linked to neoplasia. Y receptors were also found to be over-expressed in a variety of 
human cancers, mainly expressed in specific endocrine tumors and epithelial 
malignancies as well as in embryonal tumors80; 81; 82. Preliminary experimental data 
suggests that tumoral NPY receptors may be functional in vivo. They may be 
activated by intratumoral NPY peptide and may mediate NPY effects on tumor 
growth and tumoral blood supply. Moreover, NPY receptor expressing tumors are 
promising candidates for an in vivo NPY receptor targeting with radiolabeled and 
cytotoxic NPY analogs, analogous to somatostatin receptor targeting83; 84. 
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Multiple sequence alignment of human Y receptors sequences 
 
*: identical       :: highly similar    .: medium similar    
     : transmembrane domain 
>>>> : N terminus or extracellular loop 
---- : C terminus or intracellular loop 
 
            >>>>>>>>>>>>>>>>>>>>N Terminus>>>>>>>>>>>>>>>>>>>      
NPY1R       ----------MN-STLFSQVENHSVHSNFSEKNAQLLAFENDDCHLPLAMIFTLALAYGA 49 
NPY4R       ----------MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVMVFIVTSYSI 50 
NPY2R       -MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQVVLILAYCS 59 
NPY5R       MSFYSKQDYNMDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQYFLIGLYTF 60 
                       :           . .                       :   :   *   
          ---I1-----             >>>>>E1>>>>>> 
NPY1R       VIILGVSGNLALIIIILKQKEMRNVTNILIVNLSFSDLLVAIMCLPFTFVYTLMDHWVFG 109 
NPY4R       ETVVGVLGNLCLMCVTVRQKEKANVTNLLIANLAFSDFLMCLLCQPLTAVYTIMDYWIFG 110 
NPY2R       IILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMG 119 
NPY5R       VSLLGFMGNLLILMALMKKRNQKTTVNFLIGNLAFSDILVVLFCSPFTLTSVLLDQWMFG 120 
              ::*. **  ::   :: :.  ...*::* **:.:*:*:  :* *:* . .::. * :* 
    >E1>>                     ---------I2--------       
NPY1R       EAMCKLNPFVQCVSITVSIFSLVLIAVERHQLIINPRGWRPNNRHAYVGIAVIWVLAVAS 169 
NPY4R       ETLCKMSAFIQCMSVTVSILSLVLVALERHQLIINPTGWKPSISQAYLGIVLIWVIACVL 170 
NPY2R       PVLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALL 179 
NPY5R       KVMCHIMPFLQCVSVLVSTLILISIAIVRYHMIKHPISNNLTANHGYFLIATVWTLGFAI 180 
             .:*:: .: * ::: ** : *  :*: *:: *      . .   .:. *   * :.    
      >>>>>>>>>>>>>>>>>>>E2>>>>>>>>>>>>>>>>>>>>>    
NPY1R       SLPFLIYQVMTDEPFQN--VTLDAYKDKYVCFDQFPSDS---HRLSYTTLLLVLQYFGPL 224 
NPY4R       SLPFLANSILENVFHKNHSKALEFLADKVVCTESWPLAH---HRTIYTTFLLLFQYCLPL 227 
NPY2R       ASPLAIFREYS-------LIEIIPDFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPL 232 
NPY5R       CSPLPVFHSLVELQET---FGSALLSSRYLCVESWPSDS---YRIAFTISLLLVQYILPL 234 
            . *:       .    .         .   * :.:*      :   ::   *:. *  ** 
            -----------------------I3----------------------- 
NPY1R       CFIFICYFKIYIRLKRRNNMMDKMRDNKYRS----------------------------- 255 
NPY4R       GFILVCYARIYRRLQRQGRVFHKG-TYSLRA----------------------------- 257 
NPY2R       GIISFSYTRIWSKLKN---HVSPGAANDHYH----------------------------- 260 
NPY5R       VCLTVSHTSVCRSISCGLSNKENRLEENEMINLTLHPSKKSGPQVKLSGSHKWSYSFIKK 294 
              : ..:  :   :.            .                                 
            -----------------------------I3----------------------------- 
NPY1R       ------------------------------------------------------------ 
NPY4R       ------------------------------------------------------------ 
NPY2R       ------------------------------------------------------------ 
NPY5R       HRRRYSKKTACVLPAPERPSQENHSRILPENFGSVRSQLSSSSKFIPGVPTCFEIKPEEN 354 
                                                                             
    ---------C3--------------     >>>>>>E3>>>>>> 
NPY1R       ----------------SETKRINIMLLSIVVAFAVCWLPLTIFNTVFDWNHQIIATCNHN 299 
NPY4R       ----------------GHMKQVNVVLVVMVVAFAVLWLPLHVFNSLEDWHHEAIPICHGN 301 
NPY2R       ----------------QRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDLKEYK 304 
NPY5R       SDVHELRVKRSVTRIKKRSRSVFYRLTILILVFAVSWMPLHLFHVVTDFNDNLISNRHFK 414 
                             . :     *  :::.*** *:**  *:   * . : :   . : 
                                    ---------------C Terminus----------- 
NPY1R       LLFLLCHLTAMISTCVNPIFYGFLNKNFQRDLQFFFNFCDFRSRDDDYETIAMSTMH-TD 358 
NPY4R       LIFLVCHLLAMASTCVNPFIYGFLNTNFKKEIKALVLTCQQSAPLEESEHLPLSTVH-TE 360 
NPY2R       LIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIHSEVSVTFKAKKNLE 364 
NPY5R       LVYCICHLLGMMSCCLNPILYGFLNNGIKADLVSLIHCLHM------------------- 455 
            *:: : *: .* *   **::**::*.. :  :   .   .      .    . .:    . 
            ----------C Terminus------ 
NPY1R       VSKTSLKQASPVAFKKINNNDDNEKI 384 
NPY4R       VSKGSLRLSG-----------RSNPI 375 
NPY2R       VRKNSGPNDS---------FTEATNV 381 
NPY5R       -------------------------- 
              . :    .. : .. .. 
 
Figure 6. Human Y Receptors Multiple Sequence Alignment 
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1.2.3 Mutagenesis Studies of Y Receptors  
Based on pharmacological studies, Y receptors have been proven to be important 
members in the food consumption network, so they become preferable targets for 
treatment of relevant diseases, obesity in particular85. Many specific agonist and 
antagonist have been synthesized and demonstrate reasonable efficacy, unfortunately 
none of them has passed clinical trials till 2006 yet86; 87. Furthermore, many studies 
have been done in exploration of the motifs within Y receptors, which are involved in 
ligand binding and selection. Mutagenesis studies have been extensively applied to 
the human Y1 receptor, and many residues important for ligand binding have been 
identified (shown in Figure 7). Sautel and coworkers demonstrated that the 
hydrophobic binding pocket of human Y1 formed by F41 and L43 in TM1, F96 and 
Y100 in TM2, F286 in TM6, H298 in TM7 is critical for NPY binding, especially the 
Y100F Y1 mutant lost the binding ability completely, the corresponding part in NPY 
is the hydrophobic residue Y36 located in the C terminus88. Walker and co-workers 
found that acidic residues located in the extracellular loops of Y1 receptor are 
important elements for interactions with positively charged residues in NPY, in 
particular those located in the C terminus89. In mouse two in vivo-expressed splice 
variants of Y1 receptor have been found 90. The short form (307 amino acids) of the 
Y1 receptor ends a few amino acids after the third extracellular loop, yielding a 
receptor with an incomplete TM7. NPY binds to this short form of the Y1 receptor 
with similar affinity as to the complete 384 amino acid protein. However, the 
signaling of the short form of the receptor was impaired, indicating that the TM7 and 
the carboxyl-terminal tail are not essential for ligand interaction but rather for G-
protein activation. When positions 31 and 34 of NPY or PYY (Ile and Gln) are 
replaced by the corresponding amino acids in PP, Leu, and Pro, respectively, the 
resulting peptides do not bind to Y2 receptor anymore, although this peptide remains 
a potent full agonist at the other PP-fold receptors91. It was later shown that only the 
Pro34 substitution was essential for preventing Y2 receptor binding92. NPY and 
NPY2-36 are equally potent against Y5 receptor in producing a large increase in 
feeding after intracerebroventricular administration, suggesting a different mechanism 
other than Y1, Y2 and Y4. In addition, NPY with position 32 replaced with D-
tryptophan ([D-Trp32]NPY) selectively inhibited NPY-induced feeding, and it was 
found that [D-Trp32]NPY is a modestly selective agonist at Y5 expressed in HEK293 
cells acting to inhibit cAMP synthesis but with a lower potency than NPY, PYY and 
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NPY2-3693. Similarly Beck-Sickinger has mutated all the conserved residues in the 
Y5 receptor across different species with alanine and identified those that affect the 
binding with neurohormones significantly. Further more taking use of complementary 
mutagenesis between Y5 receptor and NPY, two interaction partners have been 
pinpointed: R25(NPY) and D2.68(Y5); R33(NPY) and D6.59(Y5)94. 
Some of the differences between the different mutagenesis studies can probably 
be explained by the very heterogeneous expression systems used. For instance, 
Walker and colleagues used a vaccinia virus vector to express the human Y1 receptor 
in Hela cells89and later found differences when these mutants were compared with the 
same mutants expressed in E. coli and mammalian cell lines95. It is also possible that 
the usage of different mammalian cell lines may alter the pharmacology of the very 
same receptor protein depending on what other proteins are expressed in the cells. In 
summary the interaction between NPY hormones and Y receptors is complex and 
involves hydrophobic interactions and electrostatic interactions, and it possibly 
involves the presence of other participants such as the membrane. 
  
 
Figure 7 Summary of structural and mutagenesis studies performed on the mammalian Y1 
receptor. Amino acids were mutated to alanine except in three positions. Those are indicated by a 
shaded amino acid next to the original sequence. Red indicates a loss in affinity >2.5-fold. Upper 
left: effects on NPY/PYY binding, lower right: antagonist. White: no effect. Black: not done.  
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1.2.4 Which Portions of the Y Receptors are Important for Ligand Binding? 
Most of the studies have emphasized the importance of extracellular loops, 
transmembrane domains, intracellular loops and C-terminal domains in ligand-
binding and signal transduction. However, little is known about the role of the N 
terminal domain in GPCRs. In GPCR family 2 and 3, the N terminus is known to be 
involved in the ligand-binding process (shown in Figure1b and 1c), the N-terminal 
domain of GPCR family 2 shares common features: typically 6 conserved cysteines, 2 
conserved tryptophans and an aspartate acid which has been suggested to be critical 
for ligand binding96; 97. Sun and his coworkers have solved the solution structure of 
the N-terminal domain from pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptor complexed with its ligand PACAP98. But in family 1, the  
rhodopsin-like GPCRs, little attention has been devoted to that issue. 
The N terminal sequences among the four Y receptors are not conserved (shown 
in Figure 8), however relatively high sequence similarity can be observed between Y1 
and Y4 (shown in Figure 3), which is consistent with a phylogenetic study. The non-
conserved sequences in the N termini among the whole Y receptor family indicate 
that they may play various roles in the corresponding receptors.  
 
N-Y1      MN-STLFSQVENHSVHS-NFSEKNAQLLAFENDDCHLPLAMI 
N-Y4      MNTSHLLALLLPKSPQGENRSKPLGTPYNFS-EHCQDSVDVM 
          ** * *:: :  :* :. * *:  .    *. :.*: .: :: 
Figure 8. Sequence Alignment between N-Y1 and N-Y4 
 
Based on a secondary structure prediction, the N terminal domains display 
dramatic disorder as shown in the Figure 9. The bioinformatics prediction does not 
necessarily imply the lack of structure, especially because it does not take the 
presence of a membrane into account. Furthermore, disorder often occurs in nature, 
and exits in many proteins99. Disordered regions, according to statistics, are also 
prominent in ligand recognition100. The lack of folded structure in signaling proteins 
might give these proteins a functional advantage over globular proteins with well-
defined secondary and tertiary structure: the ability to bind to multiple different 
targets without sacrificing specificity and the ability to overcome steric restrictions, 
thus enabling larger surface interactions101. 
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N-Y1:  MNSTLFSQVENHSVHSNFSEKNAQLLAFENDDCHLPLAMI 
       ------EEH----------HHHHHHHH------------- 
N-Y2:  MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQ 
       -------------HHHHHH---------------------H----HEE-- 
N-Y4:  MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVM 
       ----HHHHH-------------------------------E 
N-Y5:  MSFYSKQDYNMDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQ 
       --------------HHHHH------HH------------------------ 
Figure 9. Secondary Structure Prediction Based on Primary Sequence as predicted by the 
program nnPredict (http://alexander.compbio.ucsf.edu/~nomi/nnpredict.html) H = helix, E = 
strand, - = no prediction  
 
In the pioneering study, Monteclaro fused the N terminal domain from CCR2 
(member of the GPCR family 1) receptor to the human CD8 transmembrane and 
cytoplasmic domain. The chimera protein was expressed on the HEK-297T cell 
surfaces and binding affinity towards its ligand, the monocyte chemoattractant protein 
1 (MCP1) was measured by ELISA. The results surprisingly suggested that the N-
terminal domain alone is both necessary and sufficient for ligand binding. Based on 
the results, a two-step activation model was proposed, in which the noncovalent 
“tethering” of MCP-1 by the receptor amino terminus enhances the low affinity 
interactions with extracellular loops and eventually leads to G-protein activation 60. 
Based on a mutagenesis study, Ho and co-workers concluded that the N terminus of 
Kaposi’s sarcoma-associated herpesvirus GPCR, also a member of GPCR family 1, is 
necessary for high affinity chemokine binding but not for constitutive activity102. In 
Prado’s work, the N termini from chemokine interleukin 8 (IL-8) receptor CXCR1 
and CXCR2 were demonstrated to play a role in the interaction with and 
internalization of their ligands103. Andersson, in a study about the membrane 
assembly of the cannabnoid receptor 1 (CB1, member of GPCR family 1), also 
proposed that the N terminus might play a role in regulating the stability and surface 
expression of CB1104. In Dong’s work, the mutation of Lys 187 within the second 
extracellular loop led to silencing of signal tranduction instead of ligand binding, in 
addition the truncation of the N terminus can eliminate the negative effect of the 
mutation, which indicates there is a acidic residue in the N terminal domain that 
interacts with the basic residue lysine during signal transduction105. Gupta and 
coworkers recently found the antibodies raised with the N-terminal domain from µ-
opioid receptor (GPCR 1) can recognize the activated receptor with higher efficacy, 
indicating the N-terminal domain adopts a conformational change upon ligand 
binding, and it might also be involved in the direct ligand binding106. Regarding the 
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structure of the N-terminal domains, the crystal structure of rhodopsin reveals five 
distorted strands among which the first two antiparallel strands form a typical β sheet 
conformation22.  
Since our preliminary model indicates that the N-terminal domain might be a 
functional unit from Y receptor that can be involved in ligand recognition or binding. 
Besides, many other groups have also found the importance of the N-terminal 
domains from various GPCR families including family 1. Therefore in my Ph.D. 
studies, I started from all the N terminal domains of Y receptors. 
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1.3 The Ligands of the Y Receptors: Neuropeptide Y Hormones  
 
Neuropeptide Y (NPY) hormones are members of orexigenic neuropeptides and 
they are distributed in the central nervous system as well as in the peripheral nervous 
system. Since they play important roles in many physiological processes, such as 
regulation of food uptake, circadian rhythms and endocrine levels, a lot efforts have 
been devoted to these. 
 
1.3.1 Members of NPY Family 
NPY together with peptide YY (PYY) and pancreatic polypeptide (PP) form the 
NPY family pepitdes, which are characterized by 36 amino acid residues and 
amidation at the C terminus107. NPY is well known to be the most abundant 
neuropeptide in the central nervous system in mammals, although it is also widely 
expressed in the peripheral nervous system108. NPY has been functionally implicated 
in feeding behavior, cardiovascular regulation, control of neuroendocrine axes, affective 
disorders, seizures, and memory retention, tumor progression109, with food intake 
regulation the most noticeable110.  
PYY, sharing high sequence identity to NPY, is produced by the intestinal L-cells, 
the highest tissue concentrations of PYY are found in distal segments of the 
gastrointestinaltract, although it is present throughout the gut111. Circulating PYY 
exists in two major forms: PYY1–36 and PYY3–36. PYY3–36, the peripherally active 
anorectic signal, is created by cleavage of the N terminal Tyr-Pro residues by 
dipeptidyl peptidase 4 (DP4)112. PYY3–36 is a major form of PYY in both the gut 
mucosal endocrine cells and the circulation, however I will focus only on the full 
length PYY in my study. PYY is released into circulation following food intake, the 
concentrations are proportional to meal energy content, so that higher levels are seen 
after fat-intake as compared to sugars and proteins113. 
PP is predominantly located in endocrinic cells in the pancreas (the reason why it 
is named pancreatic polypeptide) and released into circulation as part of its 
preprotein114. Similar to NPY and PYY, it is involved in gastric emptying, glucose 
metabolism and insulin secretion115. In my research bovine PP (bPP) is used instead 
of human PP because it has been structurally characterized by Dobson116 and they 
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differ only in position 6 (V from human to E from bovine) and 23 (D from human to 
E from bovine). 
In addition to the neuropeptides mentioned above, there exist a truncated version 
of NPY and PYY, which in contrast to the full-length peptide start from position 2 or 
3 and more importantly loose their efficacy at Y1 receptor while they are active 
especially at the Y2 receptor. Dipeptidyl protease 4 (DP4) might be the major 
cleaving enzyme117. NPY3–36 and PYY3–36 have been shown to play a role in 
energy metabolism via inhibition of exocrine pancreas function118or other feeding 
associated processes119, and probably are involved in several other as yet to be 
discovered physiological functions. These regulatory processes are closely dependent 
on the expression and function of DP4-like peptidases due to their capability in 
hydrolyzing the post-proline bond between positions 2 and 3 of NPY and PYY. 
 
1.3.2 Structural Studies of NPY Members 
The first crystal structure of NPY family member, avian pancreatic polypeptide 
(aPP), was solved in 1981 by Blundell (shown in Figure 10) and was also the first 
high resolution structure of smaller peptide120. In the structure, the N terminus adopts 
a polyproline type II helix comprising residues 1-8, the C terminal residues 14-31 
form the typical α helix, the N terminal part is connected by a β turn and bent back 
onto the C terminal part. This kind of structural motif is since then named as “PP 
fold” and confirmed by the solution structure of bPP elucidated by NMR116: 
 
 
Figure 10. Crystal structure of avian pancreatic peptide (1PPT) 
 
All three neuropeptides share high sequence identity, especially between NPY and 
PYY 69% sequence identity is observed as shown in Figure 11, and the sequence 
homology is larger than 80%. Considering the relative high sequence identity, it is 
expected that the PP fold is a common and characteristic structural motif amongst 
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peptides of the NPY family, however later studies demonstrated surprising 
conformational diversity.  
NPY     YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY-NH2 36 
PYY     YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY-NH2 36 
bPP     APLEPEYPGDNATPEQMAQYAAELRRYINMLTRPRY-NH2 36 
             * :*: **::*..*::::* : **:*:*::** ** 
Figure 11. Multiple sequence alignment among neuropeptides 
However, peptides with highest sequence identity to PYY, hNPY121 and pNPY122 
revealed a unstructured N terminus in solution. In consideration of the fact that NPY 
and PYY have almost the same Y receptor affinity, it is surprising that NPY and PYY 
adopt dramatically different conformations in solution as shown in Figure 12. This 
raises the question as to what is the biological relevance of the PP fold in Y receptor 
recognition? Are there other elements that contribute to ligand recognition? 
 
Figure 12. Bundle of the NMR-derived conformers of PYY (left, 1RU5) and NPY (right, 
1RON) 
 
In our group, the structures of NPY, PYY, bPP have been determined both free in 
solution and when bound to dodecylphophocholine (DPC) micelles as shown in 
Figure 13123; 124; 125. DPC is zwitterionic detergent, that has been widely used for 
mimicking mammalian cell membranes126. DPC micelles play very important roles in 
regulating the structure and dynamics of the neuropeptides. In presence of DPC 
micelles, a common conformation is present in which the N terminus is diffusing 
freely in solution indicating the PP fold is disrupted. Using a micelle-integrating spin-
label experiment it was shown that the C terminal helix is clearly located parallel to 
the micelle surface and positioned in the lipid-water interface. According to the 
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15N{1H}-NOE data that can be used to determine the backbone stability, it was 
confirmed that DPC micelles destabilize the N-terminal part of all three 
neuropeptides. Interestingly, the C termini of NPY and PYY become more rigid after 
binding to the DPC micelles, hence extending the helix to comprise the whole C 
terminus, while binding to the DPC micelles does no change the fold of the C 
terminus of bPP significantly. The C terminal pentapeptide is believed to be important 
for receptor activation, presumably through electrostatic interaction88. R33 and/or R35 
in NPY are believed to be the key residues involved in direct contact with acidic 
residues in Y5 receptor, in another word impose specificity toward Y5 receptor127. 
Beck-Sickinger’s work is consistent with this point which suggests R33 and R35 are 
critical for NPY to bind to Y1 receptor while R35 and Y36 are important for binding 
to Y2 receptor, hence indicating different binding conformations adopted by NPY at 
the Y1 and Y2 receptors128.The similarity between the conformations of NPY and 
PYY in presence of DPC accounts for the similarity in affinities at the various Y 
receptor subtypes, and hence may indicate a common mechanism for receptor 
recognition. In addition it is consistent with the membrane compartment model129; 130 
that the DPC-bound conformation is important for Y receptor recognition. 
 
 
 
Figure 13. Comparison of structures of PYY (left), NPY (middle), and bPP (right) free in solution 
(top, single conformer) and when bound to DPC micelles (bottom, superposition of the NMR 
ensemble). The C-terminal pentapeptide of the micelles-bound peptides is depicted in red. 
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1.3.3 A Novel Binding Model of NPY Hormones with Y Receptors 
In 1984 Kaiser and Kezdy had proposed a pioneering idea that ligands that bind to 
membrane-embedded receptors recognize their targets from the membrane-bound 
state131. In their research they realized that most of the binding pocket in receptors can 
only accommodate less than five residues and that the binding is mediated by 
stereospecific interactions between the ligands and the receptors. However, most 
peptide hormones and toxins comprise around 30 residues and many of them are not 
structured in solution but form amphiphilic helices in a membrane environment132. 
Finally they concluded that the amphiphilic domain were responsible for docking the 
ligands on the membrane where the ligands were recognized by their ligands. 
Schwyzer et al. developed the concept further into the membrane compartment 
model129; 130. He proposed that ligands were recognized by their receptors after 
binding to the membrane. Upon binding to the membrane, the ligands were located in 
proximity to the receptors thereby increasing their local concentration and the 
receptor search from 3-D to 2-D. Thereby the interaction probability between ligands 
and receptors is increased. Moreover, conformations close to the bioactive form were 
induced and the entropic loss upon receptors binding was reduced.  
 
 
Figure 14. Novel ligand binding model for peptides of the NPY family to their Y receptors 
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Based on the knowledge described above, a binding model for neuropeptides was 
proposed in our group as shown in Figure 14133. Firstly, the hormones are attracted by 
the membrane through electrostatic interactions. The extent of these attractions is 
regulated by the content of the negatively charged phospholipids in the membrane 
composition and by the content of cationic ligand residues. In a second step, the 
peptide reorients such that hydrophobic residues penetrate the hydrophobic interior. 
The hormones subsequently diffuse laterally along the membrane and it is this 
particular state from which the peptide is initially recognized by the receptor. Our 
SPR data revealed a moderate binding affinity of the hormones to the membrane, 
which indicates that the membrane-bound hormones can dissociate from the 
membrane and diffuse into the binding pocket while still keeping enough affinity to 
the membrane to guide them the receptor134. In the last step, the hormone that is in 
equilibrium of a membrane-bound and a membrane-water interface state can diffuse 
into the binding pocket of the receptors. A big difference between membrane-water 
interface and water phase is observed, e.g. for the dielectric constant. Out data 
(unpublished) also present a preserved membrane-bound structure in the 
water/methanol mixture even when the dielectric constant is considerably increased. 
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1.4 Using Protein Fragments to Study Membrane Protein Structure 
 
The folding studies of soluble proteins have been the focus of many labs, books 
and conferences. However the progress towards an understanding of the underlying 
chemical and physical factors is still slow. Membrane proteins are featured with the 
presence of a stretch of apolar residues and the genome sequencing projects have 
revealed that membrane proteins comprise 20-30% of the total genome in various 
organisms and that they play a wide spectrum of functions critical for various 
physiological processes. At present, people studying folding might think that 
membrane protein folding could be easier to understand compared to folding of 
soluble proteins because the membrane environment has significantly restrained the 
conformational space thus simplifying the complete process and the subsequent 
analysis.  
 
1.4.1 The 2-Step Membrane Protein Folding Model 
 
In 1990 Popot has proposed a 2-step model to describe the folding of membrane 
proteins in vivo135; 136: first partitioning of unfolded polypeptides into the water-
membrane interface results in increased formation of backbone hydrogen bonds 
resulting in formation of secondary structure. Interactions of the side chains with the 
lipid environment lead to the insertion of transmembrane helices into the bilayer 
interior. Specific helix-helix interactions lead to formation of native tertiary structure 
(shown in Figure 15). In this model the TM domain insertion process is separated 
from tertiary and quaternary structure assembly. Accordingly elements of secondary 
structure can be thought of as independent folding units/or even functional units and 
hence be studied separately. Even though the model is simple, a large body of 
literature has demonstrated supporting information for it: the fragments of various 
membrane proteins stemmed from proteolysis137, chemical synthesis138, recombinant 
expression through plasmids138; 139; 140; 141 and cRNA142; 143 have proved to be capable 
of reconstituting into functional moieties in lipid vesicles or in various in vivo 
systems. In addition many structures of the membrane protein fragments have proved 
to be similar to corresponding parts in the whole protein. 
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As mentioned above the majority of MPs adopt alpha helical conformations, 
hence the transmembrane helix is the predominant secondary structure and the helix-
loop-helix, the so-called helical hairpin is then the most important tertiary structure as 
well as a basic folding unit.  
 
 
Figure 15. 2-step folding model for membrane protein 
 
1.4.2 Current Progress in Studies of Transmembrane Domains 
 
GPCRs are characterized with the 7 hydrophobic transmembrane helices, 
therefore many programs have been developed to predict the transmembrane borders 
on basis of hydrophobicity, which is sufficiently accurate in many cases. For example, 
a program called TM finder144 makes use of both hydrophobicity and helicity scales 
and can identify transmembrane domain with 98% accuray from the primary sequence 
when applied to the sequence database of membrane proteins. Because there are still 
ambiguities from the choice of different thresholds and the window size145,other 
parameters in addition to the hydrophobicity scale should also be employed to provide 
further support for identification of the TM borders. 
Based on artificial peptide it has been determined that the minimal transmembrane 
domain of a helical hairpin should comprise 18 residues146. Transmembrane domains 
encompassing residues between 18 and 36 have been observed147, the average 
transmembrane length is 20.3 residues148. The charged residues in short loops 
connecting the hydrophobic segments are potent topogenic determinants. The best 
known rule is the “positive-inside rule”, that states that loops containing positive 
residues tend to remain at the cytoplasmic side. This rule can not only predict the 
borders of a transmembrane helix149 but may also determine the orientation of 
transmembrane domains in the lipid environment150. In consideration of the 
considerable differences in charges and hydrocarbon length of the detergents we are 
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using, the orientation of the TM is still unpredictable. Aromatic residues have been 
observed to tend to cluster at or close to the water membrane interface151, and such 
orientational preferences can serve as the driving force for folding and stability of the 
transmembrane domain152. On basis of site-directed and saturation mutagenesis, Yuan 
has suggested that Tyr can be a primary recognition element for precise 
transmembrane positioning153. Although aromatic residues can be a strong anchor at 
the water membrane interface, Trp and Tyr but not Phe can also pull the 
transmembrane helix out of the membrane when positioned in the center154. Proline is 
undoubtedly important for the function and structure of membrane proteins as 
evidenced by the observation that Pro has one of the highest genotypic propensity in 
the analysis of transmembrane sequence from the Human Gene Mutation Database155. 
Due to the lack of the amide proton, proline is well known to be the helix breaker in 
soluble proteins, it conducts similar role in membrane proteins as well156. According 
to statistics proline occurs frequently in the center of a transmembrane helix, where it 
induces the formation of molecular hinges or kinks, which usually locate about 4 
residues N-terminal of the proline residue157. Though proline is not necessarily 
required for kink helices, the sites where proline resides is even slightly conserved in 
the aligned sequences of transmembrane domains are likely to be in kinked 
conformations across all the related proteins158. 
Now there are more and more studies focusing on helical hairpins. Hessa et al by 
using in vitro translation of a systematically designed model protein in presence of 
dog pancreas microsomes, have presented a biological hydrophobicity scale, which 
displays a nice correlation with the biophysical hydrophobicity scale, they also 
determined the position-dependent contribution of the 20 naturally occurring amino 
acids to facilitate insertion of the helix into the membrane159; 160. Johnson et al have 
proven that van der Waals packing is playing a crucial role for helical hairpin 
insertion and stability by designing a small protein which complies with the “knobs 
into holes” rule161. In addition aromatic and cation-π interactions can also enhance 
helix-helix interaction in a membrane environment162. Due to the much lower 
dielectric constant in the membrane environment, hydrogen bonds become 
significantly stabilizing for folding, dynamics and helix-helix interactions163. 
Furthermore, mutation in the transmembrane domain into polar residues can lead to 
disease because of the additional hydrogen bond interaction, such like a valine to 
aspartate mutation in TM4 in the cystic fibrosis transmembrane conductance regulator 
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protein164. Taking a poly-Leu peptide as a model protein, Magnus and his coworkers 
have determined the minimal length of a helical hairpin, which is 31 amino acids146 
and the turn forming propensity scale in membrane environment for each of the 20 
amino acids, which is shown to be largely different from the turn forming propensity 
scale for globular soluble protein165. Akos stressed the significance of turn propensity 
by suggesting that in case of a naturally occurring helical hairpin from the secretary 
Na+-K+-2Cl- cotransporter NKCCl the formation of the hairpin structure is only 
dictated by a short, but strong signal for turn formation instead of specific helix-helix 
interactions166. By comparison of the turn region of cystic fibrosis transmembrane 
conductance regulator between mutants and wide-type, Hania et al have observed a 
correlation between decreased migration rate in gel electrophoresis and increasing 
helix content, which indicates that the turn region influences the structure of 
membrane proteins167. Marika further mentioned that charged residues, especially 
lysine and aspartate in the loops regions can promote the formation of the 
transmembrane helix168. 
Because of the wide spectrum of difficulties involved in the crystallization of 
membrane proteins, nuclear magnetic resonance (NMR) becomes a valuable 
alternative technique. The less stringent requirements on the sample have allowed 
NMR to be widely applied to structural studies on MPs 28; 169; 170; 171; 172; 173; 174. More 
importantly the NMR-determined structures of the isolated loops and transmembrane 
domains displayed a surprising agreement with the already known crystal structures 
of the whole proteins175; 176; 177, which strongly supports the fragment-based approach. 
With the advance of NMR spectroscopic techniques such as TROSY, the generally 
considered molecular weight limitation has been dramatically lifted, and the so far 
largest protein studied by NMR is a bacterial chaperon GroEL-GroES complex, 
which has molecular weight of 900kDa178.   
Even though much progress has been made regarding the structure determination 
of membrane proteins by NMR, still only quite a few examples of complete NMR 
structures are available, for example for the subunit c of the F1,F0-ATPase179, the 
double transmembrane domain of the bacterial mercury transport membrane protein180 
and the human glycine receptor181, all of which comprise two transmembrane 
domains. No structural information on more than one transmembrane domain from a 
GPCR as derived from NMR measurements has been published.  
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1.4.3 Membrane Mimetics for NMR Studies  
 
Membrane proteins, also termed integral membrane proteins, can only exert their 
functions when they are inserted in the membrane. However naturally occurring 
membranes are characterized by the following features: they are patchy, with 
segregated regions of structure and function, and lipid regions also vary in thickness 
and composition(Figure 16)182.  
Therefore it is the intrinsic inhomogeneity of the membranes that confers one of 
the largest challenges for the in vitro studies of membrane proteins, in that most of 
techniques used today for structural studies such like X-ray crystallography and NMR 
need an isotropic medium to increase the signal strength. To circumvent this problem, 
various alternative media have been applied: organic solvents, micelles, bicelles, 
amphipols, nanoscale bilayes and reverse micelles. 
 
 
Figure 16. Mosaic membrane 
Historically, organic solvents have been extensively used to handle small 
hydrophobic compounds, therefore they are naturally options for hydrophobic 
biomolecules such as membrane proteins (Figure 17d). The most often used organic 
solvents include DMSO, 4 : 4 : 1 chloroform : methanol : water and 80 : 20 
hexafluoroisopropanol : water. Katragadda and coworkers have solved all the 
transmembrane domains from bacteriorhodopsin in DMSO and the resolved structures 
can be reasonalbly overlapped with the known crystal structure, which confirms the 2-
step membrane protein folding model and indicates the applicability of organic 
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solvents in NMR studies176. In another example, the subunit c of F1,F0-ATPase, has 
also been resolved to atomic level in a 4 : 4 : 1 chloroform : methanol : water 
mixture179, a solvent system in which activity is retained completely. However 
organic solvents are not always a good choice for membrane proteins, since many 
other membrane proteins have shown to be denatured in these solvents or loss of 
functions occurred. Looking at the two successful examples it seems that both 
comprise almost exclusively hydrophobic residues, on the contrary in most membrane 
proteins the domains out of membrane are additionally composed of hydrophilic 
residues, and their architecture is adjusted to the gradient in hydrophobicity 
encountered in biological membranes. Thus when placed in the isotropic organic 
environment they become leading to further conformational changes or loss of 
function. In summary, organic solvents are rarely a good choice for membrane 
proteins, and if used careful validation of the structure and function is necessary. 
Micelles are formed by detergents. When detergents are dispersed in water, they 
are mainly monomeric. However when the concentration increases above the critical 
micelle concentration (CMC), monomeric detergent molecules start associating and 
form a spherical aggregate termed a micelle (shown in Figure 17b). Hydrophilic head 
groups point outward interacting with water while the hydrophobic tails point inward 
forming an apolar environment. Detergents can be classified into the following 
categories according to charge: non-ionic (sugar-derived detergents) and ionic 
detergents. Among ionic detergents there are cationic, anionic (SDS) and zwitterionic 
(CHAPS, DPC) detergents. Detergent micelles are by far the most widely used 
membrane mimetic for solution NMR. The transmembrane domain of glycophorin A 
was determined in DPC micelles in dimeric form, and the atomic structure indicates 
that van der Waals interaction is responsible for dimerization169. Howell, et al have 
determined the structure of the double transmembrane domain of bacterial mercury 
transporter in SDS180. DHPC was applied for the structural determination of outer 
membrane protein X (OmpX) and it renders the first 3-D structure of beta barrel 
membrane protein determined by NMR183. Roosild and coworkers have determined 
the 3-D structure of a membrane-integrating sequence for translation of integral 
membrane protein constructs (MISTIC) in LDAO. The structure demonstrated a 
helical bundle with a lipid-facing surface that was surprisingly polar. Additional 
experiments suggest that MISTIC can be used for high-level production of other 
membrane proteins in their native conformations, including many eukaryotic proteins 
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that have previously been intractable to bacterial expression184. In spite of the wide 
application of micelles, extra care must be paid: i) there is no “one-for-all” rule in 
detergent selection, therefore for each membrane protein an extensive detergent 
screening is needed in order to end up with one in which the native structure and 
hopefully the native function can be retained; ii) detergents such as SDS or others 
with charges right connected to the alkyl chains have stronger denaturing activity, in 
this concern the lysolipids are preferable; iii) the detergent concentration should be 
much higher than CMC and ensure that each micelle hold only one protein 
molecule185. 
Bicelles (shown in Figure 17a) consist of one or more long chain phospholipids 
which self assemble into a bilayer, in combination with an amphiphile such as short 
chain lipid DHPC186. The amphiphile serves to form a rim around the hydrophobic 
interface of the bilayer, creating a disk-shaped domain. The appropriate size of 
bicelles can be manipulated by changing the ratio between long chain and short chain 
lipids, therefore the small bicelles can be applied in solution NMR. Bicelles have 
proven to be equally useful in solid-state NMR applications, and high-quality spectra 
are often observed due in part to the highly liquid crystalline environment of the 
bicelle lipids. Bicelles have been regarded as a better membrane model than any other 
mimetics such like micelles: i) bicelles display a disk-like surface, thus providing a 
large planar area without curvature; ii) bicelles are composed of phospholipids 
mixtures which have proved to be critical for the function of many membrane 
proteins. The best example of bicelles comes from the Staphylococcal multidrug 
resistance transporter (Smr)187. The Girvin group has identified LPPG as the best 
micellar system for structural studies of IMPs according to signal dispersion in [15N, 
1H]-HSQC spectra. In addition, equilibrium sedimentation confirmed the presence of 
the assembly of a dimeric state, and carbon chemical shift based secondary structure 
prediction indicates the presence of a 4-helix bundle. However the functional test with 
ligands demonstrated unspecific binding, indicating a non-native structure. Based on 
the functional analysis bicelles stood out as the best membrane mimetic. It is therefore 
believed that bicelles might be a generally useful membrane model for membrane 
protein studies. 
Amphipols (shown in Figure 17c) are short amphipathic polymers that can 
substitute detergents to keep membrane proteins water-soluble. Since amphipols are 
not detergents, they provide an appealing advantage to avoid the denaturing or 
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dissociating effect of detergents. However amphipols as a non-detergent polymers can 
not solubilize membrane proteins directly, which means they can only be applied after 
the membrane proteins have been extracted by detergents. Amphipols have been for 
the first time used as the medium in a study leading to a high-quality NMR spectra of 
OmpA188; 189, and it is interesting to see if this medium can be employed to other 
membrane proteins, especially to those that do not result in good spectra in 
conventional membrane mimetics. 
Reverse micelles (shown in Figure 17e) as indicated by the name have hydrophilic 
head groups pointing inward and the hydrophobic tail outward. Reverse micelles are 
formed when the bulky solution is organic solvent and a small quantity of aqueous 
solution is wrapped inside. The largest advantage of reverse micelles is that the 
tumbling of the whole aggregate is very fast if a low viscosity organic solvent is 
chosen, thus leading to extraordinarily sharp lines. Reverse micelles have been 
successfully applied to soluble proteins and the Wand lab has been working to extend 
this approach to membrane proteins190. 
 
 
                          a                                                                               b 
 
                   c                                             d                                            e 
Figure 17. Membrane mimetics,  red color indicates hydrophobic parts and blue color indicates 
hydrophilic parts. a) bicelles; b) micelles; c) amphipoles; d) organic solvent; d) reverse micelles 
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Nano-scale bilayers also called nano-discs are composed of a patch of planar lipid 
bilayers (~160 lipid molecules) surrounded by a dimmer of apolipoprotein A-I. The 
nano-disc has a disc-like shape with diameter of around 10-12 nm and a thickness of 
~4nm. While other model membranes (bicelles, micelles) display a polydisperse 
particle size distribution and can suffer from problems of inconsistency and 
instability, nano-discs demonstrate an excellent monodispersity because the particle 
size is constrained by the coat of the scaffold protein(s). This system has been 
recently adapted by Sligar group to incorporate various membrane poteins191, and the 
Arseniev group has for the first time applied this model membrane to study the 
structure of a peripheral membrane peptide by solution NMR192. Unfortunately, no 
results from integral membrane proteins have been reported yet. 
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1.5 Production of Membrane Protein Fragments 
 
The structural determination of membrane proteins is considerably lagging behind 
in comparison to the soluble counterparts, and one major obstacle is the recombinant 
production of target membrane protein in sufficient quantity. Various expression 
systems have been employed for the entire membrane proteins, on the contrary for 
membrane fragment production E.coli is still the dominant choice. Another advantage 
of E.coli over other organisms with regard to NMR is easy labeling method. For other 
organisms the isotope labeling is always problematic due to either applicability or 
high cost.  
  
1.5.1 The Fusion Method  
 
The first method is the one, which is used most widely for 2-TM constructs. In 
brief, the target protein is expressed as a fusion protein with a partner, which usually 
can be expressed to a high level thus improving the yield of the target protein. The 
fusion partner can also provide other features to the fusion protein, on basis of which 
it can be divided into two categories: soluble fusions and insoluble fusions. Soluble 
fusions, as indicated by the name, can increase the solubility of the whole fusion 
protein and thus simplify the subsequent purification. In case of membrane proteins 
highly hydrophobic trasmembrane helices are present, the relatively large soluble 
fusion proteins, such like maltose binding protein (MBP) and glutathione S 
transferase (GST), are preferred provided that the fusion protein can be expressed in 
soluble form. After purification of the soluble fusion protein, removal of the soluble 
fusion is essential, which is in most cases accomplished by enzymatic cleavage. The 
problem with the soluble fusion approach is that it is difficult to predict whether the 
fusion protein will be soluble or not. If the fusion protein is insoluble, the enzymatic 
cleavage will be problematic requiring detergent screening in order to solubilize the 
fusion protein, and low cleavage efficiency is often observed. Insoluble fusion 
partners have been widely used to isolate double transmembrane domains. In such a 
system usually a very hydrophobic protein is used as the fusion partner such like the 
ketosteroidisomerase (KSI). Since the final fusion protein is more hydrophobic, it will 
most likely accumulate as inclusion bodies. Inclusion bodies can alleviate the 
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normally encountered problems like toxicity and increase the final yield. Furthermore 
the formation of inclusion bodies can also prevent unwanted degradation during 
expression. Even though the insoluble fusion is a robust method, a magnificent 
problem is related to the cleavage of the fusion protein. Since the fusion protein is not 
soluble in most of the enzyme-compatible solutions, cyanogens bromide in guanidine 
chloride/acetate acid in most cases is employed193, which then requires that no 
methionine should be present in the target sequence. Hydroxylamine is another 
option, but its application has been severely hampered due to the poor unspecificity67. 
Another obstacle with the insoluble fusion method is that the overexpression levels 
are lower or even approaching undetectable levels when the target protein is getting 
large. In our experience in the case of the KSI system the yield of the fusion protein 
will decrease drastically once the target protein exceeds 100 residues. 
 
1.5.2 Direct Expression 
 
Direct expression is often used for the expression of large proteins, however 
seldom used for small ones, especially in case of double transmembrane segments, 
which approximately account for 10kDa. Direct expression frequently is confronted 
with problems such like cell toxicity, degradation and so on. However, in case of 
membrane protein fragments, the significant hydrophobicity will result in formation 
of inclusion bodies, therefore avoiding the potential cell toxicity and degradation. The 
non-fusion approach is seemingly complementary to the fusion method, which can 
not cope with large proteins. The advantage of this method is apparent: The 
chemical/enzymatic cleavage step is skipped, thus yields will increase and time will 
be saved. In addition, in case of one of our double transmembrane protein, this 
method has led to higher expression levels in comparison to the fusion method. The 
success of this method is difficult to predict.   
 
1.5.3 Strain Selection 
 
Although it is better to express the target protein in a closely related organism, 
E.coli is still the favorable expression host because of its rapid growth, the availability 
of cheap growth media, clearly defined genetics and the availability of various 
plasmids and mutant strains. Working with mammalian cells and yeast is more time 
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consuming and expensive, most importantly in case of isotope labeling essential for 
modern NMR studies, which requires media of defined composition often not 
applicable for higher organisms. The most commonly used strain is BL21 (DE3) for 
homologous expression as it is lon and OmpT protease deficient thus helping to 
stabilize the plasmid. Many derivatives on basis of BL21 (DE3) have been introduced 
that present additional advantages: BL21 (pLys) Rosetta contains a lysozyme gene 
which prevents leakage expression and contains extra copies of E.coli rare codons 
which corrects the codon usage bias; C41 (DE3) and C43 (DE3) are known to be 
suitable for expression of proteins which are toxic to the host; BL21-AI takes use of 
arabinose as the inducer, realizing extremely low leakage expression and increased 
resistance to toxicity.  
 
1.5.4 Conditions for Culturing 
 
As expression of proteins in E.coli is rarely trivial, modulating temperature, 
concentration of inducer or additives to the medium can significantly alter protein 
expression levels.  
It is well known that lower temperatures will result in more soluble protein 
expressed by cells, while higher temperature is detrimental since the additional stress 
induced at higher temperature will lead to formation of inclusion bodies. It is also 
noted that the proteolysis increases at higher temperature. 
Constructs controlled by inducible promoters are also subject to varying protein 
expression levels by altering concentrations of the inducing agent. As in the 
commonly used pET expression vector system, lowering IPTG concentrations may 
facilitate protein expression as low IPTG concentrations may cause incomplete or 
partial induction of protein synthesis. This reduction in protein synthesis has been 
associated with more reliable protein folding, subsequently improving the solubility 
of the product.  
It has been mentioned that altering the expression medium may also aid in 
membrane protein expression. Supplementing media with glucose (0.2–1%) can 
increase protein expression, since increasing glucose concentrations is believed to 
decrease promoter repression resulting in improved protein synthesis. In order to 
obtain functional membrane proteins, the ligands for the receptors can be added. 
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In summary there is no generally valid approach for the preparation of membrane 
proteins, therefore it is always important to conduct a thorough screening through 
expression methods, strain selection and culture conditions in order to reach optimal 
yields. 
 
1.5.5 Potential Problems 
 
Aggregation, polymerization and conformational exchange are detrimental for 
NMR studies, because they will result in line-broadening, duplicated or missing 
signals, variability in signal strength etc. Aggregation can arise from the high 
hydrophobicity, which can be dealt with by varyious different detergents. The 
presence of cysteines is also a common cause for aggregation, especially when 
bivalent cations are used in the purification, such like Ni+ in the affinity purification. 
Of course, addition of a reducing agent is the easiest way to eliminate such effect194. It  
has been observed that the aggregation is mainly mediated by special motifs present 
in the transmembrane domains, such like GXXXG195 and QXXS196. In the study of 
the rhodopsin receptor by solution NMR, it was observed that the backbone is in 
conformational exchange on the mili-to-micro second time scale 171; 172, however in 
some cases the conformational exchange will fall into a regime where NMR is not 
applicable any longer197; 198. In such a case, different detergents should be tried in 
order to manipulate the exchange rate. 
 
 48 
1.6 Summary of the Work Described in this Thesis 
 
The following chapters describe my Ph.D. work in logic order: chapter 2: “Studies 
of the structure of the N-terminal domain from the Y4 receptor, a G-protein coupled 
receptor, and its interaction with hormones from the NPY family”; chapter 3: 
“Properties of N-terminal domains from Y receptors probed by NMR spectroscopy”; 
chapter 4: “Biosynthesis and NMR-studies of a double transmembrane domain from 
the Y4 receptor, a human GPCR”, respectively.  
In chapter 2 I have tried studied the structure and function of the N terminus from 
the Y4 (N-Y4) receptor in order to test the hypothesis that peptide hormones of the 
NPY family bind to their G-protein coupled receptors via forming contacts to the N-
terminal domain in addition to established contacts to the extracellular loops. 
Therefore, I have produced the 41-mer peptide corresponding to the N-terminal 
domain via a recombinant method. Since initial trials for producing the target peptide 
with a soluble fusion partner led to unspecific degradation during expression, a novel 
method was employed. In brief, an insoluble fusion, ketosteroidisomerase (KSI), was 
used as the fusion partner which then results in accumulation in inclusion bodies and 
consequently avoids undesired degradation. Thereafter a detergent screening was 
conducted and sarcosyl, an anionic detergent, was finally chosen because it can 
solubilize the inclusion bodies and at the same time retain activity of the TEV 
protease that is used for the subsequent cleavage of the fusion protein. Following 
liberation from the fusion partner by TEV cleavage and conventional HPLC 
purification, sufficient quantities of the target peptide with good purity can be 
obtained. This recombinant method was for the first time used in our lab and we 
believe it can serve as a generic approach for the production of small peptides, in 
particular those that are soluble and susceptible to the unspecific cleavage during 
expression. The structural studies were carried out by solution NMR both in absence 
and in presence of membrane mimicking micelles using the 15N-labelled peptide. The 
peptide is unstructured in solution whereas a micelle-associated helical segment is 
formed in the presence of dodecylphosphocholine (DPC) or sodiumdodecylsulfate 
(SDS) micelles. The induced secondary structure in both DPC and SDS is identical, 
which suggests that induction of secondary structure is regulated mainly by 
hydrophobic interactions instead of the charged head groups of the detergents. The 
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hydrophobicity of the target sequence (poly-leucine) is consistent with this 
conclusion. A 12-carbon lipid chain was coupled to the C terminus of the peptide, 
which anchors the peptide on the membrane surface and mimics the first 
transmembrane domain. The high similarity of spectra recorded with N-Y4 and the 
lipid-modified N-Y4 demonstrates that the structure of the N-terminal domain from 
the Y4 receptor does not depend on the presence of the first transmembrane. As 
measured by surface-plasmon resonance spectroscopy (SPR) N-Y4 binds with 
approximately 50µM affinity to the pancreatic polypeptide (PP), a high-affinity ligand 
at the Y4 receptor, whereas binding to neuropeptide Y (NPY) and peptide YY (PYY) 
is much weaker. Using site-directed mutagenesis residues in PP and in N-Y4 critical 
for binding are identified. The data indicate that electrostatic interactions dominate 
and that acidic ligand and basic receptor residues are mediating this interaction. 
Residues of N-Y4 are likely to contribute to the binding of PP, and in addition may 
possibly also help to transfer the hormone from the membrane-bound state into the 
receptor binding pocket. 
In chapter 3 the production of all other N termini of Y receptors, namely N-Y1, N-
Y2, N-Y5 is described. Similar to N-Y4, N-Y1 was expressed as an insoluble fusion 
followed by TEV cleavage in presence of detergent, whereas N-Y2 and N-Y5 were 
expressed as soluble fusions to ubiquitin followed by cleavage with ubiquitin 
hydrolase in aqueous solution. All N-terminal domains including N-Y4 are fully 
flexible in aqueous buffer. The presence of phospholipid micelles rigidifies the the 
peptides to various extent, with N-Y2 remaining flexible, and N-Y1 and N-Y4 
becoming partially helically folded. Using chemical shift mapping techniques 
interactions of NPY, PYY and PP, the three members of the neurohormone family 
which are the Y receptors’ natural ligands, with N-Y1, N-Y2 and N-Y5 revealed 
chemical shift changes in all cases, with the largest values being encountered for PP 
interacting with N-Y1 or N-Y5. The strength of the interactions, however, is generally 
weak, and the data also point to non-specific electrostatic contacts.  
In chapter 4 on basis of N-Y4 a fragment from the Y4 receptor, that comprises the 
N-terminal domain, the first two transmembrane (TM) helices and the first 
extracellular loop followed by a (His)6 tag was recombinantly expressed and purified. 
The initial production trials as fusions (soluble and insoluble fusion) resulted in low 
overexpression levels, and therefore I optimized direct expression. To my knowledge 
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direct expression for the first time was applied to a membrane protein fragment. It 
yielded 6 mg protein after the final purification step. Two points were crucial in order 
to obtain the chemically and conformationally pure sample: i) a large quantity of 
reducing agent has to be added during purification to remove the aggregates formed 
by unspecific disulfide linkages; ii) RP-HPLC is indispensable to remove the SDS-
PAGE-invisible non-proteineous contaminants. Extensive detergent screening was 
required to yield good spectra, and only a combination of detergents provided optimal 
sample conditions. A detergent mixture 1% dodecylphosphocholine (DPC) / 6% 1-
palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] (LPPG) was selected 
finally. Therein, DPC provided sufficient solubility for the protein whereas LPPG 
helped improving spectral resolution. Under optimized conditions (detergent mixture, 
pH and temperature) almost complete assignment of the, including all resonances 
from the TM segments is possible. Data on internal backbone dynamics revealed that 
the fragment folded predominantly into secondary structure, which was further 
confirmed by CD spectroscopy. The presence of the TM helices was established 
based on secondary chemical shifts and sequential amide proton nuclear Overhauser 
effects. Interestingly, the properties of the N-terminal domain in this large fragment 
are highly similar to those determined by us previously on the isolated N-terminal 
domain in the presence of DPC micelles. This supports our notion that the structure of 
N-Y4 is formed independent from the presence of the first TM domain. Structural 
studies of GPCRs have been largely delayed by the intrinsic difficulties involved in 
the expression, purification and stabilization in membrane mimetics of this 
pharmaceutically important protein superfamily. Nonetheless, the 2-step model from 
Engelman has inspired structural studies using fragments of membrane proteins. In 
my thesis I have purified all the N-terminal domains from Y receptors. In addition to 
the structural studies, which suggest a significant effect of the membrane on the 
structure of these otherwise unstructured peptides, the binding studies of N-Y4 
revealed a specific recognition towards its native ligand bPP. This observation 
indicates that the N-terminal domain of the Y4 receptor might play a role in ligand 
recognition or in the ligand transfer to the receptor binding pocket. Though 2-TM 
domains have attracted increasing attention amongst structural biologists, so far only 
a handful of NMR structures are available: F1,F0-ATPase179, the bacterial mercury 
transport membrane protein180 and the human glycine receptor181. It seems that 
production of 2-TM domains, though only a fragment of the entire GPCR, is difficult. 
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The second part of my thesis describes ways how to express and purify a 2-TM 
fragment from the Y4 receptor. It also develops a method to optimize the detergent, 
and ends with a procedure that establishes sample conditions under which almost 
complete backbone assignment can be achieved. First of all, direct expression, which 
has been widely used to express the entire protein, is shown to be applicable to GPCR 
fragments. Secondly, the usage of a detergent mixture leads to much superior spectra, 
increases the choices of membrane mimetics by taking advantages of the individual 
properties of various detergents or lipids. The 2-TM fragment to our knowledge is the 
only fragment from a human GPCR described, and it is therefore of much interest to 
solve the structure of such a construct. I believe we have made substantial progress to 
achieve such an ambitious goal.  
 52 
1.7 References 
 
1. Stevens, T. J. & Arkin, I. T. (2000). Do more complex organisms have a 
greater proportion of membrane proteins in their genomes? Proteins 39, 417-
20. 
2. Boyd, D., Schierle, C. & Beckwith, J. (1998). How many membrane proteins 
are there? Protein Sci 7, 201-5. 
3. von Heijne, G. (1999). Recent advances in the understanding of membrane 
protein assembly and structure. Q Rev Biophys 32, 285-307. 
4. White, S. H. & Wimley, W. C. (1999). Membrane protein folding and 
stability: physical principles. Annu. Rev. Biophys. Biomol. Struct. 28, 319-65. 
5. Schleiff, E. & Soll, J. (2005). Membrane protein insertion: mixing eukaryotic 
and prokaryotic concepts. EMBO Rep 6, 1023-7. 
6. White, S. H. (2004). The progress of membrane protein structure 
determination. Protein Sci 13, 1948-9. 
7. Foord, S. M. (2002). Receptor classification: post genome. Curr Opin 
Pharmacol 2, 561-6. 
8. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. 
G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., 
Amanatides, P., Ballew, R. M., Huson, D. H., Wortman, J. R., Zhang, Q., 
Kodira, C. D., Zheng, X. H., Chen, L., Skupski, M., Subramanian, G., 
Thomas, P. D., Zhang, J., Gabor Miklos, G. L., Nelson, C., Broder, S., Clark, 
A. G., Nadeau, J., McKusick, V. A., Zinder, N., Levine, A. J., Roberts, R. J., 
Simon, M., Slayman, C., Hunkapiller, M., Bolanos, R., Delcher, A., Dew, I., 
Fasulo, D., Flanigan, M., Florea, L., Halpern, A., Hannenhalli, S., Kravitz, S., 
Levy, S., Mobarry, C., Reinert, K., Remington, K., Abu-Threideh, J., Beasley, 
E., Biddick, K., Bonazzi, V., Brandon, R., Cargill, M., Chandramouliswaran, 
I., Charlab, R., Chaturvedi, K., Deng, Z., Di Francesco, V., Dunn, P., Eilbeck, 
K., Evangelista, C., Gabrielian, A. E., Gan, W., Ge, W., Gong, F., Gu, Z., 
Guan, P., Heiman, T. J., Higgins, M. E., Ji, R. R., Ke, Z., Ketchum, K. A., Lai, 
Z., Lei, Y., Li, Z., Li, J., Liang, Y., Lin, X., Lu, F., Merkulov, G. V., Milshina, 
N., Moore, H. M., Naik, A. K., Narayan, V. A., Neelam, B., Nusskern, D., 
Rusch, D. B., Salzberg, S., Shao, W., Shue, B., Sun, J., Wang, Z., Wang, A., 
Wang, X., Wang, J., Wei, M., Wides, R., Xiao, C., Yan, C., et al. (2001). The 
sequence of the human genome. Science 291, 1304-51. 
9. Jacoby, E., Bouhelal, R., Gerspacher, M. & Seuwen, K. (2006). The 7 TM G-
protein-coupled receptor target family. ChemMedChem 1, 761-82. 
10. Hopkins, A. L. & Groom, C. R. (2002). The druggable genome. Nat Rev Drug 
Discov 1, 727-30. 
11. Horn, F., Bettler, E., Oliveira, L., Campagne, F., Cohen, F. E. & Vriend, G. 
(2003). GPCRDB information system for G protein-coupled receptors. 
Nucleic Acids Res 31, 294-7. 
12. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. & Schioth, H. B. (2003). 
The G-protein-coupled receptors in the human genome form five main 
families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol 
Pharmacol 63, 1256-72. 
13. Lagerstrom, M. C. & Schioth, H. B. (2008). Structural diversity of G protein-
coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7, 
339-57. 
 53 
14. Harmar, A. J. (2001). Family-B G-protein-coupled receptors. Genome Biol 2, 
REVIEWS3013. 
15. Baneres, J. L., Martin, A., Hullot, P., Girard, J. P., Rossi, J. C. & Parello, J. 
(2003). Structure-based analysis of GPCR function: conformational adaptation 
of both agonist and receptor upon leukotriene B4 binding to recombinant 
BLT1. J Mol Biol 329, 801-14. 
16. Kiefer, H., Vogel, R. & Maier, K. (2000). Bacterial expression of G-protein-
coupled receptors: prediction of expression levels from sequence. Receptors 
Channels 7, 109-19. 
17. Weiss, H. M. & Grisshammer, R. (2002). Purification and characterization of 
the human adenosine A(2a) receptor functionally expressed in Escherichia 
coli. Eur J Biochem 269, 82-92. 
18. Grisshammer, R., White, J. F., Trinh, L. B. & Shiloach, J. (2005). Large-scale 
expression and purification of a G-protein-coupled receptor for structure 
determination -- an overview. J Struct Funct Genomics 6, 159-63. 
19. Sarramegna, V., Talmont, F., Demange, P. & Milon, A. (2003). Heterologous 
expression of G-protein-coupled receptors: comparison of expression systems 
fron the standpoint of large-scale production and purification. Cell Mol Life 
Sci 60, 1529-46. 
20. Klammt, C., Schwarz, D., Eifler, N., Engel, A., Piehler, J., Haase, W., Hahn, 
S., Dotsch, V. & Bernhard, F. (2007). Cell-free production of G protein-
coupled receptors for functional and structural studies. J Struct Biol 158, 482-
93. 
21. Eroglu, C., Cronet, P., Panneels, V., Beaufils, P. & Sinning, I. (2002). 
Functional reconstitution of purified metabotropic glutamate receptor 
expressed in the fly eye. EMBO Rep 3, 491-6. 
22. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, 
B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. 
& Miyano, M. (2000). Crystal structure of rhodopsin: A G protein-coupled 
receptor. Science 289, 739-45. 
23. Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H. W. & Ernst, O. P. (2008). 
Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature. 
24. Murakami, M. & Kouyama, T. (2008). Crystal structure of squid rhodopsin. 
Nature 453, 363-7. 
25. Rosenbaum, D. M., Cherezov, V., Hanson, M. A., Rasmussen, S. G., Thian, F. 
S., Kobilka, T. S., Choi, H. J., Yao, X. J., Weis, W. I., Stevens, R. C. & 
Kobilka, B. K. (2007). GPCR engineering yields high-resolution structural 
insights into beta2-adrenergic receptor function. Science 318, 1266-73. 
26. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. 
S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K. & 
Stevens, R. C. (2007). High-resolution crystal structure of an engineered 
human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-65. 
27. Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, 
P. C., Henderson, R., Leslie, A. G., Tate, C. G. & Schertler, G. F. (2008). 
Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454, 486-
91. 
28. Tian, C., Breyer, R. M., Kim, H. J., Karra, M. D., Friedman, D. B., Karpay, A. 
& Sanders, C. R. (2005). Solution NMR spectroscopy of the human 
vasopressin V2 receptor, a G protein-coupled receptor. J Am Chem Soc 127, 
8010-1. 
 54 
29. Gautier, A., Kirkpatrick, J. P. & Nietlispach, D. (2008). Solution-state NMR 
spectroscopy of a seven-helix transmembrane protein receptor: backbone 
assignment, secondary structure, and dynamics. Angew Chem Int Ed Engl 47, 
7297-300. 
30. Werner, K., Richter, C., Klein-Seetharaman, J. & Schwalbe, H. (2008). 
Isotope labeling of mammalian GPCRs in HEK293 cells and characterization 
of the C-terminus of bovine rhodopsin by high resolution liquid NMR 
spectroscopy. J Biomol NMR 40, 49-53. 
31. Maggio, R., Vogel, Z. & Wess, J. (1993). Reconstitution of functional 
muscarinic receptors by co-expression of amino- and carboxyl-terminal 
receptor fragments. FEBS Lett 319, 195-200. 
32. Hebert, T. E., Moffett, S., Morello, J. P., Loisel, T. P., Bichet, D. G., Barret, 
C. & Bouvier, M. (1996). A peptide derived from a beta2-adrenergic receptor 
transmembrane domain inhibits both receptor dimerization and activation. J 
Biol Chem 271, 16384-92. 
33. Marshall, F. H., Jones, K. A., Kaupmann, K. & Bettler, B. (1999). GABAB 
receptors - the first 7TM heterodimers. Trends Pharmacol Sci 20, 396-9. 
34. Bulenger, S., Marullo, S. & Bouvier, M. (2005). Emerging role of homo- and 
heterodimerization in G-protein-coupled receptor biosynthesis and maturation. 
Trends Pharmacol Sci 26, 131-7. 
35. Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A., Engel, A. & Palczewski, 
K. (2003). Atomic-force microscopy: Rhodopsin dimers in native disc 
membranes. Nature 421, 127-8. 
36. George, S. R., Fan, T., Xie, Z., Tse, R., Tam, V., Varghese, G. & O'Dowd, B. 
F. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of 
novel functional properties. J Biol Chem 275, 26128-35. 
37. Gomes, I., Gupta, A., Filipovska, J., Szeto, H. H., Pintar, J. E. & Devi, L. A. 
(2004). A role for heterodimerization of mu and delta opiate receptors in 
enhancing morphine analgesia. Proc Natl Acad Sci U S A 101, 5135-9. 
38. Ribas, C., Penela, P., Murga, C., Salcedo, A., Garcia-Hoz, C., Jurado-Pueyo, 
M., Aymerich, I. & Mayor, F., Jr. (2007). The G protein-coupled receptor 
kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. 
Biochim Biophys Acta 1768, 913-22. 
39. Shenoy, S. K. & Lefkowitz, R. J. (2005). Seven-transmembrane receptor 
signaling through beta-arrestin. Sci STKE 2005, cm10. 
40. Morii, H. & Watanabe, Y. (1992). A possible role of carbohydrate moieties in 
prostaglandin D2 and prostaglandin E2 receptor proteins from the porcine 
temporal cortex. Arch Biochem Biophys 292, 121-7. 
41. Nakagawa, M., Miyamoto, T., Kusakabe, R., Takasaki, S., Takao, T., 
Shichida, Y. & Tsuda, M. (2001). O-Glycosylation of G-protein-coupled 
receptor, octopus rhodopsin. Direct analysis by FAB mass spectrometry. 
FEBS Lett 496, 19-24. 
42. Innamorati, G., Sadeghi, H. & Birnbaumer, M. (1996). A fully active 
nonglycosylated V2 vasopressin receptor. Mol Pharmacol 50, 467-73. 
43. Russo, D., Chazenbalk, G. D., Nagayama, Y., Wadsworth, H. L. & Rapoport, 
B. (1991). Site-directed mutagenesis of the human thyrotropin receptor: role 
of asparagine-linked oligosaccharides in the expression of a functional 
receptor. Mol Endocrinol 5, 29-33. 
44. Dattatreyamurty, B. & Reichert, L. E., Jr. (1992). Carbohydrate moiety of 
follitropin receptor is not required for high affinity hormone-binding or for 
 55 
functional coupling between receptor and guanine nucleotide-binding protein 
in bovine calf testis membranes. Endocrinology 131, 2437-45. 
45. Rens-Domiano, S. & Reisine, T. (1991). Structural analysis and functional 
role of the carbohydrate component of somatostatin receptors. J Biol Chem 
266, 20094-102. 
46. Kaushal, S., Ridge, K. D. & Khorana, H. G. (1994). Structure and function in 
rhodopsin: the role of asparagine-linked glycosylation. Proc Natl Acad Sci U S 
A 91, 4024-8. 
47. Rands, E., Candelore, M. R., Cheung, A. H., Hill, W. S., Strader, C. D. & 
Dixon, R. A. (1990). Mutational analysis of beta-adrenergic receptor 
glycosylation. J Biol Chem 265, 10759-64. 
48. Benya, R. V., Fathi, Z., Kusui, T., Pradhan, T., Battey, J. F. & Jensen, R. T. 
(1994). Gastrin-releasing peptide receptor-induced internalization, down-
regulation, desensitization, and growth: possible role for cyclic AMP. Mol 
Pharmacol 46, 235-45. 
49. Fukushima, Y., Oka, Y., Saitoh, T., Katagiri, H., Asano, T., Matsuhashi, N., 
Takata, K., van Breda, E., Yazaki, Y. & Sugano, K. (1995). Structural and 
functional analysis of the canine histamine H2 receptor by site-directed 
mutagenesis: N-glycosylation is not vital for its action. Biochem J 310 ( Pt 2), 
553-8. 
50. Piersen, C. E., True, C. D. & Wells, J. N. (1994). A carboxyl-terminally 
truncated mutant and nonglycosylated A2a adenosine receptors retain ligand 
binding. Mol Pharmacol 45, 861-70. 
51. Servant, G., Dudley, D. T., Escher, E. & Guillemette, G. (1996). Analysis of 
the role of N-glycosylation in cell-surface expression and binding properties 
of angiotensin II type-2 receptor of rat pheochromocytoma cells. Biochem J 
313 ( Pt 1), 297-304. 
52. Kowarik, M., Young, N. M., Numao, S., Schulz, B. L., Hug, I., Callewaert, 
N., Mills, D. C., Watson, D. C., Hernandez, M., Kelly, J. F., Wacker, M. & 
Aebi, M. (2006). Definition of the bacterial N-glycosylation site consensus 
sequence. EMBO J 25, 1957-66. 
53. Karnik, S. S., Ridge, K. D., Bhattacharya, S. & Khorana, H. G. (1993). 
Palmitoylation of bovine opsin and its cysteine mutants in COS cells. Proc 
Natl Acad Sci U S A 90, 40-4. 
54. Fukushima, Y., Saitoh, T., Anai, M., Ogihara, T., Inukai, K., Funaki, M., 
Sakoda, H., Onishi, Y., Ono, H., Fujishiro, M., Ishikawa, T., Takata, K., 
Nagai, R., Omata, M. & Asano, T. (2001). Palmitoylation of the canine 
histamine H2 receptor occurs at Cys(305) and is important for cell surface 
targeting. Biochim Biophys Acta 1539, 181-91. 
55. Percherancier, Y., Planchenault, T., Valenzuela-Fernandez, A., Virelizier, J. 
L., Arenzana-Seisdedos, F. & Bachelerie, F. (2001). Palmitoylation-dependent 
control of degradation, life span, and membrane expression of the CCR5 
receptor. J Biol Chem 276, 31936-44. 
56. Gao, Z., Ni, Y., Szabo, G. & Linden, J. (1999). Palmitoylation of the 
recombinant human A1 adenosine receptor: enhanced proteolysis of 
palmitoylation-deficient mutant receptors. Biochem J 342 ( Pt 2), 387-95. 
57. O'Brien, P. J. & Zatz, M. (1984). Acylation of bovine rhodopsin by 
[3H]palmitic acid. J Biol Chem 259, 5054-7. 
58. O'Dowd, B. F., Hnatowich, M., Caron, M. G., Lefkowitz, R. J. & Bouvier, M. 
(1989). Palmitoylation of the human beta 2-adrenergic receptor. Mutation of 
 56 
Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of 
the receptor. J Biol Chem 264, 7564-9. 
59. Chen, C., Shahabi, V., Xu, W. & Liu-Chen, L. Y. (1998). Palmitoylation of 
the rat mu opioid receptor. FEBS Lett 441, 148-52. 
60. Monteclaro, F. S. & Charo, I. F. (1997). The amino-terminal domain of CCR2 
is both necessary and sufficient for high affinity binding of monocyte 
chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J 
Biol Chem 272, 23186-90. 
61. Michel, M. C., Beck-Sickinger, A., Cox, H., Doods, H. N., Herzog, H., 
Larhammar, D., Quirion, R., Schwartz, T. & Westfall, T. (1998). XVI. 
International Union of Pharmacology recommendations for the nomenclature 
of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. 
Pharmacol Rev 50, 143-50. 
62. Gregor, P., Feng, Y., DeCarr, L. B., Cornfield, L. J. & McCaleb, M. L. (1996). 
Molecular characterization of a second mouse pancreatic polypeptide receptor 
and its inactivated human homologue. J Biol Chem 271, 27776-81. 
63. Larhammar, D. & Salaneck, E. (2004). Molecular evolution of NPY receptor 
subtypes. Neuropeptides 38, 141-51. 
64. Bromee, T., Sjodin, P., Fredriksson, R., Boswell, T., Larsson, T. A., Salaneck, 
E., Zoorob, R., Mohell, N. & Larhammar, D. (2006). Neuropeptide Y-family 
receptors Y6 and Y7 in chicken. Cloning, pharmacological characterization, 
tissue distribution and conserved synteny with human chromosome region. 
FEBS J 273, 2048-63. 
65. Larhammar, D., Wraith, A., Berglund, M. M., Holmberg, S. K. & Lundell, I. 
(2001). Origins of the many NPY-family receptors in mammals. Peptides 22, 
295-307. 
66. Berglund, M. M., Lundell, I., Eriksson, H., Soll, R., Beck-Sickinger, A. G. & 
Larhammar, D. (2001). Studies of the human, rat, and guinea pig Y4 receptors 
using neuropeptide Y analogues and two distinct radioligands. Peptides 22, 
351-6. 
67. Cabrele, C., Wieland, H. A., Langer, M., Stidsen, C. E. & Beck-Sickinger, A. 
G. (2001). Y-receptor affinity modulation by the design of pancreatic 
polypeptide/neuropeptide Y chimera led to Y(5)-receptor ligands with 
picomolar affinity. Peptides 22, 365-78. 
68. McCrea, K., Wisialowski, T., Cabrele, C., Church, B., Beck-Sickinger, A., 
Kraegen, E. & Herzog, H. (2000). 2-36[K4,RYYSA(19-23)]PP a novel Y5-
receptor preferring ligand with strong stimulatory effect on food intake. Regul 
Pept 87, 47-58. 
69. Pedrazzini, T., Seydoux, J., Kunstner, P., Aubert, J. F., Grouzmann, E., 
Beermann, F. & Brunner, H. R. (1998). Cardiovascular response, feeding 
behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat 
Med 4, 722-6. 
70. Thiele, T. E., Koh, M. T. & Pedrazzini, T. (2002). Voluntary alcohol 
consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci 22, 
RC208. 
71. Wheway, J., Herzog, H. & Mackay, F. (2007). NPY and receptors in immune 
and inflammatory diseases. Curr Top Med Chem 7, 1743-52. 
72. Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., 
Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., Cone, R. 
 57 
D. & Bloom, S. R. (2002). Gut hormone PYY(3-36) physiologically inhibits 
food intake. Nature 418, 650-4. 
73. Malmstrom, R. E., Hokfelt, T., Bjorkman, J. A., Nihlen, C., Bystrom, M., 
Ekstrand, A. J. & Lundberg, J. M. (1998). Characterization and molecular 
cloning of vascular neuropeptide Y receptor subtypes in pig and dog. Regul 
Pept 75-76, 55-70. 
74. Zukowska-Grojec, Z., Karwatowska-Prokopczuk, E., Rose, W., Rone, J., 
Movafagh, S., Ji, H., Yeh, Y., Chen, W. T., Kleinman, H. K., Grouzmann, E. 
& Grant, D. S. (1998). Neuropeptide Y: a novel angiogenic factor from the 
sympathetic nerves and endothelium. Circ Res 83, 187-95. 
75. Naveilhan, P., Hassani, H., Canals, J. M., Ekstrand, A. J., Larefalk, A., 
Chhajlani, V., Arenas, E., Gedda, K., Svensson, L., Thoren, P. & Ernfors, P. 
(1999). Normal feeding behavior, body weight and leptin response require the 
neuropeptide Y Y2 receptor. Nat Med 5, 1188-93. 
76. Sainsbury, A., Schwarzer, C., Couzens, M., Fetissov, S., Furtinger, S., 
Jenkins, A., Cox, H. M., Sperk, G., Hokfelt, T. & Herzog, H. (2002). 
Important role of hypothalamic Y2 receptors in body weight regulation 
revealed in conditional knockout mice. Proc Natl Acad Sci U S A 99, 8938-43. 
77. Schober, D. A., Van Abbema, A. M., Smiley, D. L., Bruns, R. F. & Gehlert, 
D. R. (1998). The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist 
for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides 
19, 537-42. 
78. Ishihara, A., Kanatani, A., Mashiko, S., Tanaka, T., Hidaka, M., Gomori, A., 
Iwaasa, H., Murai, N., Egashira, S., Murai, T., Mitobe, Y., Matsushita, H., 
Okamoto, O., Sato, N., Jitsuoka, M., Fukuroda, T., Ohe, T., Guan, X., 
MacNeil, D. J., Van der Ploeg, L. H., Nishikibe, M., Ishii, Y., Ihara, M. & 
Fukami, T. (2006). A neuropeptide Y Y5 antagonist selectively ameliorates 
body weight gain and associated parameters in diet-induced obese mice. Proc 
Natl Acad Sci U S A 103, 7154-8. 
79. Marsh, D. J., Hollopeter, G., Kafer, K. E. & Palmiter, R. D. (1998). Role of 
the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4, 718-21. 
80. Kitlinska, J., Abe, K., Kuo, L., Pons, J., Yu, M., Li, L., Tilan, J., Everhart, L., 
Lee, E. W., Zukowska, Z. & Toretsky, J. A. (2005). Differential effects of 
neuropeptide Y on the growth and vascularization of neural crest-derived 
tumors. Cancer Res 65, 1719-28. 
81. Korner, M., Waser, B. & Reubi, J. C. (2004). High expression of neuropeptide 
y receptors in tumors of the human adrenal gland and extra-adrenal 
paraganglia. Clin Cancer Res 10, 8426-33. 
82. Korner, M., Waser, B. & Reubi, J. C. (2004). Neuropeptide Y receptor 
expression in human primary ovarian neoplasms. Lab Invest 84, 71-80. 
83. Reubi, J. C., Korner, M., Waser, B., Mazzucchelli, L. & Guillou, L. (2004). 
High expression of peptide receptors as a novel target in gastrointestinal 
stromal tumours. Eur J Nucl Med Mol Imaging 31, 803-10. 
84. Korner, M. & Reubi, J. C. (2007). NPY receptors in human cancer: A review 
of current knowledge. Peptides 28, 419-25. 
85. Kamiji, M. M. & Inui, A. (2007). Neuropeptide y receptor selective ligands in 
the treatment of obesity. Endocr Rev 28, 664-84. 
86. Cabrele, C., Langer, M., Bader, R., Wieland, H. A., Doods, H. N., Zerbe, O. & 
Beck-Sickinger, A. G. (2000). The first selective agonist for the neuropeptide 
Y Y5 receptor increases food intake in rats. J Biol Chem 275, 36043-8. 
 58 
87. Balasubramaniam, A., Mullins, D. E., Lin, S., Zhai, W., Tao, Z., Dhawan, V. 
C., Guzzi, M., Knittel, J. J., Slack, K., Herzog, H. & Parker, E. M. (2006). 
Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): 
development of an anorectic Y4 receptor selective agonist with picomolar 
affinity. J Med Chem 49, 2661-5. 
88. Sautel, M., Martinez, R., Munoz, M., Peitsch, M. C., Beck-Sickinger, A. G. & 
Walker, P. (1995). Role of a hydrophobic pocket of the human Y1 
neuropeptide Y receptor in ligand binding. Mol Cell Endocrinol 112, 215-22. 
89. Walker, P., Munoz, M., Martinez, R. & Peitsch, M. C. (1994). Acidic residues 
in extracellular loops of the human Y1 neuropeptide Y receptor are essential 
for ligand binding. J Biol Chem 269, 2863-9. 
90. Nakamura, M., Sakanaka, C., Aoki, Y., Ogasawara, H., Tsuji, T., Kodama, H., 
Matsumoto, T., Shimizu, T. & Noma, M. (1995). Identification of two 
isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative 
splicing. Isolation, genomic structure, and functional expression of the 
receptors. J Biol Chem 270, 30102-10. 
91. Fuhlendorff, J., Gether, U., Aakerlund, L., Langeland-Johansen, N., 
Thogersen, H., Melberg, S. G., Olsen, U. B., Thastrup, O. & Schwartz, T. W. 
(1990). [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc 
Natl Acad Sci U S A 87, 182-6. 
92. Potter, E. K., Fuhlendorff, J. & Schwartz, T. W. (1991). [Pro34]neuropeptide 
Y selectively identifies postjunctional-mediated actions of neuropeptide Y in 
vivo in rats and dogs. Eur J Pharmacol 193, 15-9. 
93. Balasubramaniam, A., Sheriff, S., Johnson, M. E., Prabhakaran, M., Huang, 
Y., Fischer, J. E. & Chance, W. T. (1994). [D-TRP32]neuropeptide Y: a 
competitive antagonist of NPY in rat hypothalamus. J Med Chem 37, 811-5. 
94. Lindner, D., van Dieck, J., Merten, N., Morl, K., Gunther, R., Hofmann, H. J. 
& Beck-Sickinger, A. G. (2008). GPC receptors and not ligands decide the 
binding mode in neuropeptide Y multireceptor/multiligand system. 
Biochemistry 47, 5905-14. 
95. Munch, G., Walker, P., Shine, J. & Herzog, H. (1995). Ligand binding 
analysis of human neuropeptide Y1 receptor mutants expressed in E. coli. 
Receptors Channels 3, 291-7. 
96. Gaudin, P., Couvineau, A., Maoret, J. J., Rouyer-Fessard, C. & Laburthe, M. 
(1995). Mutational analysis of cysteine residues within the extracellular 
domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies 
seven mutants that are defective in VIP binding. Biochem Biophys Res 
Commun 211, 901-8. 
97. Laburthe, M., Couvineau, A. & Marie, J. C. (2002). VPAC receptors for VIP 
and PACAP. Receptors Channels 8, 137-53. 
98. Sun, C., Song, D., Davis-Taber, R. A., Barrett, L. W., Scott, V. E., 
Richardson, P. L., Pereda-Lopez, A., Uchic, M. E., Solomon, L. R., Lake, M. 
R., Walter, K. A., Hajduk, P. J. & Olejniczak, E. T. (2007). Solution structure 
and mutational analysis of pituitary adenylate cyclase-activating polypeptide 
binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci U S A 
104, 7875-80. 
99. Cheng, Y., Legall, T., Oldfield, C. J., Mueller, J. P., Van, Y. Y., Romero, P., 
Cortese, M. S., Uversky, V. N. & Dunker, A. K. (2006). Rational drug design 
via intrinsically disordered protein. Trends Biotechnol 24, 435-42. 
 59 
100. Tompa, P. (2002). Intrinsically unstructured proteins. Trends Biochem Sci 27, 
527-33. 
101. Sigalov, A. B., Aivazian, D. A., Uversky, V. N. & Stern, L. J. (2006). Lipid-
Binding Activity of Intrinsically Unstructured Cytoplasmic Domains of 
Multichain Immune Recognition Receptor Signaling Subunits. Biochemistry 
45, 15731-15739. 
102. Ho, H. H., Du, D. & Gershengorn, M. C. (1999). The N terminus of Kaposi's 
sarcoma-associated herpesvirus G protein-coupled receptor is necessary for 
high affinity chemokine binding but not for constitutive activity. J Biol Chem 
274, 31327-32. 
103. Prado, G. N., Suetomi, K., Shumate, D., Maxwell, C., Ravindran, A., 
Rajarathnam, K. & Navarro, J. (2007). Chemokine signaling specificity: 
essential role for the N-terminal domain of chemokine receptors. Biochemistry 
46, 8961-8. 
104. Andersson, H., D'Antona, A. M., Kendall, D. A., Von Heijne, G. & Chin, C. 
N. (2003). Membrane assembly of the cannabinoid receptor 1: impact of a 
long N-terminal tail. Mol Pharmacol 64, 570-7. 
105. Dong, M., Ding, X. Q., Thomas, S. E., Gao, F., Lam, P. C., Abagyan, R. & 
Miller, L. J. (2007). Role of Lysine(187) within the Second Extracellular Loop 
of the Type A Cholecystokinin Receptor in Agonist-Induced Activation. Use 
of Complementary Charge-Reversal Mutagenesis To Define a Functionally 
Important Interdomain Interaction. Biochemistry 46, 4522-31. 
106. Gupta, A., Decaillot, F. M., Gomes, I., Tkalych, O., Heimann, A. S., Ferro, E. 
S. & Devi, L. A. (2007). Conformation state-sensitive antibodies to G-protein-
coupled receptors. J Biol Chem 282, 5116-24. 
107. Larhammar, D. (1996). Evolution of neuropeptide Y, peptide YY and 
pancreatic polypeptide. Regul Pept 62, 1-11. 
108. Gray, T. S. & Morley, J. E. (1986). Neuropeptide Y: anatomical distribution 
and possible function in mammalian nervous system. Life Sci 38, 389-401. 
109. Ruscica, M., Dozio, E., Motta, M. & Magni, P. (2007). Relevance of the 
neuropeptide Y system in the biology of cancer progression. Curr Top Med 
Chem 7, 1682-91. 
110. Pedrazzini, T. (2004). Importance of NPY Y1 receptor-mediated pathways: 
assessment using NPY Y1 receptor knockouts. Neuropeptides 38, 267-75. 
111. Ekblad, E. & Sundler, F. (2002). Distribution of pancreatic polypeptide and 
peptide YY. Peptides 23, 251-61. 
112. Eberlein, G. A., Eysselein, V. E., Schaeffer, M., Layer, P., Grandt, D., 
Goebell, H., Niebel, W., Davis, M., Lee, T. D., Shively, J. E. & et al. (1989). 
A new molecular form of PYY: structural characterization of human PYY(3-
36) and PYY(1-36). Peptides 10, 797-803. 
113. Lin, H. C. & Chey, W. Y. (2003). Cholecystokinin and peptide YY are 
released by fat in either proximal or distal small intestine in dogs. Regul Pept 
114, 131-5. 
114. Schwartz, T. W. & Tager, H. S. (1981). Isolation and biogenesis of a new 
peptide from pancreatic islets. Nature 294, 589-91. 
115. Schmidt, P. T., Naslund, E., Gryback, P., Jacobsson, H., Holst, J. J., Hilsted, 
L. & Hellstrom, P. M. (2005). A role for pancreatic polypeptide in the 
regulation of gastric emptying and short-term metabolic control. J Clin 
Endocrinol Metab 90, 5241-6. 
 60 
116. Li, X. A., Sutcliffe, M. J., Schwartz, T. W. & Dobson, C. M. (1992). 
Sequence-specific 1H NMR assignments and solution structure of bovine 
pancreatic polypeptide. Biochemistry 31, 1245-53. 
117. Frerker, N., Wagner, L., Wolf, R., Heiser, U., Hoffmann, T., Rahfeld, J. U., 
Schade, J., Karl, T., Naim, H. Y., Alfalah, M., Demuth, H. U. & von Horsten, 
S. (2007). Neuropeptide Y (NPY) cleaving enzymes: Structural and functional 
homologues of dipeptidyl peptidase 4. Peptides 28, 257-68. 
118. Grandt, D., Siewert, J., Sieburg, B., al Tai, O., Schimiczek, M., Goebell, H., 
Layer, P., Eysselein, V. E., Reeve, J. R., Jr. & Muller, M. K. (1995). Peptide 
YY inhibits exocrine pancreatic secretion in isolated perfused rat pancreas by 
Y1 receptors. Pancreas 10, 180-6. 
119. Gue, M., Junien, J. L., Reeve, J. R., Jr., Rivier, J., Grandt, D. & Tache, Y. 
(1996). Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY 
of intracisternal CRF-induced inhibition of gastric acid secretion in rats. Br J 
Pharmacol 118, 237-42. 
120. Blundell, T. L., Pitts, J. E., Tickle, I. J., Wood, S. P. & Wu, C.-W. (1981). X-
ray analysis (1.4 Å resolution) of avian pancreatic polypeptide: Small globular 
protein hormone. Proc Natl Acad Sci U S A 78, 4175-79. 
121. Monks, S. A., Karagianis, G., Howlett, G. J. & Norton, R. S. (1996). Solution 
structure of human neuropeptide Y. J. Biomol. NMR 8, 379-90. 
122. Bettio, A., Dinger, M. C. & Beck-Sickinger, A. G. (2002). The neuropeptide 
Y monomer in solution is not folded in the pancreatic- polypeptide fold. 
Protein Sci 11, 1834-44. 
123. Bader, R., Bettio, A., Beck-Sickinger, A. G. & Zerbe, O. (2001).Structure and 
dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY 
and implications for receptor selection. J Mol Biol 305, 307-392. 
124. Lerch, M., Mayrhofer, M. & Zerbe, O. (2004). Structural similarities of 
micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to 
their affinity profiles at the Y receptors. J Mol Biol 339, 1153-68. 
125. Lerch, M., Gafner, V., Bader, R., Christen, B., Folkers, G. & Zerbe, O. (2002). 
Bovine pancreatic polypeptide (bPP) undergoes significant changes in 
conformation and dynamics upon binding to DPC micelles. J Mol Biol 322, 
1117-33. 
126. Seddon, A. M., Curnow, P. & Booth, P. J. (2004). Membrane proteins, lipids 
and detergents: not just a soap opera. Biochim Biophys Acta 1666, 105-17. 
127. Bader, R., Rytz, G., Lerch, M., Beck-Sickinger, A. G. & Zerbe, O. (2002). 
Key Motif to Gain Selectivity at the Neuropeptide Y5-Receptor: Solution 
Structure and Dynamics of [Ala31,Pro32]-NPY. Biochemistry 41, 8031-42. 
128. Beck-Sickinger, A. G., Wieland, H. A., Wittneben, H., Willim, K. D., Rudolf, 
K. & Jung, G. (1994). Complete L-alanine scan of neuropeptide Y reveals 
ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur 
J Biochem 225, 947-58. 
129. Schwyzer, R. (1991). Peptide-membrane interactions and a new principle in 
quantitative structure-activity relationships. Biopolymers 31, 785-92. 
130. Schwyzer, R. (1995). In search of the 'bio-active conformation'--is it induced 
by the target cell membrane? J.  Mol. Recognit. 8, 3-8. 
131. Kaiser, E. T. & Kezdy, F. J. (1984). Amphiphilic secondary structure: design 
of peptide hormones. Science 223, 249-55. 
132. Kaiser, E. T. & Kezdy, F. J. (1983). Secondary structures of proteins and 
peptides in amphiphilic environments. Proc Natl Acad Sci U S A 80, 1137-43. 
 61 
133. Bader, R. & Zerbe, O. (2005). Are hormones from the neuropeptide Y family 
recognized by their receptors from the membrane-bound state? ChemBioChem 
6, 1520-34. 
134. Lerch, M., Kamimori, H., Folkers, G., Aguilar, M.-I., Beck-Sickinger, A. G. & 
Zerbe, O. (2005). Strongly Altered Receptor Binding Properties in PP and 
NPY Chimera are Accompanied by Changes in Structure and Membrane 
Binding. Biochemistry 44, 9255 - 9264. 
135. Popot, J. L. & Engelman, D. M. (1990). Membrane protein folding and 
oligomerization: the two-stage model. Biochemistry 29, 4031-7. 
136. Popot, J. L. & Engelman, D. M. (2000). Helical membrane protein folding, 
stability, and evolution. Annu Rev Biochem 69, 881-922. 
137. Huang, K. S., Bayley, H., Liao, M. J., London, E. & Khorana, H. G. (1981). 
Refolding of an integral membrane protein. Denaturation, renaturation, and 
reconstitution of intact bacteriorhodopsin and two proteolytic fragments. J 
Biol Chem 256, 3802-9. 
138. Kahn, T. W. & Engelman, D. M. (1992). Bacteriorhodopsin can be refolded 
from two independently stable transmembrane helices and the complementary 
five-helix fragment. Biochemistry 31, 6144-51. 
139. Ridge, K. D., Lee, S. S. & Yao, L. L. (1995). In vivo assembly of rhodopsin 
from expressed polypeptide fragments. Proc Natl Acad Sci U S A 92, 3204-8. 
140. Martin, N. P., Leavitt, L. M., Sommers, C. M. & Dumont, M. E. (1999). 
Assembly of G protein-coupled receptors from fragments: identification of 
functional receptors with discontinuities in each of the loops connecting 
transmembrane segments. Biochemistry 38, 682-95. 
141. Wrubel, W., Stochaj, U. & Ehring, R. (1994). Construction and in vivo 
analysis of new split lactose permeases. FEBS Lett 349, 433-8. 
142. Kobilka, B. K., Kobilka, T. S., Daniel, K., Regan, J. W., Caron, M. G. & 
Lefkowitz, R. J. (1988). Chimeric alpha 2-,beta 2-adrenergic receptors: 
delineation of domains involved in effector coupling and ligand binding 
specificity. Science 240, 1310-6. 
143. Schmidt-Rose, T. & Jentsch, T. J. (1997). Reconstitution of functional 
voltage-gated chloride channels from complementary fragments of CLC-1. J 
Biol Chem 272, 20515-21. 
144. Deber, C. M., Wang, C., Liu, L. P., Prior, A. S., Agrawal, S., Muskat, B. L. & 
Cuticchia, A. J. (2001). TM Finder: a prediction program for transmembrane 
protein segments using a combination of hydrophobicity and nonpolar phase 
helicity scales. Protein Sci 10, 212-9. 
145. Moller, S., Croning, M. D. & Apweiler, R. (2001). Evaluation of methods for 
the prediction of membrane spanning regions. Bioinformatics 17, 646-53. 
146. Monne, M., Nilsson, I., Elofsson, A. & von Heijne, G. (1999). Turns in 
transmembrane helices: determination of the minimal length of a "helical 
hairpin" and derivation of a fine-grained turn propensity scale. J Mol Biol 293, 
807-14. 
147. Bowie, J. U. (1997). Helix packing in membrane proteins. J Mol Biol 272, 
780-9. 
148. Hildebrand, P. W., Preissner, R. & Frommel, C. (2004). Structural features of 
transmembrane helices. FEBS Lett 559, 145-51. 
149. von Heijne, G. (1992). Membrane protein structure prediction. 
Hydrophobicity analysis and the positive-inside rule. J Mol Biol 225, 487-94. 
 62 
150. Whitley, P., Nilsson, L. & von Heijne, G. (1993). Three-dimensional model 
for the membrane domain of Escherichia coli leader peptidase based on 
disulfide mapping. Biochemistry 32, 8534-9. 
151. Landolt-Marticorena, C., Williams, K. A., Deber, C. M. & Reithmeier, R. A. 
(1993). Non-random distribution of amino acids in the transmembrane 
segments of human type I single span membrane proteins. J Mol Biol 229, 
602-8. 
152. Hong, H., Park, S., Jimenez, R. H., Rinehart, D. & Tamm, L. K. (2007). Role 
of aromatic side chains in the folding and thermodynamic stability of integral 
membrane proteins. J Am Chem Soc 129, 8320-7. 
153. Yuen, C. T., Davidson, A. R. & Deber, C. M. (2000). Role of aromatic 
residues at the lipid-water interface in micelle-bound bacteriophage M13 
major coat protein. Biochemistry 39, 16155-62. 
154. Braun, P. & von Heijne, G. (1999). The aromatic residues Trp and Phe have 
different effects on the positioning of a transmembrane helix in the 
microsomal membrane. Biochemistry 38, 9778-82. 
155. Partridge, A. W., Therien, A. G. & Deber, C. M. (2004). Missense mutations 
in transmembrane domains of proteins: phenotypic propensity of polar 
residues for human disease. Proteins 54, 648-56. 
156. Senes, A., Engel, D. E. & DeGrado, W. F. (2004). Folding of helical 
membrane proteins: the role of polar, GxxxG-like and proline motifs. Curr 
Opin Struct Biol 14, 465-79. 
157. Cordes, F. S., Bright, J. N. & Sansom, M. S. (2002). Proline-induced 
distortions of transmembrane helices. J Mol Biol 323, 951-60. 
158. Yohannan, S., Faham, S., Yang, D., Whitelegge, J. P. & Bowie, J. U. (2004). 
The evolution of transmembrane helix kinks and the structural diversity of G 
protein-coupled receptors. Proc Natl Acad Sci U S A 101, 959-63. 
159. Hessa, T., Kim, H., Bihlmaier, K., Lundin, C., Boekel, J., Andersson, H., 
Nilsson, I., White, S. H. & von Heijne, G. (2005). Recognition of 
transmembrane helices by the endoplasmic reticulum translocon. Nature 433, 
377-81. 
160. Hessa, T., Meindl-Beinker, N. M., Bernsel, A., Kim, H., Sato, Y., Lerch-
Bader, M., Nilsson, I., White, S. H. & von Heijne, G. (2007). Molecular code 
for transmembrane-helix recognition by the Sec61 translocon. Nature 450, 
1026-30. 
161. Johnson, R. M., Heslop, C. L. & Deber, C. M. (2004). Hydrophobic helical 
hairpins: design and packing interactions in membrane environments. 
Biochemistry 43, 14361-9. 
162. Johnson, R. M., Hecht, K. & Deber, C. M. (2007). Aromatic and cation-pi 
interactions enhance helix-helix association in a membrane environment. 
Biochemistry 46, 9208-14. 
163. Choi, M. Y., Cardarelli, L., Therien, A. G. & Deber, C. M. (2004). Non-native 
interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance 
regulator domain modulated by polar mutations. Biochemistry 43, 8077-83. 
164. Therien, A. G., Grant, F. E. & Deber, C. M. (2001). Interhelical hydrogen 
bonds in the CFTR membrane domain. Nat Struct Biol 8, 597-601. 
165. Monne, M., Hermansson, M. & von Heijne, G. (1999). A turn propensity scale 
for transmembrane helices. J Mol Biol 288, 141-5. 
166. Nagy, A. & Turner, R. J. (2007). The membrane integration of a naturally 
occurring alpha-helical hairpin. Biochem Biophys Res Commun 356, 392-7. 
 63 
167. Wehbi, H., Rath, A., Glibowicka, M. & Deber, C. M. (2007). Role of the 
extracellular loop in the folding of a CFTR transmembrane helical hairpin. 
Biochemistry 46, 7099-106. 
168. Hermansson, M., Monne, M. & von Heijne, G. (2001). Formation of helical 
hairpins during membrane protein integration into the endoplasmic reticulum 
membrane. Role of the N and C-terminal flanking regions. J Mol Biol 313, 
1171-9. 
169. MacKenzie, K. R., Prestegard, J. H. & Engelman, D. M. (1997). A 
transmembrane helix dimer: Structure and implications. Science 276, 131. 
170. Getmanova, E., Patel, A. B., Klein-Seetharaman, J., Loewen, M. C., Reeves, 
P. J., Friedman, N., Sheves, M., Smith, S. O. & Khorana, H. G. (2004). NMR 
spectroscopy of phosphorylated wild-type rhodopsin: mobility of the 
phosphorylated C-terminus of rhodopsin in the dark and upon light activation. 
Biochemistry 43, 1126-33. 
171. Klein-Seetharaman, J., Yanamala, N. V., Javeed, F., Reeves, P. J., Getmanova, 
E. V., Loewen, M. C., Schwalbe, H. & Khorana, H. G. (2004). Differential 
dynamics in the G protein-coupled receptor rhodopsin revealed by solution 
NMR. Proc Natl Acad Sci U S A 101, 3409-13. 
172. Klein-Seetharaman, J., Reeves, P. J., Loewen, M. C., Getmanova, E. V., 
Chung, J., Schwalbe, H., Wright, P. E. & Khorana, H. G. (2002). Solution 
NMR spectroscopy of [alpha -15N]lysine-labeled rhodopsin: The single peak 
observed in both conventional and TROSY-type HSQC spectra is ascribed to 
Lys-339 in the carboxyl-terminal peptide sequence. Proc Natl Acad Sci U S A 
99, 3452-7. 
173. Schubert, M., Kolbe, M., Kessler, B., Oesterhelt, D. & Schmieder, P. (2002). 
Heteronuclear multidimensional NMR spectroscopy of solubilized membrane 
proteins: resonance assignment of native bacteriorhodopsin. ChemBioChem 3, 
1019-23. 
174. Oxenoid, K., Kim, H. J., Jacob, J., Sonnichsen, F. D. & Sanders, C. R. (2004). 
NMR assignments for a helical 40 kDa membrane protein. J Am Chem Soc 
126, 5048-9. 
175. Bennett, M., Yeagle, J. A., Maciejewski, M., Ocampo, J. & Yeagle, P. L. 
(2004). Stability of loops in the structure of lactose permease. Biochemistry 
43, 12829-37. 
176. Katragadda, M., Alderfer, J. L. & Yeagle, P. L. (2001). Assembly of a 
polytopic membrane protein structure from the solution structures of 
overlapping peptide fragments of bacteriorhodopsin. Biophys J 81, 1029-36. 
177. Katragadda, M., Chopra, A., Bennett, M., Alderfer, J. L., Yeagle, P. L. & 
Albert, A. D. (2001). Structures of the transmembrane helices of the G-protein 
coupled receptor, rhodopsin. J Pept Res 58, 79-89. 
178. Fiaux, J., Bertelsen, E. B., Horwich, A. L. & Wuthrich, K. (2002). NMR 
analysis of a 900K GroEL GroES complex. Nature 418, 207-11. 
179. Rastogi, V. K. & Girvin, M. E. (1999). Structural changes linked to proton 
translocation by subunit c of the ATP synthase. Nature 402, 263-8. 
180. Howell, S. C., Mesleh, M. F. & Opella, S. J. (2005). NMR structure 
determination of a membrane protein with two transmembrane helices in 
micelles: MerF of the bacterial mercury detoxification system. Biochemistry 
44, 5196-206. 
 64 
181. Ma, D., Liu, Z., Li, L., Tang, P. & Xu, Y. (2005). Structure and dynamics of 
the second and third transmembrane domains of human glycine receptor. 
Biochemistry 44, 8790-800. 
182. Engelman, D. M. (2005). Membranes are more mosaic than fluid. Nature 438, 
578-80. 
183. Fernandez, C., Hilty, C., Wider, G., Güntert, P. & Wüthrich, K. (2004). NMR 
structure of the integral membrane protein OmpX. J Mol Biol 336, 1211-21. 
184. Roosild, T. P., Greenwald, J., Vega, M., Castronovo, S., Riek, R. & Choe, S. 
(2005). NMR structure of Mistic, a membrane-integrating protein for 
membrane protein expression. Science 307, 1317-21. 
185. Opella, S. J., Kim, Y. & McDonnell, P. (1994). Experimental nuclear 
magnetic resonance studies of membrane proteins. Methods in enzymology 
239, 536-560. 
186. Prosser, R. S., Hwang, J. S. & Vold, R. R. (1998). Magnetically aligned 
phospholipid bilayers with positive ordering: a new model membrane system. 
Biophys J. 74, 2405-18. 
187. Poget, S. F. & Girvin, M. E. (2007). Solution NMR of membrane proteins in 
bilayer mimics: small is beautiful, but sometimes bigger is better. Biochim 
Biophys Acta 1768, 3098-106. 
188. Zoonens, M., Catoire, L. J., Giusti, F. & Popot, J. L. (2005). NMR study of a 
membrane protein in detergent-free aqueous solution. Proc Natl Acad Sci U S 
A 102, 8893-8. 
189. Gohon, Y., Dahmane, T., Ruigrok, R. W., Schuck, P., Charvolin, D., 
Rappaport, F., Timmins, P., Engelman, D. M., Tribet, C., Popot, J. L. & Ebel, 
C. (2008). Bacteriorhodopsin/amphipol complexes: structural and functional 
properties. Biophys J 94, 3523-37. 
190. Shi, Z., Peterson, R. W. & Wand, A. J. (2005). New reverse micelle surfactant 
systems optimized for high-resolution NMR spectroscopy of encapsulated 
proteins. Langmuir 21, 10632-7. 
191. Nath, A., Atkins, W. M. & Sligar, S. G. (2007). Applications of phospholipid 
bilayer nanodiscs in the study of membranes and membrane proteins. 
Biochemistry 46, 2059-69. 
192. Lyukmanova, E. N., Shenkarev, Z. O., Paramonov, A. S., Sobol, A. G., 
Ovchinnikova, T. V., Chupin, V. V., Kirpichnikov, M. P., Blommers, M. J. & 
Arseniev, A. S. (2008). Lipid-protein nanoscale bilayers: a versatile medium 
for NMR investigations of membrane proteins and membrane-active peptides. 
J Am Chem Soc 130, 2140-1. 
193. Cohen, L. S., Arshava, B., Estephan, R., Englander, J., Kim, H., Hauser, M., 
Zerbe, O., Ceruso, M., Becker, J. M. & Naider, F. (2008). Expression and 
biophysical analysis of two double-transmembrane domain-containing 
fragments from a yeast G protein-coupled receptor. Biopolymers 90, 117-30. 
194. Getz, E. B., Xiao, M., Chakrabarty, T., Cooke, R. & Selvin, P. R. (1999). A 
comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine 
and dithiothreitol for use in protein biochemistry. Anal Biochem 273, 73-80. 
195. Russ, W. P. & Engelman, D. M. (2000). The GxxxG motif: a framework for 
transmembrane helix-helix association. J Mol Biol 296, 911-9. 
196. Sal-Man, N., Gerber, D., Bloch, I. & Shai, Y. (2007). Specificity in 
transmembrane helix-helix interactions mediated by aromatic residues. J Biol 
Chem 282, 19753-61. 
 65 
197. Sanders, C. R. & Sonnichsen, F. (2006). Solution NMR of membrane 
proteins: practice and challenges. Magn Reson Chem 44 Spec No, S24-40. 
198. Fernandez, C. & Wuthrich, K. (2003). NMR solution structure determination 
of membrane proteins reconstituted in detergent micelles. FEBS Lett 555, 144-
50. 
 
 
 66 
Chapter 2 
  
Studies of the structure of the N-terminal domain 
from the Y4 receptor, a G-protein coupled receptor, 
and its interaction with hormones from the NPY 
family 
 
2.1 Introduction 
 
Neuropeptide Y receptors, so-called Y receptors, are members of the rhodopsin-
like G-protein coupled receptor (GPCR) family 1b. The neurohormones neuropeptide 
Y (NPY), peptide YY (PYY) and the pancreatic polypeptide (PP) target a 
heterologous population of at least five different receptor subtypes Y1, Y2, Y4, Y5 
and y61. Their physiological role in the regulation of blood pressure, memory 
retention, food uptake and seizure has been demonstrated. Y4 receptors for example 
have been shown to play a pivotal role in cardiac function, glucose metabolism in 
chronic pancreatitis patients, and mediation of intestinal absorption of electrolytes and 
water.2 NPY and PYY posses a similar pharmacology displaying nanomolar affinities 
for all receptor subtypes3, whereas PP binds with very high affinity and selectivity to 
the Y4 receptor.4 
Little structural information is available for GPCRs. In fact, bovine rhodopsin for 
a long time was the only GPCR for which experimental coordinates at atomic 
resolution have been published 5 until very recently a structure for the b-adrenergic 
receptor appeared.6; 7 The data of rhodopsin confirmed the arrangement of the 7 
transmembrane (TM) bundle postulated based on the lower-resolution cryo-EM data 
8, but also revealed the non-anticipated presence of a short anti-parallel beta-sheet in 
the N-terminal domain. In contrast, the N-terminal domain of the b-adrenergic 
receptor was shown to be disordered.6  
The N-terminal domains of other GPCRs (sub)families are known to play 
important roles in ligand binding. All the hormone receptors from GPCR family 2 
contain a conserved region in the N-terminal domain, which is responsible for ligand 
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binding.9 The N termini from family 3 GPCRs are the largest among all GPCRs, 
comprising usually more than 500 amino acids.9 Grafting and mutagenesis studies 
have demonstrated conserved serine and threonine residues in these domains are 
directly involved in ligand binding.10 Surprisingly, the expressed N terminus alone 
can bind the ligand with affinity similar to the one from the full-length receptor.11  
In contrast, the N-terminal domains from family 1 GPCRs have received little 
attention, most likely because of their short length, usually less than 70 amino acids. 
However, recent studies have suggested a pivotal role of N termini from GPCRs of 
this class in ligand recognition and binding12; 13; 14. Furthermore, mutagenesis data 
highlight the prominent role of charged residues for ligand binding15; 16. Koller 
demonstrated that the N terminus of the calcitonin-like receptor is not only essential 
for binding to the ligands but also presents a determinant for ligand specificity.17 The 
35 amino-terminal residues of CCR2, expressed as a membrane-bound fusion protein, 
bind to its ligand with an affinity similar to that of the intact, wild-type receptor, 
indicating that the N terminus is sufficient for ligand binding in that case.18 Based on 
the mutagenesis data on the N terminus of CX3C receptor and previous studies, Chen 
has proposed a two-step binding model, which comprises ligand binding followed by 
receptor activation. Therein, the residues located in the N-terminal domain play 
distinct roles during the different processes19. 
Complementary to the biological work described above GPCR fragments have 
been also studied using NMR. For example, Pervushin investigated the N-terminal 
domain of bacteriorhodopsin, a protein that is structurally highly related to GPCRs, in 
SDS micelles20, and Ulfers studied the extracellular domain of the neurokinin-1 
receptor in DPC micelles21. Riek presented a high-quality 3D NMR structure of the 
extracellular domain of CRF-R2β in complex with the peptide antagonist astressin22. 
The group of Yeagle has determined conformational preferences for peptides 
corresponding to the cytosolic loops23, the 6th TM helix24 and the N-terminus23 of 
rhodopsin and Pellegrini studied the cytosolic domain25 and the extracellular loops26; 
27 of the PTH1 receptor in the presence of DPC micelles. Furthermore, we recently 
determined the conformation of a polypeptide corresponding to the 7th TM helix of 
the yeast Ste2p receptor extended by 40 residues from the cytosolic tail 28 when 
integrated into DPC micelles. 
In this work we focus on structural studies of the isolated 41 residue N terminus of 
the Y4 receptor, a family 1b GPCR that is targeted by members of the NPY family. 
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The location of this segment in the context of the entire human Y4 receptor is shown 
in snake plot in Fig. S1(see Supp. Mat.). In addition, we investigate possible 
interactions with the hormones both qualitatively and quantitatively. By limiting the 
system of the study to just the N-terminal domain and with the help of various 
biophysical methods we were able to develop a rather detailed picture, that would 
presently be difficult to achieve using the entire receptor.  Moreover, we report on the 
synthesis of the difficult to express N-terminal domain suggesting a generally useful 
method to produce these polypeptides in isotopically-labelled form. The structure of 
N-Y4 and its topology in the presence of DPC or SDS micelles was elucidated by 
high-resolution NMR techniques. While unstructured in solution, in the presence of 
micelles a hydrophobic segment associates with the micelle and folds into a a-helix. 
Chemical shift mapping revealed potential interaction sites between PP and N-Y4. 
SPR techniques quantified the strength of this interaction. Mutagenesis studies 
identified residues of PP that are likely to be important for binding N-Y4. The data 
indicate that the isolated N- Y4 is capable of weakly binding to PP, and that much of 
the binding affinity is due to electrostatic interactions. To simulate the receptor milieu 
the carboxyl terminus of N-Y4 was additionally conjugated to a C12 fatty amino 
alcohol (dodecylphospho-ethanolamine) chain thereby mimicking its conjugation to 
the first TM helix in the entire receptor. In this lipopeptide the structure of the N-Y4 
was not significantly affected. The study shows that PP associates to the flexible, 
central segment of N-Y4 and we speculate that transient binding to the N-terminal 
domain may facilitate transferring PP from the membrane-bound state into the 
receptor binding pocket.  
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2.2 Results 
2.2.1 Recombinant Production of N-Y4 
 
The N terminus of the Y4 receptor comprises 41 residues and is highly water-
soluble. However, attempts to express it in form of a soluble ubiquitin fusion in E. 
coli resulted in unspecific fragmentation. To circumvent this problem, the N-Y4 was 
expressed as a fusion to the highly insoluble protein ketosteroidisomerase (KSI), 
which resulted in accumulation of the fusion protein in inclusion bodies. A TEV 
protease cleavage site was introduced to facilitate removal of the fusion partner.29; 30 
The sequence recognized by the TEV protease is ENLYFQ with Q as the P1’ residue. 
To achieve the natural peptide sequence after cleavage, the P1’ residue was replaced 
with the first residue from the target sequence (here it is Met)31, and an additional 
GSGSGS linker was inserted to prevent steric hindrance during cleavage.  
A problem of the chosen strategy was that the fusion protein must be solubilized 
in detergent that is compatible with the active protease. After extensive detergent 
screening, we observed that the ionic detergent sarcosyl solubilizes the fusion protein 
while preserving TEV protease activity to some extent. As shown in Fig. 1 cleavage 
efficiency is around 40% allowing recovery of about 2mg of 15N-labeled N-Y4 from 
1L of culture.  
 
 
Figure 1: SDS-PAGE of the cleavage product of the ketosteroid isomerase- N-Y4 fusion after 
cleavage with the TEV protease. A size marker is shown on the left. Note that N-Y4 due to its 
small size cannot be detected on the gel. 
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2.2.2 The Structure of N-Y4 
Although the size of the N-terminal domain is rather small, reduced chemical shift 
dispersion due to the fact that the peptide in water is largely unstructured complicated 
its analysis. Nevertheless, using 3D 15N-resolved NOESY and TOCSY spectra it was 
possible to assign the 15N,1H-correlation map. Furthermore, no NOE crosspeaks 
between amide protons could be detected. Recording a second set of 2D and 3D 
spectra in the presence of DPC micelles resulted in large chemical shift changes in 
some parts of the sequence (see Fig.2).  
 
 
Figure 2: Differences of backbone amide 1H (top) and 15N (bottom) chemical shifts of N-Y4 in the 
presence and absence of DPC micelles.  
 
Moreover, sequential NOEs between amide protons as well as HaHb (i,i+3) 
contacts usually only observed in helices were seen (see Supp. Mat.). A structure 
calculation using restraints derived from the NOESY spectra revealed the presence of 
a helical stretch encompassing residues 5 to 10 (shown in Fig.3). 
To verify formation of stable secondary structure 15N{1H}-NOE spectra were 
recorded both in the absence as well as in the presence of DPC. The heteronuclear 
NOE sensibly reports on the rigidity of the backbone at the corresponding residue, 
with negative values characteristic of flexible parts and values larger than 0.5 usually 
observed in elements of secondary structure. The 15N{1H}-NOE data show dramatic 
differences in aqueous medium and DPC. Residues 1-27 have values <0 for N-Y4 in 
water whereas all of these residues have 15N{1H}-NOE values >0 in the DPC bound 
state (Fig. 4). Strikingly, residues 5-10 have a 15N{1H}-NOE >0.5. Interestingly, a 
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segment encompassing residues 26 to 33 is rather rigid, in both environments. We 
observed  
 
 
Figure 3: Comparison of the structures calculated for N-Y4 in the presence of DPC (left) or SDS 
(right) micelles (only bonds from backbone atoms are depicted). Bonds from disordered residues 
16-41 are not shown for clarity. 
 
sequential amide proton contacts in that region for almost all residues, but the 
corresponding Ha Hb (i,i+3) contacts were generally missing. When comparing 
chemical shifts of amide protons in the two environments the largest differences were 
observed in that segment that obviously becomes structured in the presence of the 
micelle, indicating the presence of a nascent helix in that part. To conclude, the N 
terminus is largely unstructured in the absence of a membrane whereas a short helical 
stretch comprising a hydrophobic segment in the N terminus of the sequence is 
formed in presence of DPC micelles.  
 
 
Figure 4: Values of the 15N{1H}-NOE of N-Y4 in plain buffer (black spheres) and in the 
presence of DPC micelles (red diamonds). Data were recorded on 1mM samples at pH=5.6, 
310K, at 700 MHz proton frequency. 
 
 72 
Considering the importance of electrostatic interactions for ligand binding and to 
investigate whether (stabilizing) interactions of the N-terminal domain with the 
membrane head groups might be formed we further initiated structural studies of N-
Y4 in the presence of SDS micelles, a negatively charged membrane mimetic. Values 
of the 15N{1H}-NOE rapidly revealed that N-Y4 was not significantly better 
structured in this environment. Moreover, a structure calculation again revealed the 
presence of an a-helix spanning the region between residues 3 to 10. NOEs between 
sequential amide protons were seen at the C-terminal end from residue 36 on, but the 
corresponding Ha,Hb (i,i+3) contacts were missing, indicating that a transient helix is 
formed towards the C terminus. Interestingly, this part in the full-length receptor is 
connected to the first TM. In general, sequential amide proton contacts in the more 
flexible regions were stronger when compared to the data recorded in the presence of 
DPC suggesting that the negatively charged surface promotes the formation of 
transient helical structures to a slightly larger extent. This fact is particularly well-
documented in the heteronuclear NOEs for residues of the segment encompassing 
residues 19-25, which is much less flexible in the presence of SDS micelles (see Fig. 
S8).  But in general the structural features of the peptide in DPC and SDS were 
similar (for more data on the SDS-recorded sample see the Supp. Mat.) 
 
2.2.3 Topology of Membrane-Association 
 
The proximity of protons of the N-terminal domain to the micelle surface was 
probed by using micelle-integrating spin labels.  The paramagnetic moiety of 5-doxyl 
stearic acid was shown to reside in the headgroup region32 Consistent with the 
assumption that structuring of the N-terminal segment is induced by binding to the 
micelle, signals from the amide moieties within that segment experienced the largest 
signal reduction (see Fig. S9). The spin-label data indicate that the N-terminal helix is 
tightly associated with the micelle, whereas the central segment makes more transient 
contacts. Motions in that region are likely limited at both ends by the adjacent 
hydrophobic residues 24-30 and the membrane-anchored N-terminal helix.  It was 
previously demonstrated that attenuations in helical regions of surface-associated 
peptides follow periodic patterns.33; 34 The present data indicate that the helical region 
is not bound in a parallel fashion to the micelle-surface. Moreover, from the lack of a 
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clear pattern in the attenuation we conclude that this part is also not anchored in a 
precisely defined mode.  
We have additionally tested whether binding of bPP to N-Y4 could possibly 
trigger dissociation of the N terminus from the micelle. However, no decrease of 
signal reduction from the spinlabel could be detected upon addition of bPP to micelle-
bound N-Y4, indicating that N-Y4-micelle contacts are largely unchanged, even in the 
presence of a large excess of bPP (concentration ratio of N-Y4 to bPP 1:30) (data not 
shown). This indicates that bPP cannot initiate detachment of N-Y4 from the micelle 
surface, supporting the view that the contact site between bPP and Y-4 is not located 
in the helical segment of Y-4 and hence does not interfere with micelle association. 
 
2.2.4 Immobilizing the N Terminus on the Membrane 
 
In the native Y4 receptor the segment that has been studied in this work is 
connected to the first TM helix. In order to address whether anchoring of N-Y4 at its 
C-terminal end to the membrane influences the structure or the binding properties of 
the N-terminal domain a lipopeptide was chemically synthesized, in which receptor 
residues 1-41 were covalently linked at their C-terminus to dodecylethanolamine to 
provide stable anchoring of the lipopeptide in the micelles. The lipopeptide was 
prepared using standard amino-acid coupling chemistry, purified, and could be tightly 
integrated into the DPC micelles. A superposition of the NOESY spectra of N-Y4 and 
the lipopeptide in the presence of DPC micelles revealed that chemical shift 
differences are exclusively observed in vicinity of the lipid attachment site. Moreover, 
cross peaks between amide protons occur at identical positions, indicating that the 
secondary structure of both the peptides is highly similar. To conclude, anchoring of 
N-Y4 onto the micelle does not influence its secondary structure, which more likely is 
determined by partitioning of residues of the hydrophobic Leu-rich segment into the 
membrane. As evident from Fig. 3 the carboxyl terminal segment of N-Y4 possesses 
high flexibility both in the presence and in the absence of DPC micelles. Whether this 
will also be true when the C-terminus is linked to the first TM helix is presently under 
investigation.   
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2.2.5 Interaction between N-Y4 and Neuropeptides from the NPY Family 
Possible interactions between peptides from the NPY family and N-Y4 were 
probed both by chemical shift mapping as well as by surface plasmon resonance 
(SPR). PP represents a natural ligand for the Y4 receptor, and accordingly the binding 
affinity between N-Y4 and PP was measured under physiological conditions (10mM 
HEPES pH 7.4, 150mM NaCl) both in absence and presence of DPC micelles. The 
data for chemical shift mapping were acquired using 15N-labeled NPY,PP or PYY and 
unlabeled N-Y4 as well as using 15N-labeled NY-4 and unlabelled neuropeptides. The 
shift mapping experiments revealed significant shift changes in the PP-N-Y4 
interaction studies (see Fig. 5). Large changes in the PP/N-Y4 system occurred close 
to positions that were later on shown to be sensitive to replacement by Ala residues 
(vide infra). In addition, the shift changes involving PYY and NPY are generally 
much smaller compared to those with PP (data not shown). 
 
 
Figure 5: Differences of chemical shifts of amide proton and nitrogen frequencies of backbone 
resonances of bPP in the presence and absence of N-Y4 (Dd= d(bPP(N-Y4)) – d (bPP) (left) and 
of N-Y4 upon addition of bPP (right). Values are computed according to Ddc(1H,15N) = SQR 
[(Dd1H)2 + 0.2*(Dd15N)2]. Positions at which mutations were performed (E4K, Q19R and E23A in 
PP and K13A, R20A and K23A in N-Y4) are indicated by grey bars. 
 
The strength of the interaction of PP with N-Y4 was quantified by SPR in absence 
of detergent. Therein, the N-terminally biotinylated neuropeptides were immobilized 
on a Streptavidin-coated chip, and the cells were flushed with solutions of N-Y4 (see 
Fig. 6). The KD derived from both kinetic and steady-state analysis was 50mM for 
bPP, whereas binding affinity for NPY and PYY was too low to be measured with 
this technique (> 1mM).  
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Figure 6: Left: SPR sensogram of the interaction of N-Y4 with bPP for various concentrations of 
N-Y4 (in the range of 5 to 100 µM). Right: Plot of the steady-state value of the sensograms vs. the 
concentration of N-Y4, used for extraction of the dissociation constant KD. 
 
Measuring binding of membrane-immobilized peptides towards N-Y4 by SPR 
methods is technically very challenging, and hence KD in the presence of micelles 
were measured using NMR data by fitting changes in chemical shifts as derived from 
peak positions of the neuropeptides in [15N,1H]-HSQC spectra in the  presence of 
varying amounts of  N-Y4. For micelle-bound bPP the KD to N-Y4 is approx. 600mM 
and experiments, in which varying amounts of PP were added to N-Y4, resulted in a 
very similar value. Apparently, the KD in the presence of micelles is much lower than 
in the absence of micelles. This is not really surprising since it presents the affinity of 
the ligand towards the N-terminal domain in the presence of competing membrane 
binding, and hence reflects the difference in binding affinity between the two sites. 
NPY and PYY possess 80% sequence identity between each other35, while PP 
only shares about 50% homology to each of them. All these neuropeptides display a 
remarkable separation of charges along the sequence: The positively charged residues 
occur in the C-terminal half of PP from almost all organisms sequenced so far (see 
Table 1). In order to identify residues that may contribute significantly to the different 
pharmacological profiles of NPY/PYY and PP at the Y4 receptor we have aligned the 
sequences. Particular attention was paid to charged or aromatic residues that are 
known to be generally involved in GPCR-ligand interactions. The N termini of all Y 
receptor subtypes are generally negatively charged with the exception of N-Y4 that 
contains a net positive charge (see Table 1). Considering the high number of positive 
charges in N-Y4 and negative charges in the N-terminal half of bPP electrostatic 
interactions are likely to be responsible for binding, and such forces are also expected 
to result in the observed rather weak binding affinities.  
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Table 1. Sequence alignment of the principal members of the NPY family and of the N-terminal 
domains from the various Y receptor subtypes. Positions in bPP and hN-Y4 replaced by other 
amino acids in this work have been underlined. 
 
pNPY: YPSKPDNPGE DAPAEDMARY YSALRHYINL ITRQRY-NH2 
pPYY: YPAKPEAPGE DASPEELSRY YASLRHYLNL VTRQRY-NH2 
bPP :   APLEPEYPGD NATPEQMAQY AAELRRYINM LTRPRY-NH2 
          *  *  *    *  *    *    ** * *   ** **   
hN-Y1: MNSTLFSQVE NHSVHSNFSE KNAQLLAFEN DDCHLPLAMI 
hN-Y2: MGPIGAEADE NQTVEEMKVE QYGPQTTPRG ELVPDPEPEL IDSTKLIEVQ 
hN-Y4: MNTSHLLALL LPKSPQGENR SKPLGTPYNF SEHCQDSVDV M 
hN-Y5: MSFYSKQDYN MDLELDEYYN KTLATENNTA ATRNSDFPVW 
DDYKSSVDDL Q 
 
As depicted in Table 1 common acidic residues in PP, NPY and PYY are located 
at positions 6, 10 and 15. PP mutants E4K, Q19R and E23A were produced by site-
directed mutagenesis in order to probe for the importance of differently charged 
residues between PP and NPY/PYY at these positions. The dissociation constant for 
Q19R-bPP was only marginally reduced to 89mM, whereas binding of E4K-bPP and 
E23A-bPP to N-Y4 was too weak to be detected by SPR. The data indicate that it is 
the additional negative charges in PP and their distribution along the sequence that 
may be important for its different binding affinities at the N-Y4.  
In order to verify that electrostatic interactions between acidic residues of PP and 
basic residues in the N-Y4 are contributing to binding, the K13A, R20A and K22A 
mutants of the N-terminal domain of the Y4 receptor were synthesized and 
investigated by SPR. In all of these mutants binding to bPP was significantly reduced. 
The measured values for the KD were 249 mM (R20A), 281mM (K22A) and for 
K13A binding was too weak to be detected by SPR. The combination of the 
mutagenesis studies performed on acidic residues of PP and basic residues of N-Y4 
suggests that the binding affinity between the two is determined by electrostatic 
interactions to a large extent. In this work we have abstained from experiments in 
which residues in PP and N-Y4 were charged-reversed simultaneously because in 
those mutants electrostatics are likely to be perturbed in both molecules, and hence it 
is questionable whether activity could have been rescued. 
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2.3 Discussion 
 
The mechanism for recognition of ligands by their receptors is of prime biological 
and pharmaceutical interest. Due to the enormous problems in expression, purification 
and reconstitution of sufficient amounts of GPCRs, little progress has been made in 
structural studies over the last decade, and so far bovine rhodopsin and the b-
adrenergic receptor are the only GPCRs for which high-resolution X-ray data are 
published. In this work we have attempted to investigate the structure of the isolated 
N-terminal extracellular domain of the Y4 receptor, a GPCR targeted by hormones of 
the NPY family, and which binds to PP with very high affinity. Moreover, we 
determined the interaction with PP and the other members of the NPY family and 
investigated the role of specific residues for binding.  
Structural studies of GPCR fragments could possibly suffer from the fact that 
interactions with the remainder of the receptor are missing that may be structurally 
relevant. As to the present analysis the N-terminal domain of the published crystal 
structure of b-adrenergic receptor was largely unstructured, and did not display 
interactions with other parts of this GPCR, in particular not with the extracellular 
loops. This supports our contention that the conformations of the N-terminal domains 
of a GPCR are not significantly determined by interactions with the remainder of the 
receptor. Such a study also allows us to directly define contributions of residues from 
the N-terminus of the Y-4 receptor to ligand binding.  
While the N-terminal domain of Y4 is largely unfolded in solution upon binding 
to zwitterionic (DPC) or negatively charged (SDS) micelles, a hydrophobic segment 
comprising residues 5 to 10 forms a rather stable a-helix, and the nascent helix 
encompassing residues 26-35 is slightly rigidified. The central region and the C-
terminal hexapeptide remain largely unstructured. The helical segment comprising 
residues 5 to 10 is entirely formed by hydrophobic residues. The structural data and 
the internal backbone dynamics of N-Y4 in the presence of zwitterionic (DPC) and 
anionic (SDS) headgroups display only minor differences indicating that the 
conformation does not depend on specific features of the surrounding lipids. Both 
formation of secondary structure and association with the membrane seem to be 
controlled by the hydrophobicity of the residues and their partitioning into the 
membrane36  Strongly favorable values for the latter are encountered only in the a-
 78 
helical stretch and in the segment between residues 24 to 30, exactly those regions for 
which the spin-label data indicate proximity to the water-membrane interface. Spin-
label, dynamics and structural data of Y-4 reveal the central segment to be rather 
flexible. The segregation of N-Y4 into structured and flexible regions is very similar 
in the presence of zitterionic or negatively charged lipid headgroups. As a 
consequence of these features it appears likely that this domain may perform larger 
movements on the membrane surface, and hence could possibly undergo various 
structural or translational transitions in order to interact with the extracellular loops or 
with the membrane-bound ligands. We like to mention at this point that the N-
terminal domain of the b-adrenergic receptor was also disordered in the crystal 
structure from Kobilka6; 7, and that the N-terminal domains from many other class-1 
GPCRs are predicted to be largely unfolded. This indicates that the fact that N-Y4 is 
mainly flexible is likely not an artifact due to the usage of a receptor fragment but 
rather reflects a commonly encountered feature of these receptors. 
We have recently proposed that binding of hormones from the NPY family to 
their receptors is preceded by association of the ligands to the membrane. According 
to ideas originally proposed by Kezdy and Kaiser37; 38 and later developed into the 
membrane-compartment model by Schwyzer39; 40 binding to the membrane reduces 
the search for the receptor to two dimensions, increases the concentration in the 
vicinity of the receptor and possibly induces conformations that facilitate receptor 
binding. Structural studies of porcine (p) NPY33 and PYY41 and of bovine (b) PP42 
bound to membrane-mimicking dodecylphosphocholine (DPC) micelles revealed 
large structural changes occurring during membrane association.43 From this picture 
the important question arises how the hormones enter the binding pocket, once the 
membrane-bound species has laterally diffused along the membrane into the 
proximity of the receptor. The seven-helix bundle provides a rather rigid scaffold that 
does not allow large rearrangements of the extracellular loops in order to facilitate 
diffusion of the membrane-bound ligand into the binding pocket. Therefore the 
hormones need to detach from the membrane. Data for binding affinities of the 
hormones towards phospholipid membranes determined by us using SPR indicate that 
membrane binding is only moderate.41 Any part of the receptor that possesses higher 
affinity to the peptides than the membrane does, and which could be accessed by a 
ligand that is in proximity to the membrane surface, may help to guide the ligand into 
the binding pocket. The N-terminal domains of the Y receptors are 40-50 amino acid 
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residue long polypeptide segments located in the extracellular space44, and hence 
present potential interaction sites for the ligands. This work now indicates that at least 
for PP transient association with the N-Y4 may be part of the cascade of events 
leading to receptor activation. It should be emphasized here that transient binding to 
the N-terminal domain does not exclude larger structural changes in the 
conformations of loop residues that may occur later on when the ligands have diffused 
into the genuine receptor binding pockets. Such changes or rotations of the TM 
helices are believed to be important for receptor activation, and the above-described 
events merely serve to guide the ligand from the membrane-bound state into the 
binding pocket. 
Binding of PP to the N-terminal domain of the Y4 receptor, which is often 
referred to as the PP-preferring receptor, is moderate with a dissociation constant of 
about 50mM. NPY and PYY, two hormones from the NPY family with very similar 
pharmacology and high sequence similarity with respect to each other, do not bind to 
this domain. Sequence alignments reveal that PP overall is more negatively charged 
than NPY or PYY, particularly in the N-terminal region, and our studies show that 
replacement of E4 or E23 in PP largely abolished binding to N-Y4. Furthermore, 
introduction of Arg into position 19 lead to only marginal changes in binding affinity. 
The N-Y4 domain, in contrast to the N-terminal domains from all other receptor 
subtypes, contains a comparably large number of positively charged residues (K13, 
R20 and K22), which are also relatively close to each other in sequence. Their 
replacement by Ala as described above leads to significant losses in binding affinity. 
To conclude taking the importance of acidic PP and basic N-Y4 residues into account 
we speculate that electrostatic interactions between PP and N-Y4 are crucial for this 
interaction. However, it must be emphasized that a priori it is not clear in our case 
whether residues from the N terminus are interacting with residues from the 
extracellular loops thereby modulating the effective charge experienced by the 
peptides. This question can only be addressed experimentally with confidence when 
structural studies of the full-length receptor in a functional state become available.  
Unfortunately, not much pharmacological data is available for the entire Y4 
receptor. In case of the human Y1 receptor an Asp residue at the interface between 
TM helix 6 and the third extracellular loop was proposed to contribute largely to 
binding NPY45 in the full-length Y1 receptor. Considering that Asp at this position is 
conserved amongst all Y receptor subtypes it was speculated that this residue 
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generally contributes to binding in all subtypes. Nicole et al. investigated the role of 
this Asp6.59 in more detail46 and verified the proposed interaction of Arg33 or Arg35 
with acidic third extracellular loop (ECL3) residues in the other Y receptor subtypes. 
Our data now indicate that in addition to the above-described interaction additional 
contacts between acidic residues of PP and basic residues of the N-terminal domain of 
the Y4 receptor may contribute to binding. Association of the N-Y4 with PP may be 
therefore not only be of transient nature helping the ligand to be transferred from the 
membrane-bound state into the receptor binding pocket, but may also exist in the 
ligand-bound state, contributing to the high binding affinity and selectivity of PP at 
the Y4 receptor.  
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2.4 Conclusions 
 
Based on the data described above, we speculate that the N-terminal domain of 
the Y4 receptor may help in transferring PP from the membrane-bound state into the 
receptor binding pocket (see Fig. 7). As proposed by us in case of ligands of the Y 
receptors43 PP initially associates with the membrane. By binding to the membrane 
the effective concentration in vicinity of the receptor is increased, the search is 
reduced from three to two dimensions, and conformations closer to those of the bound 
state may be induced according to the membrane-compartment model.39; 40 BIACore 
data of PP binding to phospholipid surfaces indicated that binding to membranes is 
moderate.47 Accordingly, an equilibrium is formed, in which PP rapidly diffuses on 
and off the membrane, but mostly remains in vicinity of the membrane. When PP has 
diffused into proximity of the receptor where interactions with the latter can occur it 
may transiently bind to N-Y4 from solution. Whether the complex of PP and N-Y4 
itself will move into vicinity of the extracellular loops, or whether the position of N-
Y4 is fixed by interactions with the membrane or the remaining portion of the 
receptor is presently unclear.  
A scenario, in which N-Y4-bound PP would be transferred into the binding pocket 
by a translational movement of parts of the N-terminal domain is at least compatible 
with the experimental data. These indicate that the binding region for PP is located in 
its central segment, which at the same time is the only part of N-Y4 that is not making 
significant contacts with the membrane surface, and which also possesses sufficient 
internal flexibility to allow the necessary movements. We presently favor a view that 
describes the N-terminal domain as a large flexible loop, anchored onto the membrane 
at the amino terminus via the membrane-associated helix and at the C terminus via the 
first TM. This view is also supported by the recent crystal structures of the b-
adrenergic receptor in which the N-terminal domain is so flexible that electron density 
in this part could not be traced.6; 7 We have now initiated work on constructs that 
include parts of the TM bundle to see whether conformational preferences of N-Y4 
are influenced by the remainder of the receptor. 
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2.5 Materials and Methods 
 
Expression of the N-Y4 sequence as a soluble fusion to ubiquitin resulted in 
heterogeneous fragmentation. In order to prevent in-vivo processing the N-terminal 
domain was fused to the highly insoluble protein ketosteroidisomerase that is encoded 
in the commercial plasmid pET 31b, from which it was liberated by cleavage with the 
TEV protease in mild detergent. 
 
2.5.1 Plasmid Construction, Expression and Purification of N-Y4 
 
The cDNA of the Y4 receptor was obtained from the University of Missouri-Rolla 
(UMR) cDNA Resource Center. The following two primers were used to amplify the 
cDNA corresponding to N-Y4 by PCR. Forward primer: 
GCGCTCGAGGGTTCCGGTTCCGGTTCCGAAAACCTGTACTTCCAGATGA
ACACCTCTCACCTGCTGGC, in which italic letters denote a XhoI cleavage site, 
bold letters denote a Gly-Ser linker sequence and underlined letters identify a TEV 
cleavage sequence; backward primer: 
CTGGCTGAGCTCACATCACGTCCACGGAATCCT with italic letters denoting an 
EspI cleavage site. The amplified PCR product and the target vector, pET 31b  
(Novagen), were simultaneously digested with XhoI and EspI, and ligated into the 
vector with T4 ligase. The construct was confirmed by DNA sequencing (Synergene 
Biotech, Switzerland). All mutants were constructed by site-directed mutagenesis 
using the QuikChange Kit (Stratagene, USA).  
The fusion protein was expressed in inclusion bodies using the BL21(DE3) E.coli 
strain. Protein expression was performed by growing cells at 37°C using minimal 
media containing 15N-NH4Cl as the sole nitrogen source for 15N labeled peptide. 1mM 
IPTG was added to induce protein expression when the OD600 reached 0.8 and cells 
were harvested after 5-6 hours. The fusion protein was purified from inclusion bodies 
in 6M guanidinium hydrochloride by Ni-NTA affinity chromatography. After 
removal of GdnHCl by dialysis the precipitated fusion protein was solubilized in 
50mM Tris pH 8.0 in the presence of 2% N-lauryl sarcosine upon sonication to a final 
concentration of 2mg/ml. The resulting solution was dialyzed against a 20-fold excess 
of 50 mM Tris, pH 8.0 for 4-6 times. The solution was diluted 10 times with 50 mM 
 83 
Tris pH 8.0 and EDTA and DTT were added to a final concentration of 0.5 mM and 1 
mM, respectively. TEV protease was added to a final concentration of 100 mM and 
the cleavage mixture was kept at 4°C over night. The target peptide was purified by 
C18-RP-HPLC (Vydac, USA) and the correctness of the peptide was verified by 
MALDI-TOF MS: 15N labeled N-Y4: 4614 Da (theoretical mass (for 100% labeling): 
4611.1 Da). 
 
2.5.2 Synthesis and Purification of the Neuropeptides and of Unlabelled N-
terminal Fragments 
 
15N-labeled peptides from the NPY family were expressed as soluble fusions to 
Ubiquitin. Ubiquitin was liberated from the neuropeptide using the yeast ubiquitin 
hydrolase, and C-terminal amidation was performed using the a-amidating peptidyl 
glycine amidase (PAM). We have used the protocols for expression, ubiquitin 
cleavage and C-terminal amidation many times before and described in them much 
detail elsewhere, e.g. in Bader et al.33   
Wild-type and mutant N-Y4 peptides and peptides from the NPY family 
containing 15N nuclei at natural abundance were prepared by solid-phase peptide 
synthesis using a robot system (ABI433A, Applied Biosystems). 2-chlorotrityl 
chloride resin preloaded with Fmoc-Met-OH was used to assemble the linear peptide 
using standard Fmoc chemistry (20% piperidine in DMF for Fmoc deprotection, 4 
equiv. HOBt/HBTU for activation, diisopropylethylamine as base, and N-
methylpyrrolidone as solvent). The peptides were cleaved from the resin and 
deprotected with TFA/water/1,2-ethanedithiol/triisopropylsilane 95/2.5/2.5/2.5. The 
product was lyophilized and purified by C18 RP-HPLC and correctness was 
confirmed by ESI-MS: wild-type N-Y4: 4556.8 Da (theoretical mass: 4556.1 Da); 
K13A N-Y4: 4501 Da (theoretical mass: 4499 Da); R20A N-Y4: 4473 Da (theoretical 
mass: 4471 Da); K22A N-Y4: 4501 Da (theoretical mass: 4499 Da). 
In order to synthesize the N-terminally biotinylated forms the peptides were 
mixed with biotin-(PEO)4-NHS-propionate (Molecular Biosciences, USA) in a 1:2 
ratio in 100mM phosphate buffer, pH 7.0 and incubated for 2 hours at RT and 
afterwards purified by C18 RP-HPLC and confirmed by ESI-MS. To confirm that in 
case of E4K-bPP, the biotin was coupled to the N-terminus instead of the side chain 
of lysine, the biotinylated peptide was first digested with pepsin, and subsequently the 
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fragment containing residue 1-16 was analyzed by MALDI-TOF MS-MS. The result 
from this analysis demonstrated that the biotin was exclusively coupled to the N 
terminus. 
 
2.5.3 Dodecylphosphoethanolamine Coupling to the Carboxyl Terminus of N-Y4 
 
The peptide from solid-phase peptide synthesis was cleaved off the resin with 
TFA (0.8 vol %) in DCM with all the protecting groups remaining intact. Following 
removal of solvents the protected peptide was precipitated in cold water, lyophilized 
and redissolved in DMF. The solution was stirred at RT for 5 hours with 3 equivalents 
of dodecylphosphoethanolamine (3 equiv.) in presence of of HATU (1 equiv.), HOAt 
(1 equiv.) and of DIEA(1.5 equiv.). After extraction with a ethyl-acetate:water 
mixture (1:1 v/v) the lipopeptide was deprotected under the same conditions as 
described above. Finally, the lipopeptide was purified by C4 RP-HPLC (Vydac, 
USA), lyophilized and purity higher than 95% was confirmed by MALDI-TOF-MS: 
4848 Da (theoretical mass: 4847.1 Da) and LC-MS. 
 
2.5.4 NMR Experiments  
 
All samples of N-Y4 for structural studies were measured at 1mM concentration, 
40mM d-MES at pH 5.6. For measurements mimicking membrane environments 
300mM d38-DPC or 300mM d25-SDS were added. All experiments were performed at 
700 MHz, 310K using a triple-resonance cryoprobe. Resonance assignments were 
initially performed in the absence of DPC or SDS using [15N,1H]-HSQC, 3D 
[15N,1H]-HSQC-TOCSY (80ms mixing time) and 300ms 3D [15N,1H]-HSQC-NOESY 
experiments. Details of the spectroscopy were similar to those described by us 
earlier.48 Spectra were analyzed using the programs CARA49 and XEASY.50 After 
nearly complete resonance assignments in water were obtained, a 200ms 3D [15N,1H]-
HSQC-NOESY was recorded in the presence of DPC, and the assignments in water  
adjusted to the DPC spectra. Upper distance restraints in DPC or SDS were then 
derived from 50ms 2D NOESY spectra. Internal backbone dynamics were studied by 
measuring a 1H-detected version of a 15N{1H}-NOE experiment. Structures were 
computed based on upper-distance restraints derived from the NOESY spectra using 
the program CYANA51; 52 following the standard simulated annealing protocol. 
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15N{1H}-NOEs were computed from the ratio of integrals from signals in the presence 
to those in the absence of amide proton irradiation.53 Chemical shifts of the 15N,1H-
correlation map in the absence and full assignments in the presence of DPC and SDS 
can be found in the Supp. Mat. Proton chemical shifts were referenced to the water 
line, taken as 4.63 ppm at 310K, from which the nitrogen scale was derived indirectly 
through multiplication with the factor g(15N)/g(1H). 
The coordinates, chemical shift values and heteronucelar NOEs of NY-4 in the 
presence of SDS and DPC have been deposited in the BMRB database under the 
accession number 15708. 
 
2.5.5 Membrane-Association Topology Using Spin Labels 
 
In the spin label studies [15N,1H]-HSQC spectra of 0.5mM solutions of 15N-N-Y4 
containing 300mM DPC were measured in absence and presence of 7mM and 8.8mM 
5-doxyl and 16-doxyl stearic acid, respectively. Signal attenuation was computed 
from the ratio of integrals from peaks in the corresponding spectra. The signal 
attenuation in the presence of the spin label is related to proximity of protons to the 
label. In another set of experiments 0.1mM 15N-labeled N-Y4 was mixed with various 
concentrations of bPP in order to test whether N-Y4 is released from the micelle upon 
interaction with PP. 
 
2.5.6 Surface Plasmon Resonance (SPR) Studies 
 
HBS buffer (10mM HEPES, pH 7.4, 150mM NaCl, 3.4mM EDTA, 0.005% P20) 
was used as the running buffer to achieve physiological pH. N-terminally biotinylated 
neuropeptides were immobilized onto the sensor chip SA (BiaCore, Sweden), which 
contains a streptavidin-coated surface, resulting in about 200 response units (RU) on a 
BIAcore 1000 instrument (BIAcore, Sweden). Different concentrations of N-Y4 
spanning a range of 5 to 100µM were applied to the surface for 30 seconds at a flow-
rate of 20ml/min at 25°C. After each injection of analytes, the flow-cell was flushed 
with regeneration buffer  (1M NaCl, 50mM NaOH) for 30 seconds. Since unspecific 
binding at concentrations higher than 100µM occurred, KD larger than 100µM could 
not be determined precisely. Nevertheless, trends in reduction of binding could still be 
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computed from a limited set of data points, in which values at high concentrations 
were excluded from the analysis. All sensograms were analyzed with the BIA 
evaluation software using a two-state binding model. 
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2.8 Supplementary Materials 
 
Fig. S1: “Snake”-plot type presentation of the human Y4 receptor. The plot was 
downloaded from the GPCR.org website. Note that to enhance clarity not all residues 
from the N-terminal domain and the long loops are shown 
 
 
 
 
 
 
 
Fig. S2: Summary of the meaningful distance restraints as derived from the 
unambiguously assigned inter-residue NOEs between backbone HN,Hα and Hβ of N-
Y4 bound to DPC micelles.  
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Fig. S3: Expansion of the 100ms NOESY displaying the region involving NOEs 
between sequential amide protons (DPC micelles) 
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Table S4: Chemical shifts for N-Y4 bound to DPC micelles a referenced to the signal 
of residual HDO at 4.63 ppm 
 
Residue HN H'a Hb others 
Met 1 - 4.07 -, - gCH2 -, -; eCH3 - 
Asn 2 8.99 4.92 2.92, 2.80 dNH2 7.66, 6.90 
Thr 3 8.63 3.89 4.20 gCH3 1.20; gOH - 
Ser 4 8.43 4.14 3.91, 3.91 gOH - 
His 5 8.11 4.50 3.25, 3.25 dNH -; d2H 6.89; eH 7.66; e2NH - 
Leu 6 7.69 3.98 1.74, 1.74 gH 1.67; dCH3 0.90, 0.84 
Leu 7 8.01 3.91 1.75, 1.75 gH 1.58; dCH3 0.85, 0.85 
Ala 8 7.52 4.03 1.44  
Leu 9 7.40 4.09 1.89, 1.89 gH 1.47; dCH3 0.83, 0.83 
Leu 10 7.43 4.20 1.72, 1.72 gH 1.55; dCH3 0.83, 0.79 
Leu 11 7.50 4.51 1.65, 1.65 gH 1.50; dCH3 0.87, 0.87 
Pro 12  - 2.29, 1.86 gCH2 1.98, 1.98; dCH2 3.54, 3.69 
Lys 13 8.35 4.30 1.70, 1.70 gCH2 1.42, 1.42; dCH2 1.78, 1.78; eCH2 
2.96, 2.96; zNH3  - 
Ser 14 8.30 4.68 3.81, 3.81 gOH - 
Pro 15  4.40 2.24, 1.88 gCH2 1.97, 1.97; dCH2 3.69, 3.79 
Gln 16 8.37 4.27 2.08, 1.94 gCH2 2.33, 2.33; eNH2 7.45, 6.78 
Gly 17 8.27 3.90, 3.90   
Glu 18 8.22 4.26 2.01, 1.88 gCH2 2.24, 2.24; eH - 
Asn 19 8.45 4.64 2.79, 2.71 dNH2 7.53, 6.86 
Arg 20 8.26 4.31 1.85, 1.71 gCH2 1.58, 1.58; dCH2 3.14, 3.14; eNH -; 
hNH2 -, - 
Ser 21 8.22 4.37 3.80, 3.80 gOH - 
Lys 22 8.10 4.57 1.65, 1.65 gCH2 1.76, 1.76; dCH2 1.41, 1.41; eCH2 
2.95, 2.95; zNH3  - 
Pro 23  4.40 2.27, 2.27 gCH2 1.98, 1.98; dCH2 3.55, 3.55 
Leu 24 8.34 4.26 1.63, 1.63 gH 1.55; dCH3 0.86, 0.86 
Gly 25 8.27 3.92, 3.92   
Thr 26 7.94 4.53 4.08 gCH3 1.15; gOH - 
Pro 27  - 2.47, 2.14 gCH2 1.96, 1.82; dCH2 3.75, 3.57 
Tyr 28 7.91 4.34 2.79, 2.79 dH 6.92, 6.92; eH 6.71, 6.71; hOH - 
Asn 29 8.08 4.61 2.71, 2.59 dNH2 7.48, 6.79 
Phe 30 8.21 4.44 3.13, 3.05 dH 7.24, 7.24; eH 7.14, 7.14; zH - 
Ser 31 8.07 4.39 3.81, 3.81 gOH - 
Glu 32 8.08 4.16 1.94, 1.85 gCH2 2.21, 2.21; eH - 
His 33 8.24 4.59 3.28, 3.09 dNH -; d2H -; eH -;   NH - 
Cys 34 8.20 4.39 2.86, 2.86  SH - 
Gln 35 8.43 4.25 2.08, 1.96  CH  2.31, 2.31;  NH  7.43, 6.76 
Asp 36 8.25 4.64 2.76, 2.64  H - 
Ser 37 8.13 4.42 3.80, 3.80  OH - 
Val 38 8.01 4.11 2.06  CH  0.86, 0.86 
Asp 39 8.27 4.26 2.74, 2.60  H - 
Val 40 7.94 4.09 2.09  CH  0.87, 0.87 
Met 41 7.87 4.26 1.94, 1.94  CH  -, -;  CH  2.04 
a 1mM in 300mM DPC / 90% H2O/10% 2H2O at 310 K ,  20mM MES and pH 5.6 
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Table S5: 1HN and 15N chemical shifts of N-Y4 in water in the presence and absence 
of DPC micelles. 
Res. δ(1H) [ppm] δ(15N) [ppm] δ(
1H) [ppm] 
DPC 
δ(15N) [ppm] 
DPC 
M1 - - - - 
N2 - - - - 
T3 8.171 119.838 8.637 116.741 
S4 8.290 114.787 8.413 117.173 
H5 8.260 127.348 - - 
L6 - - 7.652 118.535 
L7 8.006 121.818 8.000 116.495 
A8 7.953 123.247 7.521 118.535 
L9 7.817 119.790 7.395 115.914 
L10 7.915 121.832 7.422 115.509 
L11 7.897 123.675 7.494 117.061 
P12 - - - - 
K13 8.257 120.984 8.350 120.579 
S14 8.221 117.544 8.319 118.053 
P15 - - - - 
Q16 8.338 119.671 8.355 119.671 
G17 8.243 109.457 8.255 109.367 
E18 8.225 120.207 8.232 120.105 
N19 8.454 119.731 8.449 119.615 
R20 8.252 121.321 8.247 121.173 
S21 8.211 116.370 8.214 116.299 
K22 8.092 123.461 8.095 123.333 
P23 - - - - 
L24 8.423 122.478 8.319 121.952 
G25 8.315 109.153 8.286 108.684 
T26 7.874 115.514 7.910 115.127 
P27 - - - - 
Y28 - - 7.886 118.731 
N29 8.083 120.162 8.045 119.607 
F30 7.989 120.843 8.083 120.695 
S31 8.069 116.045 8.084 115.520 
E32 8.133 121.685 8.162 121.566 
H33 8.288 117.461 8.332 117.816 
C34 - - - - 
Q35 8.430 121.020 8.460 121.068 
D36 8.224 120.984 8.289 121.269 
S37 8.096 115.276 8.123 115.324 
V38 8.002 120.362 8.008 120.111 
D39 8.251 122.983 8.247 122.843 
V40 7.918 119.379 7.925 119.118 
M41 7.850 128.423 7.831 127.626 
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Fig. S6: Summary of the meaningful distance restraints as derived from the 
unambiguously assigned inter-residue NOEs between backbone HN,Hα and Hβ of N-
Y4 bound to SDS micelles.  
 
 
 
 
Fig. S7: Comparison of [15N,1H]-HSQC data of N-Y4 in the presence of DPC  (left) 
or SDS (right) micelles: 
 
 
 
 
Fig. S8: Comparison of 15N{1H}-NOE data of N-Y4 in the presence of DPC  (red 
diamonds) or SDS (black circles) micelles: 
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Fig. S9: Left: Residual signal intensity of cross peaks in the [15N,1H]-HSQC in the 
presence of 5-doxylstearate relative to those in the absence of the spinlabel. Right: 
Free energies of transfer for whole amino acids from bulk aqueous solution into the 
water-membrane interface. Values were taken from Wimley et al.[36] 
 
 
 
 
 
 
 
Fig. S10: Left: Overlay of NOESY spectra of N-Y4 with the construct containing the 
C-terminal lipid attachment (green) (all spectra recorded in the presence of DPC 
micelles). Right: Expansion showing the assignment of the helical segment of N-Y4. 
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Table S11: Chemical shifts for N-Y4 bound to SDS micellesa referenced to the 
signal of residual HDO at 4.63 ppm 
 
Residue HN H'  H  Others 
Met 1 - 4.19 2.19  CH 2.55;  CH  2.19 
Asn 2  8.66 4.98 2.98 , 2.79  NH  7.57, 6.86 
Thr 3 8.28 4.26 4.04  CH  1.22;  OH - 
Ser 4 8.28 4.23 3.92  OH - 
His 5 8.06 4.57 3.3  NH -;   H 7.34;  H 8.64;   NH - 
Leu 6 7.84 3.99 1.69, 1.78  H 1.57;  CH  0.87, 0.94 
Leu 7 8.03 3.95 1.57, 1.78  H 1.58;  CH  0.87, 0.93 
Ala 8 7.52 4.05 1.47  
Leu 9 7.47 4.14 1.70, 1.87  H 1.54;  CH  0.86, 0.93 
Leu 10 7.59 4.22 1.75, 1.80  H 1.55;  CH  0.82, 0.86 
Leu 11 7.65 4.37 1.77  H 1.56;  CH  0.90, 0.94 
Pro 12  4.45 2.35, 2.05  CH  2.0,  CH  3.54, 3.77 
Lys 13 7.90 4.44 1.81  CH  1.46;  CH  1.63 ;  CH  - ;  NH  
6.96 
Ser 14 7.95 3.88 3.80  OH - 
Pro 15  4.46 2.31, 1.99  CH  2.06;  CH  3.80, 3.75  
Gln 16 8.30 4.31 2.15, 1.97  CH  2.30, 2.37;  NH  7.42, 6.72 
Gly 17 8.18 3.93   
Glu 18 8.14 4.30 2.08, 1.94  CH  2.33;  H - 
Asn 19 8.30 4.71 2.84, 2.71  NH  7.49, 6.83 
Arg 20 8.0 4.35 1.86, 1.78  CH  1.64;  CH  3.20;  NH 7.2;  NH  - 
Ser 21 8.22 4.43 3.83  OH - 
Lys 22 7.99 4.35  1.87  CH  1.45;  CH  1.75 ;  CH -;  NH  - 
Pro 23  4.44 2.30, 1.98  CH  1.91;  CH  3.77, 3.68 
Leu 24 8.03 4.34 1.72, 1.68  H 1.58;  CH  0.94, 0.89 
Gly 25 7.98 4.00, 3.91   
Thr 26 7.82 4.61 4.17  CH  1.21;  OH - 
Pro 27   4.39 2.17  CH  2.17;  CH   3.58 
Tyr 28 7.61 4.34 2.71, 2.67  H 6.88;  H 6.71;  OH - 
Asn 29 7.93 4.68 2.80, 2.63  NH  7.42, 6.76 
Phe 30 8.08 4.43 3.20, 3.07  H 7.28;  H 7.21;  H 7.07 
Ser 31 8.18 4.31 3.93, 3.92  OH - 
Glu 32 7.85 4.23 2.03, 1.91  CH  2.23;  H - 
His 33 8.12 4.62 3.34, 3.20  NH -;   H7.31;  H -;   NH - 
Cys 34 8.15 4.66 3.22, 2.98  SH - 
Gln 35 8.24 4.33 2.11, 1.98  CH  2.34;  NH  7.41, 6.75 
Asp 36 8.31 4.65 2.75, 2.69  H - 
Ser 37 8.18 4.45 3.85  OH - 
Val 38 8.00 4.14 2.09  CH  0.89, 0.85 
Asp 39 8.30 4.62  2.60  H - 
Val 40 7.94 4.12 2.09  CH  0.90 
Met 41 7.89 4.34 1.92  CH  2.34;  CH  - 
                a1mM in 300mM SDS / 90% H2O/10% 2H2O at 310 K, 20mM MES and pH 5.6 
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Selective N-terminal biotinylation: Proof by MS-MS 
A P L K P E Y P G D N A T P E QMA Q Y A A E L R R Y I N M L T R P R Y-NH2 
MW=4224.8 Da 
Biotin-(PEO)4-NHS-propionate (NHS-(PEO)4-Biotin): MW=588.67 Da, mass added 
to the target: 474.6.Da 
Pepsin was used to digest the biotinylated peptide yielding a fragment corresponding 
to biotinylated 1-16 N-Y4. TOF-TOF MS was utilized to analyze this fragment:  
 
 
The non-biotinylated sample served as a control, and the TOF-TOF result is as 
follows: 
 
 
 
 y3 y4 y5 y6 y7 y8 y9 y10 y11 y12 y13 y14 y15 y16 
Expected 372.3 473.4 544.5 658.6 773.7 830.8 927.9 1091.1 1220 1317.3 1445.5 1558.6 1655.7 1726.8 
Observed  373.4 474.5 544.5 659.5 774.4  928.8 1091.9  1317.8 1445.8  1656.1 1726.9 
 
Almost all expected ions from the digest are observed.  Thereafter, the biotinylated 
sample was fragmented under the same conditions, and the TOF-TOF MS spectrum is 
depicted below: 
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If we assume that biotin was coupled to the N terminus, the following expected y ions 
as listed 
 
 y4 y5 y6 y7 y8 y9 y10 y11 y12 y13 y14 y15 y16 
Expected1 473.4 544.5 658.6 773.7 830.8 927.9 1091.1 1220 1317.3 1445.5 1558.6 1655.7 2201.1 
Expected2 473.4 544.5 658.6 773.7 830.8 927.9 1091.1 1220 1317.3 1920.1 2033.2 2130.3 2201.1 
Observed  474.6 545.6 659.8   928.9 1091.8  1317.7 1445.8 1558.9 1656.1 2200.1 
Expected1: expected y ions if biotin was coupled to the N terminus 
Expected2: expected y ions if biotin was coupled to lysine 
 
The observed and expected y ions have been summarized in the table above. It is 
evident that the observed y ions, in particular y ions 13-16 correspond to those where 
biotin was coupled to the N terminus. In addition b1 ions 545.6 can be identified 
corresponding to biotinylated N terminus residue (MW of biotinilyated Alanine b 
ion=546.0). None of the fragments occurring only for Lys-biotinylated peptide was 
observed. 
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Chapter 3 
  
Properties of the N-terminal domains from Y 
receptors probed by NMR spectroscopy 
 
3.1 Introduction 
G-protein coupled receptors (GPCRs) present the pharmacologically most 
important class of receptors and the most important target for pharmaceutical drugs1. 
Although significant progress has been made in structural studies of GPCRs, a much 
more detailed picture still is highly desirable. Nevertheless, the structures of bovine 
rhodopsin2, the very recently published data on the b-adrenergic receptor3; 4 and on 
squid rhodopsin5 have improved our understanding of this biologically important 
class of proteins. 
Generally the structure of GPCRs can be described as an extracellular N terminal 
domain (ranging in size from ten to several thousand residues), which is anchored in 
the plasmamembrane by 7 transmembrane helices (7TM segment). The latter are 
interconnected between themselves by three intra- and three extracellular loops. The 
7TM segment is followed by a cytoplasmic C terminal domain. 
While the extracellular N-terminal domain of bovine rhodopsin was surprisingly 
well-structured and revealed the non-anticipated presence of a short anti-parallel beta-
sheet, the corresponding segment of the b-adrenergic receptor could not be traced in 
the electron maps presumably because of its inherent flexibility3; 4. Previously, we 
have in detail investigated structural properties of a 41 amino acid fragment 
corresponding to the N-terminal domain of the Y4 receptor (N-Y4)6. This receptor 
belongs to a class of GPCRs targeted by neurohormones of the neuropeptide Y 
family7; 8. The Y receptors are comprised of four subtypes called Y1, Y2, Y4, and Y5 
with Y4 showing high affinity and specificity for the pancreatic polypeptide (PP). 
While unstructured in solution a short a-helical stretch comprising residues 5 to 11 
was observed in the presence of phospholipids micelles for N-Y4.6 In this work we 
now report on our recent studies on structural properties of all other N-terminal 
domains from the human Y receptors. Synthetic routes for recombinant production of 
the polypeptides in isotopically-labeled form are described and compared to each 
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other. In general the N-terminal domains from the Y1 and Y4 receptors behave 
similarly, and the same is true for those from the Y2 and Y5 receptors. Expression of 
N-Y1 and N-Y4 required fusion to the insoluble protein ketosteroidisomerase, from 
which it was liberated by enzymatic cleavage using the TEV protease in the presence 
of a mild detergent. In contrast, N-Y2 and N-Y5 could be expressed as soluble 
ubiquitin fusions, and cleavage was easily achieved with the help of yeast ubiquitin 
hydrolase. 
The N-terminal domains from all Y receptors are fully unstructured in aqueous 
solution, as shown by measurements of the internal backbone dynamics. In contrast, 
in the presence of phospholipid micelles N-Y4 adopts a short a-helix in a segment 
mainly comprised of hydrophobic residues. N-Y1 is largely helical although 
remaining flexibility precludes a detailed structural analysis. N-Y5 is segregated into 
more structured and rather flexible regions, similarly to N-Y4. However, 
measurements of internal backbone dynamics revealed secondary structure to be less 
stable than in N-Y4. N-Y2 does not interact with the micelles and remains 
unstructured also in that environment. 
In our previous work we demonstrated that N-Y4 interacts with PP6. Surface 
plasmon resonance (SPR) measurements indicated weak (Kd 50mM) binding, and 
subsequent mutagenesis experiments revealed that electrostatic interactions from 
anionic ligand and cationic N-Y4 residues contributed to that interaction. In this work 
we also tested binding of the principal members of the NPY family (the neuropeptide 
Y (NPY), the pancreatic polypeptide (PP) and the peptide YY (PYY)) to all other N-
terminal domains from this class of GPCRs. 
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3.2 Results 
 
3.2.1 Expression of N-terminal Domains in Isotopically-labeled Form 
The structure of peptides can mostly be solved by relying solely on homonuclear 
1H-1H correlation experiments. Such peptides are therefore usually produced by solid 
phase peptide synthesis (SPPS)9; 10. Isotope labeling, however, is required for the 
study of backbone dynamics using 15N relaxation, and such labeling also facilitates 
chemical shift mapping experiments for the study of macromolecular interactions.  
The high cost of 13C- and/or 15N-enriched amino acids usually prohibits the usage of 
SPPS and necessitates recombinant production. E.coli is still the expression system of 
choice for most proteins because of the ease of its genetic manipulation and because 
of the ability of E.coli to synthesize amino acids from glucose and inorganic ammonia 
salts serving as the sole sources of carbon and nitrogen, respectively11.  
Since peptides are rapidly degraded in E.coli, they are usually expressed linked to 
a (more) stable fusion partner. The chosen fusion partner should allow the expression 
of the fusion constructs in high amounts and it should allow the specific separation of 
the fusion partner and the peptide after the purification of the fusion construct12. The 
first aim can usually be achieved by selecting a protein as fusion partner, which itself 
can be produced in high yields in E.coli. Specific cleavage from the fusion partner can 
be accomplished for systems for which a specifically hydrolase is available (method 
1), or by introducing a unique cleavage site between the fusion partner and the peptide 
sequence of interest (method 2) (see Fig. 1). Such a scission site can be either an 
amino acid sequence specifically recognized by a protease (method 2a) or a site prone 
to chemical cleavage (method 2b).  
The most convenient strategy in terms of workload is usually method 2b. In this 
method high yield is achieved by fusing the peptide to a highly water insoluble 
protein which will lead to the accumulation of the fusion construct in inclusion 
bodies11. Inclusion bodies already contain the target protein at high concentrations, 
and typically require only very few additional steps of purification. In case of 
cyanobromide cleavage very high efficiencies have been reported13, but the target 
sequence is not allowed to contain Met residues. Other methods such as 
hydroxylamine cleavage14, are much less efficient, and often result in further chemical 
modifications of the target peptide. Methods that use enzymatic cleavage (methods 1 
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and 2a) require that the fusion protein is soluble under conditions that are compatible 
with enzymatic activity. 
 
Figure 1: Scheme showing the two strategies used to produce peptides corresponding to the N-
terminal domains of the Y receptors in isotope-labeled form. 
 
Since the four Y receptor N-terminal fragments studied herein are all reasonably 
water-soluble and contain Met residues we initially decided to express them in 15N-
labelled form as C-terminal fusions to N-terminally decahistidine-tagged yeast 
ubiquitin15. After purification of the fusion construct by Ni-affinity chromatography 
the desired peptide was liberated with a hexahistidine-tagged yeast ubiquitin 
hydrolase (YUH). This system allowed the recovery of about 6 mg of 15N-labelled N-
Y2 and N-Y5 from 1 L of culture. Unfortunately, attempts to express N-Y1 and N-Y4 
using this method resulted in unspecific C-terminal degradation (see supplementary 
Table S10). To circumvent intracellular proteolysis, N-Y1 and N-Y4 were expressed 
as a fusion to the highly water-insoluble protein ketosteroidisomerase (KSI), which 
resulted in accumulation of the fusion protein in inclusion bodies. A TEV protease 
cleavage site was introduced between KSI and the target peptide16; 17. The sequence 
recognized by the TEV protease is ENLYFQ with Q as the P1’ residue. To achieve 
the natural peptide sequence after cleavage, the P1’ residue was replaced with the first 
residue from the target sequence (here it is Met)16, and an additional GSGSGS linker 
was inserted to prevent steric hindrance during cleavage.  
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A problem of the chosen strategy was that the water-insoluble fusion protein must 
be solubilized in detergent that is compatible with activity of the TEV protease18. 
After extensive detergent screening, we observed that the ionic detergent sarcosyl 
solubilizes the fusion protein while preserving TEV protease activity to a satisfactory 
extent (see Table S10). Cleavage efficiency for this system is around 40% allowing 
recovery of about 2 mg of 15N-labelled N-Y1 and N-Y4 from 1 L of bacterial culture. 
 
 
Figure 2: [15N,1H]-HSQC spectra of all Y receptor N-terminal domains, recorded at 310 K in the 
presence of DPC micelles. Top left: N-Y1, top right: N-Y2, bottom left: N-Y4, bottom right: N-
Y5. 
 
3.2.2 Assignment of Chemical Shifts 
Sequence-specific resonance assignments were done using the strategy developed 
by Wüthrich and coworkers19. In this strategy spin systems are assigned by 
experiments based on scalar couplings (e.g. COSY-type or TOCSY-type transfer) and 
NOEs are used to link them in sequential order. Due to extensive resonance overlap of 
the poorly folded peptides 15N-resolved three-dimensional TOCSY or NOESY data 
had to be utilized for this task. Representative [15N,1H]-HSQC spectra of all four 
peptides are depicted in Fig. 2. In case of N-Y5 a 13C,15N-labelled sample, allowing 
the acquisition of triple resonance spectra, was required. For N-Y1, a set of 
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experiments was first recorded in aqueous buffer. After completed analysis in water 
the assignments were transferred and adjusted to the spectra recorded in the presence 
of DPC micelles with the help of NOESY spectra. A set of tables containing complete 
assignments for all the proton-nitrogen correlation maps, as well as almost all proton 
chemical shifts of N-Y1 can be found in the supplementary materials S1-S5 
 
3.2.3 Screening Structural pProperties Ssing 15N Relaxation and CD 
Spectroscopy 
CD spectroscopy is a convenient tool to estimate the type and content of secondary 
structure in peptides and proteins. The CD spectra of all N-terminal domains in the 
presence of DPC micelles are depicted in Fig 3. The spectrum of N-Y2 displays its 
maximum around 197 nm, the typical absorption band of unstructured peptides. For 
all other peptides the main band is red-shifted and indicates population of helical 
substructures. The intensities of the absorptions, however, also clearly show that the 
helical content is very low in all cases, and the typical bands at 208 and 222 nm are 
not visible. For N-Y4, for which we previously observed an a-helix involving residues 
4 to 11, the absorption is stronger than for the other peptides. 
 
 
Figure 3: CD spectra of peptides from all N-terminal domains, recorded at 37 °C in 300 mM 
DPC, 20 mM MES pH 5.6 solution. Data are shown for N-Y1 (solid line), N-Y2 (dotted line), N-
Y4 (dash-dotted line) and N-Y5 (dashed line). Data are converted to molar ellipticities. 
 
The dispersion of the NMR signals in the region of the amide protons is 
traditionally used to estimate to which extent a peptide or protein is folded20. In case 
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of the N-terminal domains from the Y receptors signal dispersion of all peptides was 
small, indicating that they were largely unfolded. To better access whether these 
peptides still contained folded segments we recorded the 1H-15N{1H}-NOEs (H-
NOEs). These values range from 0.6 and 0.8 for well-folded elements of secondary 
structures, and progressively decreases for more flexible amide moieties resulting in 
negative values for fully flexible segments21. The H-NOE data for all N-terminal 
peptides reveal that all peptides are essentially unstructured in aqueous buffer (data 
not shown). 
 
 
Figure 4: Values of the 15N-{1H}NOE, recorded at 700 MHz proton frequency along the sequence 
for Y1 (top left), Y2 (top right), Y4 (bottom left) and Y5 (bottom right). The area containing 
values larger than 0.6, indicating rather wellfolded segments, has been shaded in gray. 
 
Since in the naturally occurring GPCR the N termini are attached to a membrane-
protein the backbone dynamics were additionally probed in the presence of a 
commonly used membrane-mimicking detergent, dodecylphosphocholine (DPC)22 
(see Figure 4). Again the peptides are not rigidly structured. In the case of N-Y4 we 
could previously show that a rather stable hydrophobic a-helix is formed between 
residues 4 and 11, present both in zwitterionic (DPC) as well as in anionic (SDS) 
micelles6, reflected by H-NOEs exceeding values of 0.6. In contrast, the N termini 
from all other Y receptors are less well ordered.The N-Y2 is fully flexible most likely 
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due to the complete lack of interactions with  hospholipids surfaces. The absence of 
such contacts is supported by the fact that essentially no chemical shift changes occur 
between N-Y2 in aqueous buffer and in DPC micelles. In contrast, both N-Y1 and N-
Y5 reveal short stretches of the polypeptide chain that become rigidified in the 
presence of the micelles. 
 
3.2.4 Structures of the N-terminal Domains in Presence of Phospholipid Micelles 
 
The NOE data of N-Y4 revealed the presence of a hydrophobic helix in the 
segment comprising residues 5 to 11. In addition, a nascent helix was observed in the 
region including residues 26 to 35. Inspection of the H-NOE data depicted in Figure 4 
clearly indicates that N-Y2 is devoid on any structured segments. Moreover, the H-
NOE of N-Y5 is generally below 0.6 and mostly values are even smaller than 0.4. In 
our experience secondary structure cannot reliably be determined in these cases. We 
speculate that the molecule, similarly to N-Y4, is segregated into a N-terminal helical 
region, and a much more destabilized shorter C-terminal helical region separated by a 
longer non-ordered segment, but the peptide is not ordered sufficiently well to allow 
for structural characterization by NMR in detail. 
In case of N-Y1, however, elevated values of the H-NOE are observed indicating 
that this polypeptide may be amenable to more detailed structural studies. 
Accordingly, we have assigned all proton and nitrogen resonances of N-Y1. Little 
chemical shift dispersion of amide proton resonances complicated the assignment 
process, and use of 3D 15N-resolved NOESY or TOCSY spectra had to be made. 
During assignment a larger number of contacts involving sequential amide protons 
were observed, indicating that the fy space of helical backbone conformations was 
significantly populated. Such stretches were for example observed involving residues 
4 to 9 and residues 24 to 32. An expansion of the spectral region of the [1H,1H]-
NOESY that displays the sequential amide proton NOEs in the segment from 24 to 32 
is shown in Figure S6 in the supplementary materials. However, except for two a,N 
(i,i+3) NOEs observed in the segment 4-9 no medium-range contacts were found. The 
relative strength of intra-residual and sequential aH,NH contacts changes between 
extended and helical conformations23, with the intra-residual distance in helices 
stronger than the sequential one, whereas in extended or unfolded segments the 
sequential distance is much shorter. A comparison of peak intensities revealed that the 
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sequential NOEs were generally stronger, and in the light of sequential contacts of 
amide protons, indicate conformational averaging between helical and extended 
conformations to some extent. Considering this observation it was not really 
surprising that persistent violations remained in the structure calculations, and helical 
conformations were only seen involving residues 4 to 9, a region, in which the H-
NOE is larger than 0.6. The 3J(HN,Ha couplings were larger than 6.5 Hz throughout 
the sequence (data not shown), reflecting the remaining conformational instability of 
N-Y1. To our surprise we have not been able to detect any medium range contacts in 
the segment 15 to 28, which according to the dynamics data should also be better 
ordered. We suspect this region to be transiently helical considering the occurrence of 
sequential amide proton contacts throughout this segment.  
To summarize, the spectroscopic data indicate that N-Y4 and N-Y5 are similar in 
that both contain two helical regions separated by a flexible central segment, with 
only the N-terminal helix in N-Y4 being well ordered. N-Y1 is largely helical 
between residues 4 and 28, but the remaining conformational flexibility precludes its 
detailed structural analysis. N-Y2 is fully flexible and devoid of any detectable 
residual structure.  
 
3.2.5 Interaction Studies with Neuropeptides from the NPY Family 
 
We have recently proposed that the peptides of the NPY family may transiently 
bind to the N-terminal domains in order to become transferred from the membrane-
bound state into the genuine binding pocket of the receptor6; 24. While in that work 
surface plasmon resonance was used to establish the strength of the bPP-NY4 
interaction, preliminary experiments using bPP or pPYY and the N-terminal domains 
from the other receptors have indicated that the interaction between the peptides and 
the other N-terminal domains are too weak to be detected by SPR. In this work we 
have now utilized chemical shift mapping experiments both in the presence and 
absence of DPC micelles in order to derive preliminary data on binding of the 
peptides from the NPY family to N-Y1, N-Y2 and N-Y5. The changes of chemical 
shifts of the neuropeptides upon adding 2 equivalents of the N-terminal domains are 
summarized in Figure 5. First of all we noticed that the magnitude of the changes is 
larger in the presence of DPC micelles as compared to aqueous buffer. This was 
surprising considering that in case of N-Y4 the interaction in the absence of micelles 
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was stronger than in the presence as judged by SPR6. It should be mentioned, 
however, that changes in chemical shift mapping depend on both the population 
difference between bound and free species, but also on the type of structural changes. 
Contacts with aromatic residues for example will for instance result in larger changes 
than contacts with polar side chains. Detachment of peptides from the micelle surface, 
possibly required for binding to the receptor N termini, will transfer part of the 
residues into a completely different environment, and we believe this effect to account 
for the larger changes observed in DPC micelles. 
In the presence of lipids, chemical shift changes for bPP are much larger than for 
the other peptides. When adding N-Y1 or N-Y5 to bPP the same residues of bPP are 
affected in a similar manner. In all cases the largest changes occur in the N-terminal 
half of bPP or in the segment from residues 26 to 35.  In case of pNPY changes are 
only appreciable for residues 14 and 15 upon addition of N-Y5. Changes in pPYY are 
very similar for all the N-terminal domains, and largest for residues 21, 26 and 27.  
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Figure 5: Chemical shift deviation of bPP (top panel), pPYY (middle panel) and pNPY (bottom 
panel) upon addition of N-Y1(orange bars), N-Y2 (pink bars) and N-Y5 (gray bars) in aqueous 
buffer (left column) or in the presence of DPC micelles (right column). 
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In the absence of lipids, larger changes are detected for pNPY throughout the 
sequence upon adding N-Y1 or N-Y2, but are fairly small for bPP and pPYY, except 
for residue 4 of bPP  upon addition of N-Y1. Pronounced differences are observed for 
pNPY residues 6, 14, 24, 26 and 36, and for residues 4 and 10 when adding N-Y1 or 
N-Y2, respectively. We like to emphasize here that the spectra of bPP and pPYY in 
water are concentration independent whereas the oligomerization state of pNPY is 
strongly concentration dependent25; 26; 27. In addition, the spectrum of pNPY is highly 
dependent on pH and other environmental variables. Although we tried to control 
these as tightly as possible we cannot fully exclude that part of the observed changes 
may relate to issues not directly linked to binding. 
To investigate whether pNPY really associates with N-Y2 we have performed a 
titration experiment, in which up to 10 equivalents of pNPY were added to 15N-
labelled N-Y2 (see Fig. 6). The data clearly show concentration-dependent changes of 
positions of resonances from the N-Y2. Resonances in the segments comprising N-Y2 
residues 16-21 and 33-50 are mostly affected. The data point to a low-affinity 
interaction of pNPY towards N-Y2 without much specificity. 
 
Figure 6: Chemical shift deviation of N-Y2 after addition of 1 and 10 equivalents of pNPY (from 
left to right). For additional data points at 0.5, 2 and 4 equivalents see Figure S12.  
 
To summarize the interaction studies we can say that significant and reliable 
effects were only detected in the presence of DPC micelles and that all peptides 
interact with the three N-terminal domains. The interaction with bPP results in the 
largest changes. 
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3.3 Discussions 
We have postulated that binding of ligands to Y receptors is preceded by 
association of the ligands to the plasma membrane. Thereby, the apparent 
concentration of the ligand is increased and the search for the receptor reduced from 
three to two dimensions 28; 29. We now studied whether parts of the receptor that 
protrude into the extracellular compartment may help in transferring ligands, which 
have accumulated in vicinity of the membrane, into the binding pocket. Such portions 
of receptor that point into the extracellular space are the N-terminal domains. Herein, 
we have developed strategies to produce these polypeptides recombinantly in 
isotopically-enriched form for use in high-resolution NMR studies. 
The work has demonstrated that these peptides can all be expressed as soluble 
fusions to ubiquitin. However, N-Y4 and N-Y1 are degraded in the intracellular 
milieu, and hence much better yields were obtained using insoluble fusions. Cleavage 
of the target sequence from the insoluble fusion partner could be obtained by 
solubilizing the fusion protein in the mild detergent sarcosyl, which proved to be 
compatible with enzymatic activity of the TEV protease used to cleave the peptide 
from the fusion protein. 
Studies on the structure and dynamics of the peptides using NMR revealed that 
they are all completely disordered in aqueous buffer. In the presence of 
 hospholipids micelles, segments of most receptor N termini became 
conformationally stabilized, with the exception of N-Y2, which remained. Otherwise, 
more (N-Y4) or less stable (N-Y1 or N-Y5) helical segments occurred within the 
sequences. For all N-terminal peptides chemical shit changes occurred in the presence 
of DPC micelles, except for N-Y2. This implies that all other peptides associate with 
the micelle to some extent. Previously, we have made extensive use of the 
thermodynamic data of Wimley and White for partitioning of single amino acids into 
the water-membrane interface or the membrane interior30 to rationalize how peptides 
interact with phospholipids micelles. A common observation was that the occurrence 
of the aromatic residues Trp and Tyr help in anchoring peptides in the interface31. The 
partitioning values of the four sequences of the N-terminal domains from the Y 
receptor subtypes are shown in Figure S7 in the supplementary materials. In N-Y4 a 
stretch comprising residues 5 to 11 is predicted to show partitioning into the micelle 
interior. This corresponds exactly to the region that becomes helically structured in 
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the presence of micelles. In case of N-Y2 many negatively charges residues occur 
throughout the sequence, while they are clustered in the central (unstructured) 
segment in N-Y4. Even more importantly, many Pro residues are present in N-Y2 that 
might prevent formation of secondary structure. The sequence of N-Y5 in comparison 
to N-Y2 is much more amphiphilic in nature, and therefore more likely to favorably 
interact with the micelles. Again, the regions that become better structured in the 
presence of DPC micelles correspond to stretches rich in hydrophobic/aromatic 
residues and hence are predicted to partition into the micelles. 
Our interaction studies using chemical shift mapping indicated that bPP strongly 
interacts with all N-terminal domains, but differences in the sensitivity of certain 
positions are observed. In contrast, for pPYY the changes are smaller, but more 
uniform upon addition of the different N termini. For pNPY the changes are very 
small, although the sequence of pNPY displays more than 80% homology to the one 
of pPYY. The difference between pNPY and pPYY is very intriguing. We speculate 
that this difference may be due to structural transitions occurring in pPYY when 
transiently associating with the N-terminal domain. pPYY in aqueous buffer displays 
the so-called PP-fold32, and tertiary structure is lost when pPYY associates with the 
membrane surface, or is transferred into a more hydrophobic solvent (e.g. 
methanol)33. Transient binding of PYY to any of the N-terminal domains is expected 
to alter the equilibrium between membrane-associated peptide, which is devoid of 
tertiary structure, and the membrane-detached peptide, that could possibly re-adopt its 
PP fold. Such a change will result in large chemical shift changes and would explain 
why the differences in pPYY are so much larger than for pNPY upon addition of the 
different N termini. In addition the changes due to such a structural transition may be 
much larger than those due to direct contacts, and therefore can possibly explain, why 
the changes in pPYY are so uniform across the different N-termini. Considering the 
sensitivity of the chemical shift mapping methodology to structural changes, but on 
the other hand the inherently low sensitivity of NMR, we consider results from SPR 
measurements to be more reliable for quantifying (but not for detecting) such 
interactions. In our BiaCore measurements we could detect strongest binding (Kd 
approx. 50 mM) for the bPP-NY4 interaction, and chemical shift mapping also 
revealed the largest changes for bPP upon addition of N-Y4. 
To summarize this work has described synthetic methods to produce all N-
terminal domains in isotopically labeled form in quantities sufficient, for the analysis 
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by various biophysical methods. Structural studies revealed them to be fairly flexible. 
However, while N-Y2 is fully unfolded residual helical structures were detected in N-
Y1 and N-Y5. For the case of N-Y4 we could previously detect a short rather rigid a-
helical stretch in the presence of DPC micelles. In contrast to N-Y4, the nascent 
helical regions of N-Y1 and N-Y5 contain too much residual motion, so that structure 
calculations did not fully converge towards a-helical structures. All peptides interact 
with the N terminal domains of N-Y1, N-Y2 and N-Y5, but the interactions are 
weaker than those previously described for bPP binding to N-Y4. 
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3.4 Materials and Methods 
3.4.1 Materials 
15NH4Cl was from Spectra Isotopes (Columbia, USA), d38-DPC- (99%-d), and 
D2O was from Cambridge Isotope Laboratories (Andover, Massachusets, USA). 5-
doxylstearic acid was from Aldrich (Buchs, Switzerland). Oligonucleotide primers 
were synthesized by Microsynth GmbH (Balgach, Switzerland). 
 
3.4.2 Expression and Purification of N-terminal Domains 
Depending on their stability against proteolysis the N-terminal domains were 
either expressed as fusions to ubiquitin (N-Y2 and N-Y5) or to ketosteroidisomerase 
(N-Y1 and N-Y4).  
In case of N-Y2 and N-Y5 the amino acid sequence was reverse translated into a 
DNA sequence taking into account the preferred E.coli codon usage including a 
terminal stop codon and a SalI restriction site. The resulting fragments were purified 
by electrophoresis and gel extraction and digested with SalI, resulting in fragments 
that were then blunt-ended on one side and contained SalI-cohesive end on the other 
end. These fragments were ligated into the pUBK19 vector (gift from T. Kohno, 
Mitsubishi Kasei Institute of Life Science, Tokyo, Japan), which had been digested 
with NsiI and SalI and purified before. The resulting plasmids were sequenced and 
transformed into C41 cells34. For production of 15N-labeled peptides M9 minimal 
media containing 15N-ammoniumchloride as the sole nitrogen source was used, 
otherwise expression was done on LB medium. In each case 1 liter of medium 
containing 50 mg/ml kanamycin was inoculated with 10 ml of an overnight LB 
culture. Cultures were induced at OD600 around 0.5 with 0.4 mM IPTG. LB- and 
minimal medium cultures were grown under induction for 4 h and 11 h, respectively. 
Cells were harvested by centrifugation on a Sorval GSA rotor at 4 °C and stored at -
20 °C. The cell pellets were thawed on ice for 1 h and resuspended in 25 ml 
denaturing basic buffer (50 mM Tris pH 8, 6 M GdnHCl, 100 mM NaCl, 1 mM 
bmercaptoethanol). The suspension was lysed by sonication on ice.  
The ubiquitin fusion proteins were purified by Ni-NTA chromatography. 
Refolding was achieved by applying a linear gradient to exchange the denaturing 
basic buffer to native binding buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM b-
mercaptoethanol, 20 mM imidazole), and the protein was eluted with binding buffer 
 116 
containing 200 mM imidazole. The eluates were diluted 10-fold with basic buffer (50 
mM Tris pH 8, 100 mM NaCl, 1 mM b-mercaptoethanol) and a 1 mg/ml YUH-
solution (for expression and purification of YUH see supplementary S8) was added in 
a 20-fold dilution. The cleavage reactions were allowed to proceed for 3 hours at 37 
°C. 
In case of N-Y1 and N-Y4 the DNA sequences were subcloned from wt cDNA of 
the corresponding Y receptor (University of Missouri-Rolla (UMR) cDNA Resource 
Center by PCR). During PCR, a GSGSGS linker followed by TEV cleavage sequence 
was introduced at the N terminus of the target sequence. After digestion with XhoI 
and EspI, the fragments were ligated with T4 DNA ligase into the pET31b vector, 
which had been digested with XhoI and EspI. The correctness of the constructs was 
verified by DNA sequencing (Synergene Biotech, Switzerland). The resulting 
plasmids were transformed into BL21(DE3) for expression. For production of 15N-
labeled peptides M9 minimal media containing 15N-ammoniumchloride as the sole 
nitrogen source was used, otherwise expression was done in LB medium. In each case 
1 liter of medium containing 50 mg/ml kanamycin was inoculated with 10 ml of an 
overnight LB culture. Cultures were induced at OD600 of 0.7 with 1 mM IPTG, 
harvested after 5 hours by centrifugation on a Sorval GSA rotor at 4 °C and the pellets 
were stored at -20 °C.  
The fusion proteins were purified from inclusion bodies by Ni-NTA 
chromatography in presence of 6 M GdnHCl. After removal of GdnHCl by dialysis 
the precipitated fusion protein was solubilized in 50 mM Tris pH 8.0 in the presence 
of 2% N-lauryl sarcosine upon sonication to a final concentration of 2 mg/ml. The 
resulting solution was dialyzed against a 20-fold excess of 50 mM Tris, pH 8.0 for 4-6 
times. The solution was diluted 10 times with 50 mM Tris pH 8.0 and EDTA and 
DTT were added to a final concentration of 0.5 mM and 1 mM, respectively. TEV 
protease (for expression and purification of TEV protease see supplementary 
materials S9) was added to a final concentration of 100 mM and the cleavage mixture 
was incubated at 4°C over night. 
All target peptides were finally purified by C18-RP-HPLC (Vydac, USA) by 
using a water/acetonitrile/0.1% TFA gradient. Yields ranged from 3 mg to 20 mg 
peptide from 1 liter of culture. The mass of all peptides was confirmed by MALDI-
TOF MS or ESI MS: N-Y1: 4532.9 Da (theoretical value: 4533.0 Da); 15N-N-Y1: 
4587.0 Da (theoretical value: 4587.0 Da); N-Y2: 5509.3 Da (theoretical value: 5510.0 
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Da); 15N-N-Y2: 5568.0 Da (theoretical value: 5570.0 Da); N-Y4: 4554.0 Da 
(theoretical value: 4556.1 Da); 15N-N-Y4: 4614.0 Da (theoretical value: 4611.1 Da); 
N-Y5: 6053.7 (theoretical value: 6053.4); 15N-N-Y5: 6119.5 Da (theoretical value: 
6118.4 Da). 
 
3.4.3 NMR Spectroscopy 
For studies of structure or backbone dynamics 1 mM solution of the peptides at 
pH 5.6, 20 mM d13-MES, 300 mM d38-DPC were used. All spectra were recorded on 
an AV-700 Bruker NMR spectrometer at 310 K. Chemical shifts were calibrated to 
the water line at 4.63 ppm and nitrogen shifts were referenced indirectly to liquid 
NH3{Live et al., 1984, #80817}. The spectra were processed using the Bruker 
Topspin2.0 software and transferred into the XEASY35 or CARA36 programs for 
further analysis.  
For chemical shift assignments 3D 15N-resolved TOCSY and NOESY37 were 
used. In case of N-Y5 we decided to use 13C,15N labeling in combination with 
experiments that directly correlate sequential amide moieties38. In general 
experiments used coherence selection schemes via pulsed-field gradients39 and 
sensitivity-enhancement building blocks40 whenever possible. Upper-distance limits 
for structure calculations of N-Y1 were derived from a 70 ms NOESY spectrum41. 
Structures were calculated in the program CYANA42, that uses restraint molecular 
dynamics in torsion angle space, and the implemented standard simulated annealing 
protocol in CYANA was used for that task.  
A proton-detected version of the steady-state 15N{1H} heteronuclear Overhauser 
effect sequence were used for measurement of the hetereonuclear NOE43. Therein, the 
buildup of the NOE was achieved through a pulse train of 120 degree proton pulses 
separated by 5 ms over a period of 3 seconds. 
For measurements of interactions by chemical shift mapping methodology 0.1 
mM solutions of the 15N-labeled neurohormones were mixed with the corresponding 
peptides from the N-terminal domains, and the deviations of peak positions were 
extracted from the [15N,1H]-HSQC spectra and computed according to 
Dd=SQRT(D(1H)2+0.2*D(15N)2). Particular care was taken to ensure that no shifts in 
pH occurred when adding the N-Y peptides. In case of addition of various equivalents 
of pNPY to 15N-labelled N-Y2 in the presence of DPC micelles (please describe the 
conditions here) 
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3.7 SUPPLEMENTARY MATERIALS 
 
In tables S1-S4 chemical shifts were referenced to the water line taken at 4.63 ppm at 310K. The 15N 
scale was derived indirectly by multiplying the frequency of 0 ppm for protons (the Bruker parameter 
SF) by 0.101329118. Chemical shifts have been deposited in the BMRB data base under deposition 
codes 80.8933262 (N-Y1), 80.6873033 (N-Y2) and 80.74817093 (N-5). 
 
Table S1: Chemical Shifts of N-Y1 in the presence of DPC micelles 
 
 HN H’α Hβ others 
Met 1 - - -, - γCH2 -, -; εCH3 - 
Asn 2 - - -, - δNH2 -, - 
Ser 3 8.52 4.42 -, - γOH - 
Thr 4 8.32 4.28 4.01 γCH3 1.17; γOH - 
Leu 5 8.23 4.03 1.86, 1.86 γH 1.17; δCH3 0.79, 0.72 
Phe 6 7.97 4.46 2.96, 3.18 δH 7.19; εH -, - ; ζH - 
Ser 7 8.02 4.31 3.86, 3.86 γOH - 
Gln 8 8.25 4.28 2.04, 2.04 γCH2 2.33; εNH2 7.44 
Val 9 7.90 3.94 2.05 γCH3 0.88 
Glu 10 8.26 4.09 1.85, 1.88 γCH2 2.33; εH - 
Asn 11 8.29 4.51 2.69, 2.69 δNH2 7.58, 6.86 
His 12 8.32 4.57 3.05, 3.19 δ1NH -; δ2H 7.09; ε1H -; ε2NH - 
Ser 13 8.18 4.40 3.79, 3.79 γOH - 
Val 14 8.15 4.00 2.01 γCH3 0.81 
His 15 8.30 4.61 3.09, 3.09 δ1NH -; δ2H 7.05; ε1H -; ε2NH - 
Ser 16 8.22 4.62 3.77, 3.80 γOH - 
Asn 17 8.17 4.19 2.63, 2.63 δNH2 7.50, 6.81 
Phe 18 8.22 4.50 2.99, 3.10 δH 7.17; εH 7.25; ζH - 
Ser 19 8.17 4.29 3.79, 3.79 γOH - 
Glu 20 8.38 4.14 1.96, 1.96 γCH2 2.22; εH - 
Lys 21 8.15 4.18 1.71, 1.71 γCH2 1.37; δCH2 1.94, 2.02; εCH2 2.74; ζNH3+ - 
Asn 22 8.13 4.57 2.68, 2.68 δNH2 7.49, 6.81 
Ala 23 8.13 4.11 1.36  
Gln 24 8.13 4.15 2.02, 2.02 γCH2 2.31; εNH2 7.49 
Leu 25 8.01 4.16 1.64, 1.64 γH 1.54; δCH3 0.88, 0.81 
Leu 26 7.83 4.17 1.57, 1.57 γH 1.46; δCH3 0.83, 0.79 
Ala 27 7.74 4.19 1.23  
Phe 28 7.97 4.55 3.13, 3.13 δH 7.20; εH 7.04 ; ζH - 
Glu 29 8.33 4.20 1.87, 1.87 γCH2 2.18; εH - 
Asn 30 8.30 4.62 2.78, 2.78 δNH2 7.58, 6.86 
Asp 31 8.19 4.50 2.58, 2.58 δH - 
Asp 32 8.07 4.29 2.78, 2.78 δH - 
Cys 33 8.29 4.75 2.59, 2.65 γSH - 
His 34 8.36 4.66 3.09, 3.09 δ1NH -; δ2H 7.13; ε1H -; ε2NH - 
Leu 35 8.32 4.51 1.62, 1.62 γH 1.44; δCH3 0.86 
Pro 36  4.44 1.91, 1.96 γCH2 2.19,2.22 ; δCH2 3.78, 3.83 
Leu 37 8.05 4.18 1.57, 1.57 γH -; δCH3 0.87, 0.81 
Ala 38 8.18 4.27 1.32  
Met 39 8.22 4.38  2.06 γCH2 2.55, 2.66; εCH3 1.96 
Ile 40 7.38 4.01 1.79 γCH2 1.09, 1.37;  δCH3 0.82 
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Table S2: Amide proton and 15N chemical shifts of N-Y1 
 
 N HN 
Met 1     
Asn 2     
Ser 3 116.26 8.52 
Thr 4 116.44 8.36 
Leu 5 122.7 8.27 
Phe 6 115.8 7.99 
Ser 7 114.84 8.04 
Gln 8 120.6 8.25 
Val 9 118.8 7.9 
Glu 10 122.35 8.27 
Asn 11 118.23 8.29 
His 12 119.81 8.26 
Ser 13 115.76 8.24 
Val 14 120.68 8.18 
His 15 120.62 8.38 
Ser 16 116.22 8.2 
Asn 17 119.23 8.2 
Phe 18     
Ser 19 115.9 8.21 
Glu 20 122.3 8.41 
Lys 21 120.03 8.16 
Asn 22 118.11 8.13 
Ala 23 123.09 8.16 
Gln 24 117.35 8.13 
Leu 25 120.96 8.03 
Leu 26 118.6 7.84 
Ala 27 122.05 7.74 
5Phe 28 117.83 7.98 
Glu 29 120.35 8.34 
Asn 30 118.61 8.31 
Asp 31 120.03 8.31 
Asp 32 118.07 8.08 
Cys 33 120.08 8.47 
His 34 119.74 8.39 
Leu 35 122.68 8.39 
Pro 36     
Leu 37 120.63 8.05 
Ala 38 122.21 8.2 
Met 39 118.15 8.23 
Ile 40 122.86 7.38 
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Table S3: Amide proton and 15N chemical shifts of N-Y2 
 
 N HN 
Met 1   
Gly 2 112.1 8.59 
Pro 3   
Ile 4 120.1 8.16 
Gly 5 112.9 8.42 
Ala 6 123.6 8.07 
Glu 7 119.4 8.39 
Ala 8 123.9 8.14 
Asp 9 119.1 8.12 
Glu 10 120.9 8.3 
Asn 11 118.7 8.37 
Gln 12 120.3 8.15 
Thr 13 115.7 8.15 
Val 14 122.2 8.09 
Glu 15 123.8 8.33 
Glu 16 121.5 8.26 
Met 17 121.1 8.22 
Lys 18 122.8 8.18 
Val 19 121 8.02 
Glu 20 123.9 8.37 
Gln 21 120.6 8.15 
Tyr 22 120.4 8.12 
Gly 23 109.8 8.06 
Pro 24   
Gln 25 119.8 8.49 
Thr 26 114.7 8.08 
Thr 27 118.5 8.09 
Pro 28   
Arg 29 121 8.33 
Gly 30 109.4 8.28 
Glu 31 119.9 8.15 
Leu 32 122.8 8.19 
Val 33 122.6 8.04 
Pro 34   
Asp 35 121.3 8.23 
Pro 36   
Glu 37 121.8 8.3 
Pro 38   
Glu 39 120.1 8.37 
Leu 40 123.3 8.18 
Ile 41 121.2 7.98 
Asp 42 123.9 8.26 
Ser 43 117.8 8.36 
Thr 44 114.9 8.21 
Lys 45 122.2 7.83 
Leu 46 122.2 7.92 
Ile 47 120.2 7.83 
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Glu 48 124.4 8.26 
Val 49 121.4 8.06 
Gln 50 128.5 7.89 
 
Table S4: Amide proton and 15N chemical shifts of N-Y4 
 
Met 1   
Asn 2 8.171 119.838 
Thr 3 8.29 114.787 
Ser 4 8.26 127.348 
His 5   
Leu 6   
Leu 7 8.006 121.818 
Ala 8 7.953 123.247 
Leu 9 7.817 119.79 
Leu 10 7.915 121.832 
Leu 11 7.897 123.675 
Pro 12   
Lys 13 8.257 120.984 
Ser 14 8.221 117.544 
Pro 15   
Gln 16 8.338 119.671 
Gly 17 8.243 109.457 
Glu 18 8.225 120.207 
Asn 19 8.454 119.731 
Arg 20 8.252 121.321 
Ser 21 8.211 116.37 
Lys 22 8.092 123.461 
Pro 23   
Leu 24 8.423 122.478 
Gly 25 8.315 109.153 
Thr 26 7.874 115.514 
Pro 27   
Tyr 28   
Asn 29 8.083 120.162 
Phe 30 7.989 120.843 
Ser 31 8.069 116.045 
Glu 32 8.133 121.685 
His 33 8.288 117.461 
Cys 34   
Gln 35 8.43 121.02 
Asp 36 8.224 120.984 
Ser 37 8.096 115.276 
Val 38 8.002 120.362 
Asp 39 8.251 122.983 
Val 40 7.918 119.379 
Met 41 7.85 128.423 
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Table S5: Amide proton and 15N chemical shifts of N-Y5 
 N HN 
Met 1   
Ser 2   
Phe 3 118.81 7.84 
Tyr 4 118.03 7.63 
Ser 5 115.85 8.1 
Lys 6 122.27 8.25 
Gln 7 119.04 8.18 
Asp 8 119.37 8.03 
Tyr 9 120.84 8.43 
Asn 10 119.6 8.25 
Met 11 120.23 8.22 
Asp 12 120.96 8.38 
Leu 13 121.09 7.9 
Glu 14 120.56 8.39 
Leu 15 121.51 8.39 
Asp 16 118.01 8.47 
Glu 17 118.35 8.04 
Tyr 18 117.72 7.86 
Tyr 19 118.5 8.1 
Asn 20 117.52 8.21 
Lys 21 118.77 7.9 
Thr 22 113.27 7.8 
Leu 23 121.69 7.83 
Ala 24 122.63 7.76 
Thr 25 112.49 7.92 
Glu 26 122.74 8.19 
Asn 27 120.23 8.43 
Asn 28 119.29 8.35 
Thr 29 114.05 8.05 
Ala 30 125.61 8.17 
Ala 31 122.26 8.07 
Thr 32 112.43 7.92 
Arg 33 122.34 8.32 
Asn 34 119.25 8.36 
Ser 35 115.51 8.17 
Asp 36 121.69 8.26 
Phe 37 120 8.11 
Pro 38   
Val 39 117.15 8.04 
Trp 40 122.72 8.12 
Asp 41 118.58 8.12 
Asp 42 118.49 7.95 
Tyr 43 119.01 7.82 
Lys 44 121.02 7.75 
Ser 45 115.33 8.12 
Ser 46 117.18 8.06 
Val 47 118.82 7.84 
Asp 48 122.02 8.04 
 127 
Asp 49 119.12 8.03 
Leu 50 121.18 7.9 
Gln 51 124.45 7.67 
 
 
 
 
 
Figure S6: Expansion of the 70 ms NOESY of N-Y1, displaying the assignment of 
residues 24 to 31: 
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Figure S7: Free energies for partitioning residues of the Y receptor N-terminals (top 
left: N-Y1, top right: N-Y2, bottom left: N-Y4 and bottom right: N-Y5) domains into 
the water-membrane interface (circles) or into the membrane interior (diamonds) 
(data taken from ref. 24). Regions of favorable values are shaded in grey.  
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S8: Expression and purification of YUH 
Yeast ubiquitin hydrolase (YUH) was expressed with a C-terminal hexahistidine 
tag and purified on a Ni-NTA column. The plasmid coding for the YUH-construct 
pYUHK20b was a generous gift from Toshiyuki Kohno (Mitsubishi Kasei Institute of 
Life Science, Tokyo, Japan). 
5 ml of LB-broth containing 50 µg/ml kanamycin were inoculated with a colony 
of BL21 DE3 pYUHK20b cells, streaked onto plate from a glycerol stock, and 
incubated for 12 h at 37 ˚C and 220 rpm. 0.5 liter of LB-broth containing 50 µg/ml 
kanamycin were inoculated with the 5 ml overnight culture and incubated at 37 ˚C 
and 240 rpm in a 2 l Erlenmeyer flask. The culture was induced with 0.4 mM IPTG at 
an OD600 of 0.6-0.7 and grown for another 5 h to a final OD600 of around 5. The culture 
was harvested by centrifugation at 5000 rpm and 4 ˚C for 20 min. 7 g of wet biomass 
were obtained from 1 l of culture. The cell pellet was frozen at -20 ˚C. 
The cell pellet was thawed on ice and resuspended in 40 ml resuspension buffer 
(50 mM Tris pH 8, 100 mM NaCl, 1 mM β-mercaptoethanol). 9 mg of lysozyme were 
added and the mixture incubated on ice for 15 min. The resuspension mixture was 
sonicated on ice with a Branson Digital Sonifier.  
The lysate was centrifuged twice at 190000 rpm and 4 ˚C for 45 min and loaded 
onto a 10 ml column volume (CV) Ni-NTA-agarose column previously equilibrated 
with running buffer (50 mM Tris pH 8, 100 mM NaCl, 1 mM β-mercaptoethanol, 10 
mM imidazole). Bound protein was eluted with elution buffer (50 mM Tris pH 8, 100 
mM NaCl, 1 mM β-mercaptoethanol, 100 mM imidazole). The eluate was confirmed 
to contain the target protein by SDS-PAGE. To 10 ml of eluate 1.1 ml of glycerol 
were added to yield a final glycerol concentration of 10%. The YUH-concentration of 
this mixture was determined by a Bradford assay to be 7 mg/ml. This solution was 
stored at -20 °C in 1 ml aliquots. 
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S9: Expression and purification of TEV protease 
The plasmid pTH241 was transformed to Rosetta(DE3) pLys cells. 0.5 ml of an 
overnight LB culture containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol 
were used to inoculate 1 liter of TB also containing 100 µg/ml ampicillin and 34 
µg/ml chloramphenicol. The culture was incubated at 37 °C. When it  reached an 
OD600 of 0.6 it was induced with 0.1 mM IPTG and the temperature was lowered to 
20 °C. After 20 hours the cells were harvested by centrifugation and the cell pellet 
was stored at –20 °C. 
The cell pellet from 1 liter culture was resuspended in 40 ml washing buffer (50 
mM sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 7). The resuspension 
mixture was sonicated on ice with a Branson Digital Sonifier. After centrifugation at 
4 °C at 30000 g for 30 min the supernatant was loaded onto a Ni-NTA column. 
Unbound protein was eluted with washing buffer and bound protein was eluted with 
elution buffer (washing buffer with 200 mM imidazole). EDTA and DTT were added 
to a final concentration of 2 and 10 mM, respectively. 10 ml eluate were dialyzed over 
night against 1 liter dialysis buffer (25 mM sodium phosphate, 200 mM NaCl, 2 mM 
EDTA, 2 mM DTT, pH 8) at 4 °C. 10% glycerol were added and the protease solution 
was stored at –20 °C. 
Susanne van den Berg, Per-Ake Lofdahl, Torleif Hard, Helena Berglund, Improved 
solubility of TEV protease by directed evolution,  2006, J. Biotechnol., 121, 291-298 
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Table S10: MS fingerprinting of cleavage products from the N-Y4 expression: 
Exp. Theor. _Mass Peptide fragment 
2701 2701.279 0.278 (L)PKSPQGENRSKPLGTPYNFSEHCQ(D) 12-35 
2701 2701.482 0.481 MNTSHLLALLLPKSPQGENRSKPLG(T) 1-25 
2899 2899.582 0.582 MNTSHLLALLLPKSPQGENRSKPLGTP(Y) 1-27 
3176 3176.688 0.688 MNTSHLLALLLPKSPQGENRSKPLGTPYN(F) 1-29 
3323 3323.757 0.756 MNTSHLLALLLPKSPQGENRSKPLGTPYNF(S) 1-30 
4554 4554.221 0.221 MNTSHLLALLLPKSPQGENRSKPLGTPYNFSEHCQDSVDVM 1-41 
 
 
 
 
 
Table S11: Screening of suitable detergents for enzymatic cleavage of the N-Y-KSI 
fusion peptides:  
name characteristics concentration 100mMNaCl 
added 
n-Decanoylsucrose nonionic  9mM cannot solubilze the  
peptide 
Improved a little 
dihexanoylphosphatidylcholine zwitterionic 4mM cannot solubilze the  
peptide 
 
n-Octyl-β-D-glucopyranoside nonionic 35mM cannot solubilze the  
peptide 
 
n-Dodecyl-β-D 
maltopyranoside 
nonionic 1-6x CMC cannot solubilze the  
peptide 
 
Fos-choline zwitterionic 1-6x CMC cannot solubilze the  
peptide 
Improved a little 
n-Octyl-β-D-glucopyranoside nonionic 1-6x CMC cannot solubilze the  
peptide 
 
n-Nonyl-β-D-maltoside nonionic 1-6x CMC cannot solubilze the  
peptide 
 
n-Decyl-β-D-glucopyranoside nonionic 1-6x CMC cannot solubilze the  
peptide 
 
Sarcosyl anionic 0.4% can solubilze the  peptide completely 
soluble 
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Figure S12: Titration of N-Y2 with 0.5 (yellow), 1 (orange), 2 (red), 4 (purple), and 
10 (blue) equivalents of pNPY. 
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Chapter 4 
  
Biosynthesis and NMR-studies of a double 
transmembrane domain from the Y4 receptor, a 
human GPCR  
 
4.1 Introduction 
Membrane proteins are the most abundant class of proteins in prokaryotic and 
eukaryotic organisms and account for 20-30% of the total genome 1; 2. Amongst these, 
G-protein coupled receptors (GPCRs) constitute the largest membrane protein family 
3, accounting for 2% of the genome 4. GPCRs play critical roles in molecular 
recognition and signal transduction and are among the most pursued pharmaceutical 
targets 5. Around 30% of all marketed prescription drugs act on GPCRs, making this 
class of proteins a most successful therapeutic target 6. 
Despite their prime biological importance surprisingly little structural information 
is available due to the tremendous difficulties encountered in producing GPCRs in 
active form and the problems associated with their structural study by crystallography 
or NMR. Recent advances in the expression and purification of membrane proteins 
have been described for various expression hosts, for example: Escherichia coli 7; 8; 9, 
yeast 10; 11, insect cells 12, mammalian cells 13; 14 and cell-free systems 15. However, 
from approximately 1000 known GPCRs, only five high-resolution 3-D structures of 
two distinct receptor types have been reported: bovine rhodopsin 16 and opsin 17, squid 
rhodopsin 18, the human β2-adrenergic receptor 19; 20 and the turkey β1-adrenergic 
receptor 21.  
As long as structural studies on intact GPCRs remain complicated by technical 
difficulties, the study of fragments of these receptors can deliver potentially valuable 
insights into the structure and function of these molecules. Studies on fragments may 
also help to establish methods required to tackle more complex systems, in particular 
by providing information concerning protein-lipid interactions. While fragments of 
domains from soluble proteins are often not stably folded, in integral membrane 
proteins the additional stabilizing interactions that occur between TM helices and the 
surrounding lipids can result in stretches of the polypeptide that are conformationally 
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defined and can be studied on their own. In 1990 Popot proposed a two-step model, 
the so-called partitioning-folding model, to describe assembly of membrane proteins 
in vivo 22; 23, that was later extended by White 24: Initially, partitioning of the protein 
into the water-membrane interface results in formation of secondary structure. 
Interactions of the hydrophobic side chains with the surrounding lipid environment 
then lead to insertion of the transmembrane domains into the membrane interior. 
Finally, the functional protein is assembled via formation of the proper helix-helix 
contacts. According to this model the transmembrane domains can be thought of as 
independent folding units and be studied separately. A large body of literature 
supports the basic assumption of the model: For example, proteolysis of membrane 
proteins resulted in fragments containing entire TM sequences 25, and chemically or 
recombinantly synthesized TM peptides spontaneously assembled thereby rescuing 
receptor activity 26; 27; 28; 29. Finally, peptides corresponding to the N and C terminus 30; 
31, loop domains 32; 33; 34; 35 and transmembrane domains 33; 34; 36; 37; 38; 39; 40; 41; 42 from 
GPCRs have been found to fold to distinct secondary structures which in certain cases 
resembled the structures of the corresponding regions of the intact receptor.  
TM domains usually contain about 25 residues 43; 44, therefore double-TM 
constructs in phospholipid micelles should be applicable to high-resolution NMR 
study. Though much effort has been devoted to the study of membrane proteins both 
by NMR and crystallography, so far few membrane protein structures have been 
determined by the former technique, amongst these the F1,F0-ATPase 45, the bacterial 
mercury transport membrane protein 46 and the human glycine receptor 47, all of 
which comprise two TM domains. One reason why there are still so few NMR studies 
of larger membrane proteins published is due to the fact that sufficient quantities of 
labeled protein are often not available for the required trials to optimize sample 
conditions. In the current study we therefore tried to optimize expression of a double 
transmembrane fragment of the NY-4 receptor. We consider that the solutions to 
problems addressed in this work might be generally applicable to researchers working 
on polytopic membrane polypeptides.  
X-ray diffraction analysis of integral membrane proteins requires high quality 
single crystals. In contrast NMR in solution and the solid state is independent of 
protein crystallization and provides complementary information to that obtained by 
X-ray investigations 48; 49; 50; 51; 52; 53; 54. However, NMR studies on GPCRs or large 
fragments of these integral membrane proteins require isotopic enrichment. This 
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requirement makes production impossible in expression systems such as mammalian 
hosts, because deuteration has not been achieved to date. Moreover, membrane 
proteins must be studied in a membrane-like environment such as detergent micelles. 
The concomitant increase in molecular weight as a consequence of micelle 
incorporation results in a dramatic decrease in spectral quality. In addition, slow 
conformational exchange processes lead to additional line-broadening. This has led to 
the frequently encountered experience that signals from the TM regions of membrane 
proteins remain invisible 54. The lack of availability of fully deuterated detergents, 
compounds the technical difficulty of obtaining high resolution spectra for GPCRs or 
their fragments in micelles. 
 
 
Figure 1: “Snake”-plot type presentation of the human Y4 receptor. The plot was modified from 
a download from the GPCR.org website. The part of the receptor that has been expressed in this 
work is shaded in gray. Note that the expressed polypeptide additionally contains a C-terminal 
(His)6 tag. The omitted sequences for parts of the N terminus and the E1 loop are indicated 
separately in the figure. 
 
Herein, we report on the expression and purification of a 115-residue (121 
residues with the His tag) fragment from the neuropeptide Y4 GPCR containing the N 
terminus, the first transmembrane domain (T1), the first intracellular loop (I1), the 
second transmembrane domain (T2), and the first extracellular loop  (E1) followed by 
a (His)6 tag. This peptide (N-TM1-TM2) comprises about one third of the total length 
of the receptor (Fig. 1) and was obtained in multimilligram quantities. Importantly, 
the construct contains no fusion that needs to be removed after expression, and hence 
bypasses problems associated with chemical cleavage in the presence of residues like 
Met, or the enzymatic cleavage of hydrophobic sequences in the presence of 
detergents. Spectra with good quality could only be obtained when working under 
 136 
reducing conditions which eliminated fragment oligomerization. Detergent mixtures 
proved to be necessary to yield the high quality spectra required for our analyses. 
Using a 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)] 
(LPPG)/dodecyl-phosphocholine (DPC) mixture and uniform 2H,13C,15N labeling, 
TROSY-based 3D triple-resonance spectra could be recorded that allowed almost 
complete assignment of the backbone nuclei. The secondary chemical shifts indicate 
that the peptide is largely helical except for a mostly unfolded N-terminal domain.  
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4.2 Results 
4.2.1 Optimization of Protein Expression  
In order to obtain maximum expression of N-TM1-TM2 four different strains, 
BL21(DE3), C41(DE3) 55, BL21-AI and BL21-pLys(DE3), were evaluated. Amongst 
these BL21(DE3) is the most widely used expression host, while the other strains 
have been developed to express toxic proteins. Expression was tested for each strain 
at 37 °C and 20 °C. As shown in Fig. 2 temperature has a dramatic effect on the 
expression level of the target protein, which is significantly higher at 20 °C than at 37 
°C. Although BL21(DE3) expresses the target protein at 20 °C, the reduced levels in 
comparison to the other strains that we tested indicates that the target protein may be 
toxic to this strain. Considering the perfect control of leakage expression, BL21-AI 
was chosen as the host for large-scale expression; nevertheless the difference in 
comparison to strains C41 or BL21pLys(DE3) is small.  
 
 
Figure 2: Selection of strain and expression conditions shown for BL21 and C41 (left) and for 
BL21-AI and BL21 pLys (right). B denotes “before induction”, 37 denotes “induction at 37 °C” 
and 20 denotes “induction at 20 °C”. 
 
The chosen construct comprises six cysteine residues, some of which will 
spontaneously form disulfide bonds, in particular in the presence of the divalent 
cation Ni2+. Protein preparations in both reducing and non-reducing sample buffer 
were analyzed by SDS-PAGE. It was observed that dimers, trimers and other 
oligomeric forms are observed in the non-reducing sample. Furthermore, we noticed 
the presence of a smear in the gel suggesting the occurrence of non-specific 
aggregation. Upon addition of 100 mM DTT to the sample buffer the smearing 
disappeared and the oligomerization was dramatically reduced indicating that 
disulfide bond formation was responsible for aggregation.  
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4.2.2 Optimization of Purification and Detergent 
 
The protein recovered after Ni affinity chromatography and treatment with DTT 
was fairly homogeneous as judged by SDS-PAGE. Nevertheless, the [15N,1H]-
TROSY spectrum still displayed too few peaks, and peak intensities varied 
considerably. The latter characteristic is most likely due to conformational exchange 
processes. We reasoned that lipid components from the cell membrane or other 
hydrophobic impurities that co-elute with N-TM1-TM2 from the affinity column may 
result in a conformationally heterogeneous interaction/integration into the 
phospholipid micelles. Using this protein preparation we were unable to identify 
detergents that resulted in better spectra (vide infra). Accordingly the eluant from the 
Ni affinity column was subjected to C4 reverse-phase HPLC. The detrimental effects 
on spectral quality of contaminants remaining after Ni affinity chromatography have 
also been recently discussed by Page et al 56. The overall yield from a 1 L M9 culture 
of transformed BL-21AI cells after this additional step of chromatography was 
approximately 6 mg. We also noticed to our surprise that after lyophilization the 
solubility of the HPLC-purified protein in certain detergents had completely changed.  
In order to obtain resolved TROSY spectra with sharp peaks a number of 
detergents were screened, including anionic (SDS, sarcosyl, LPPG, LMPG), 
zwitterionic (DPC, DHPC, LDAO) and non-ionic (OGP, DDM) detergents, and 
proton-nitrogen correlation spectroscopy was used to assess the suitability of the 
resulting samples for structural studies. As shown in Fig. 3 different detergents 
resulted in vastly different spectra. In some detergents tested the target protein was 
insoluble. Spectra measured in most detergents that dissolved the protein were of poor 
quality in that most of the expected peaks were missing and that some lines were very 
broad (Fig. 3G and H). Spectra recorded in the presence of SDS micelles resulted in 
too many peaks albeit that they were very sharp (Fig. 3F). In addition, measurements 
of the 15N{1H}-NOE indicated that the protein was highly flexible.  
While the protein after elution from the Ni affinity column was nicely soluble in 200 
mM LPPG solution, it turned out to be largely insoluble in the same detergent after 
the additional HPLC step. In contrast, it was now well soluble in DPC solution, a 
detergent in which the eluant from the Ni-affinity column was insoluble. Since it was 
observed that low-concentration samples prepared in LPPG resulted in good spectra, 
 139 
and considering the fact that DPC can solublize the protein well, we tested mixtures 
of these two detergents to exploit the individual advantages of both. First the minimal  
 
 
 
Figure 3: Plots of the two-dimensional [15N,1H]-HSQC spectra of N-TM1-TM2 recorded on 
samples of varying degrees of purity (spectra A to D) in various detergents (spectra E to H).  
Spectra were recorded using 0.3mM samples of the protein at pH 6.0 in 200mM LPPG (A,B,D), 
30mM DPC/ 120mM LPPG (C), 150mM DPC (E), 170mM SDS (F), 170 mM OGP (G) and 
100mM DHPC (H) at pH 6.0. The spectra on the left display protein samples directly after the 
Ni-affinity chromatography (A), after additional reduction with 100mM DTT and 250mM 
mercaptoethanol (B), after additional RP-HLPC in LPPG/DPC (C) and after purification and 
refolding using a method proposed by Page et al. 56 (D). The spectra on right were recorded with 
protein samples of highest purity and homogeneity. All data were recorded at 47 °C at 700 MHz 
proton frequency and the recognizable peak numbers out of the expected 115 are 74 (B), 109 (C), 
97 (D), 63 (E), 161 (F), 12 (G), 15 (H), respectively, and is impossible to determine in (A).  
 140 
concentration of DPC required to dissolve at least 0.5 mM protein was determined. 
Then increasing amounts of LPPG were added to DPC until a good-quality spectrum 
was obtained, and no further chemical shift changes upon addition of more LPPG 
occurred. The final detergent mixture consisted of 6% LPPG and 1% DPC and was 
used in all subsequent studies. The TROSY spectra recorded on such a sample 
displayed rather uniform linewidths. In addition, the 15N{1H}-NOE data indicated that 
the backbone is rather rigid and that secondary structures are likely formed (see Fig. 
6). Estimation of the overall correlation time derived from the 15N R2/R1 ratio 
resulted in a value of 11.4 ns at 47°C. 
 
4.2.3 Spectroscopy and Backbone Assignment 
 
Considering the rather large molecular weight of the N-TM1-TM2/DPC/LPPG 
mixed micelle deuteration of the peptide was essential to yield spectra of sufficient 
quality. For backbone assignment a threefold strategy was pursued: i) matching of 
amide moieties via common Cab resonances in the HNCACB and HN(CO)CACB 
experiment, ii) matching via common CO frequencies in the HNCO and HN(CA)CO 
experiments, and iii) NOEs between sequential amide protons. Approx. 70% 
deuteration and the comparably narrow amide lines allowed for efficient TROSY-type 
triple resonance experiments. Alpha helical transmembrane proteins have intrinsically 
less signal dispersion and only constant-time 13C and 15N evolution in combination 
with mirror-image linear prediction provided sufficient resolution. Correlations in the 
triple-resonance HNCA and HNCACB spectra were observed for more than 80% of 
all residues. In the HNCO/HN(CA)CO pair correlations were almost always present. 
Representative strips from the assignment process are depicted in Fig. 4. Matching 
strips could be confirmed in the 15N-resolved NOESY for all residues within the 
helical region with sufficient resolution in the proton frequency. In the end all HN,N 
,Ca and Cb nuclei could be assigned except for residues number 2 and 5, which are 
located in the flexible N terminal domain (see supplementary Table S3). Chemical 
shifts have been deposited in the BMRB database under accession code 15921. 
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Figure 4: Plot displaying strips from the HNCACB (top), the HN(CA)CO (middle) and 15N-
NOESY spectra for the TM segment comprising residues Val54 to Cys61. Only Cα  resonances 
are connected in the top panel. Strips were extracted at the 15N chemical shifts of the 
corresponding amide nitrogen. All data were recorded at 700 MHz at 47 °C using the 2H,13C,15N 
triply labeled protein in the 28 mM DPC/ 118 mM LPPG detergent mixture in 40 mM phosphate 
buffer, pH 6.0. 
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4.2.4 Secondary Structure  
The CD spectrum of N-TM1-TM2 in DPC/LPPG mixed micelles is depicted in 
Fig. 5. For technical reasons, 50uM polypeptide was used in comparison to 0.5mM in 
the NMR sample. However based on the NMR spectra no aggregation occurred at the 
higher concentration and we believe the data obtained from the CD and NMR study is 
comparable. The CD spectrum clearly shows the presence of minima at 208 and 222 
nm, typical for predominantly alpha helical conformations. In addition, deconvolution 
of the CD spectrum into contributions from the different secondary structural 
elements using the program K2D (http://www.embl-heidelberg.de/~andrade/k2d/) 
allowed estimating the content in a-helix to be around 57%. The CD analysis 
indicates that secondary structure under these conditions is properly formed.  
 
 
 
Figure 5: CD spectrum of 50 mM N-TM1-TM2 recorded at 47 °C in 40 mM phosphate buffer 
(pH 6.0) containing a mixture of 28 mM DPC and 118 mM LPPG. Data are converted to mean 
residue ellipticity. 
 
In order to verify the results from the CD analysis, we have evaluated the 
15N{1H}-NOE to derive information on the rigidity at residue resolution. The data are 
depicted in Fig. 6 and compared to structural and dynamical properties of the isolated 
N-terminal domain from the Y4 receptor recently determined by us in the presence of 
pure DPC micelles at pH 5.6 57. The latter structural studies revealed the presence of a 
short a-helical stretch comprising residues 5 to 10, followed by a longer flexible loop 
in the segment between residues 11 and 25. Interestingly, the data on the construct 
described in this work indicated the presence of this flexible loop even when the N-
terminal domain was fused to the first two helices. Otherwise the data indicate that 
with the exception of the N-terminal domain the protein is highly structured. 
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Surprisingly, little difference in rigidity is observed between residues from the 
putative TM helices and the loops. In addition the long first extracellular loop (E1), 
that in our construct lacks its native connection to the third TM, is rather rigid. Amide 
hydrogen exchange as measured in a [15N,1H]-HSQC experiment with and without 
presaturation of the water resonance revealed accelerated exchange only for the N-
terminus, for the long unstructured loop in the N-terminal domain (see supplementary 
Figure S2) and in vicinity to the charged residue within TM1. Surprisingly, even in 
the I1 or E1 loop, hydrogen exchange is relatively slow indicating that these segments 
are reasonably folded and/or protected from solvent access. 
 
 
Figure 6: Comparison of the 15N{1H}-NOE values for N-TM1-TM2 (black spheres) described in 
this work and the isolated N-terminal domain from the Y4 receptor (N-Y4, red diamonds). All 
values were measured on the 600 MHz spectrometer. Data of N-Y4 are taken from Zou et al57. 
 
Sidechain assignment is presently in progress, which will help establishing 
secondary structure based on characteristic medium-range NOEs. However, backbone 
15N, Ca, Cb and C’ shifts have already been assigned and hence the location and type 
of secondary structure can be predicted based on secondary chemical shifts 58; 59. The 
output of the program TALOS 60 is depicted in Fig. 7. It predicts 74% of the 77 
residue C-terminal fragment (the 2 TM helices plus the loops) to be helical. 
Interestingly, in both TM helices TALOS predictions indicate the TM helices to be 
destabilized adjacent to the internal polar residues Glu51and Thr52 in TM1 or Ser86 
and Asp87 in TM2. Accordingly, no predictions were made for these regions. The 
locations of helical segments were also probed using proton,proton NOEs. In helices 
comparably short distances occur between sequential amide protons. Fig. 4 shows 
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contacts within the segment encompassing residues Val54 to Cys61 that are consistent 
with such short distances. Comparably strong NOEs between sequential amide 
protons occur through most of the residues in the TM1/TM2 segments. Additionally 
they are observed for most of the residues from the I1 and E1 loops. 
 
 
Figure 7: Summary of the 15N{1H}-NOE values for N-TM1-TM2 (bottom), predicted regions of 
helical structure based on 15N,13Cα β  and C’ chemical shifts using the program TALOS (middle)  
and the presence of NOEs between sequential amide protons (top). Amide moieties displaying 
NOEs to both preceding and following residues are indicated by squares, and by triangles with 
the top to the left or right for those residues that only display contact to predecessors or 
successor, respectively. All segments with degeneracy of proton chemical shifts that does not 
allow identification of NOE cross peaks are indicated by crosses. 
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4.3 Discussions 
Considering the tremendous difficulties encountered during expression, 
purification, reconstitution and the spectroscopic evaluation of entire GPCRs, new 
strategies to derive useful structural information are highly desired. Accordingly, in 
this work we developed synthetic approaches for a double-TM construct that 
additionally contains the N-terminal domain and the first extracellular loop.  
To our knowledge despite the success reported on the expression of polytopic 
bacterial membrane proteins56, most multiple-TM polypeptides from higher 
organisms have been expressed as fusion proteins followed by either enzymatic or 
chemical cleavage from their fusion partners. Enzymes used to release the 
hydrophobic membrane peptides are often deactivated by the detergents that are 
required to solubilize the expressed fusion proteins. Thus yields are poor and much 
material is wasted. Cyanogen bromide (CNBr) is usually the chosen reagent for 
chemical cleavage, but is incompatible with the occurrence of internal methionine 
residues, limiting its general usage. In this study a relatively long double-TM domain 
(approx. one third of the sequence of the entire receptor) from a human receptor was 
expressed without a fusion partner. This approach allowed expression of the wild-type 
protein sequence, eliminated the cleavage step, simplified purification and resulted in 
a final yield of six mg/L of culture. It should be noted that expression of entire 
GPCRs has been accomplished in various hosts, as fusion proteins as well as directly, 
and work in this area has been reviewed 61; 62. 
Purity and homogeneity are critical factors affecting the quality of NMR spectra. 
Considering that 15N-NH4Cl is comparably cheap and that [15N,1H]-TROSY spectra 
deliver a wealth of information on the state of the protein, we decided to monitor each 
step of purification using 15N,1H-correlation spectroscopy using only 15N-labeled 
protein. We noticed a number of interesting points: (1) The Ni-NTA affinity 
chromatography seemed to result in pure protein as visualized by SDS-PAGE, 
however the spectral quality from such samples was clearly insufficient (see 
supplementary Figure S1); (2) due to the presence of 6 cysteines, the protein was 
prone to forming aggregates that result in severe line broadening, and work-up under 
strongly reducing conditions was mandatory (see supplementary Figure S1); (3) the 
dramatic improvement after HPLC purification indicated the presence of non-
proteinaceous contaminants, which cannot be readily removed by affinity 
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chromatography. The chemical nature of the contaminants has not been identified so 
far, but we suspect them to be molecules that strongly associate with the protein so 
that they are not stripped off during the hydrophilic elution conditions of the affinity 
chromatography. This result suggests that they may be lipids or other hydrophobic 
components of the plasma membrane, that possibly also associate with the receptor in 
its natural environment. Another possibility is that they are proteins that bind to the 
metal affinity column. The presence of such contaminants apparently leads to 
heterogeneity in the microenvironment of the protein chains, in particular in the 
vicinity of the TM segments. This could affect the conformational exchange processes 
leading to the observed line-broadening. While HPLC purification is a standard 
technique for peptide chemists, it is often not used by protein biochemists because the 
solvent conditions denature most globular proteins. The possible presence of 
associating non-proteinaceous or proteinaceous contaminants is relevant to 
crystallographers who usually judge protein purity from SDS-PAGE gels. Perhaps 
screening of sample purity by 15N,1H NMR, at least for some of the smaller 
membrane proteins systems, could prove useful prior to embarking on crystallization 
attempts. We are aware that the proposed procedure requires a refolding step. In the 
context of entire GPCRs such refolding may not be achieved easily. However, in 
literature precedents that such refolding is possible can be found 63; 64; 65. 
Membrane proteins can only properly exert their function when inserted in the 
membrane. Natural membranes, however, are characterized by the following features: 
they are patchy, with segregated regions of different chemical composition, variable 
thickness and distinct function 66. To mimic this environment various media have 
been developed such as detergent micelles 67, bicelles 68; 69; 70 amphipols 71; 72, and 
very recently nanoscale bilayers 73 (for a general review on the usage of detergents in 
NMR studies of membrane proteins see 74; 75; 76. For reasons of simplicity micelles 
have been frequently employed for NMR studies. In our study a wide range of 
detergents have been tested: Sarcosyl, LDAO, and DDM did not solubilize N-TM1-
TM2. LPPG and LMPG only dissolved it to a very low extent, and others including 
DPC, OGP and DHPC dissolved the protein, but resulted in extremely broad spectra. 
Based on heteronuclear NOE analyses SDS resulted in a non-uniquely structured 
protein, an observation frequently also reported by other groups 67. The result of the 
detergent screening conducted in this study indicated that it may be useful to consider 
detergent mixtures when optimizing membrane protein solubility and integration into 
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micelles. In the case of N-TM1-TM2 neither LPPG nor DPC gave satisfactory results, 
but the combination of these detergents resulted in a high-quality [15N,1H]-TROSY 
spectrum, in which 107 out of the expected 109 (without counting residues from the 
His-tag) peaks were observed. The final composition exhibited long-term stability and 
allowed us to run all of the three dimensional experiments required for a structural 
analysis. Natural membranes are heterogeneous mixtures of a variety of lipids and 
proteins. We suspect that various detergents can play different roles in solubilizing the 
peptide, aiding its integration into the lipid-like environment and forming a relatively 
stable composition. In the present example the LPPG head group is likely a much 
better mimic of head groups of naturally occurring lipids than DPC because the 
central glycerol component is retained. For reasons that are unclear to us at the 
moment, LPPG’s capability to spontaneously allow insertion of the N-TM1-TM2 
protein is low and it does not solubilize the purified polypeptide. In contrast DPC 
micelles readily integrate the membrane protein but give extremely broad lines in the 
HSQC spectra, possibly reflecting the presence of conformational exchange. The ratio 
between DPC and LPPG was, therefore, chosen to represent the minimal amount of 
DPC required to dissolve the protein. The optimized composition gave a highly 
resolved HSQC spectrum perhaps indicating that LPPG-peptide contacts are 
maximized in the TM region resulting in a relatively homogeneous microenvironment 
that led to good spectroscopic properties. By using a combination of detergents the 
number of membrane mimetic environments can be greatly increased and the 
possibility for trials that can exploit the synergistic contributions of different head 
groups and hydrophobic matches is maximized. It is important to note that protein 
detergent complexes are not idealized micelles and the insertion of detergents with 
different chain lengths at various positions in an asymmetric composition might, from 
a thermodynamic perspective, be predicted to lead to an optimally packed protein-
lipid.  
Inspection of NOEs between sequential amide protons, and restraints from 
chemical shifts delivered by TALOS allowed the derivation of the first low-resolution 
picture of secondary structure in the N-TM1-TM2 polypeptide. Stretches of the 
putative TM helices are predominantly helical (see Fig. 7). However, in the regions 
proximal to polar residues in the TMs (E and D in TM1 and TM2, respectively) the 
helices are destabilized, as judged by the reduction in the heteronuclear NOEs, by the 
TALOS predictions, by enhanced amide proton exchange and by the absence of 
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contacts between sequential amide protons. Buried glutamic acid and aspartic acid 
residues are rarely found in TM domains of integral membrane proteins, and we have 
noted such increased flexibility on another isolated TM domain in DPC micelles42. 
The biological significance of these findings will be subject to future work. A 
particularly interesting finding is, that the I1 and E1 loops are predominantly helical. 
The sequence of the beginning of the I1 loop is amphiphilic, and may possibly form a 
surface-associated helix. The sequence of the E1 loop is also amphiphilic in nature. In 
addition, it is rich in aromatic residues that are expected to position it in the interfacial 
compartment. Given the strong energetic driving force to place E1 in the interface 
compartment it is unlikely that E1 forms a flexible loop that diffuses into bulk 
solution. In the published crystal structures from rhodopsin 16 and the b-adrenergic 
receptors 20; 21, the long E2 loop contained elements of secondary structure; in the case 
of rhodopsin a short  b-sheet, in the case of the β1- and β2-adrenergic receptors a-
helices. However, the I1 and the E1 loops were devoid of regular secondary structure. 
Whether the helical nature of the E1 and I1 domains of N-TM1-TM2 is biologically 
relevant awaits additional studies on larger Y4 receptor fragments. At present it is 
also unclear how the I1 and E1 helices would connect the TM helices and reinsert 
smoothly into the membrane. However, in GPCR structures published to date we note 
that the length of the TM helices is not generally conserved, e.g. the TM5 and TM6 of 
squid rhodopsin were surprisingly deeply penetrating into the cytosol 18. 
Previously, we reported the conformational preferences of the isolated N-terminal 
domain in the presence of DPC micelles 57. The comparison of the dynamics data 
indicate that the latter and the corresponding fragment from the N-TM1-TM2 protein 
are highly similar in that they contain a short helix comprising residues 5 to 10, 
followed by a long and unstructured loop between residues 11 and 30. The segment 
that connects that loop to the first TM (residues 31 to 40) is rather flexible in the 
isolated N-Y4 peptide, but mostly helical in N-TM1-TM2. The amphiphilic sequence 
of the N-terminal region of N-TM1-TM2 is compatible with the presence of a surface-
associated helix. Such a helix was also observed by us on a similar construct from the 
Ste2p receptor, a family D GPCR from yeast (unpublished results). 
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4.4 Conclusions 
To conclude we have developed a synthetic route for directly expressing and 
isolating double-domain mammalian GPCR fragment in isotopically-labelled form in 
good yield. Rigorous purification using a combination of affinity chromatography and 
reversed-phase HPLC resulted in a sample with dramatically altered biophysical 
properties. A rational method for NMR sample optimization is introduced that relies 
on mixtures of detergents.  The methodology allowed the collection of good-quality 
3D NMR spectra, and preliminary results indicated the protein to be highly structured 
in the LPPG/DPC mixed micelles. Future work will be aimed at fully establishing the 
secondary and tertiary structure of this important domain of human N-Y4. We believe 
that the presented methodology may also be useful in the studies of even larger 
fragments or entire receptors.  
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4.5 Materials and methods 
4.5.1 Plasmid Construction 
The forward primer CGCGCTCATATGATGAACACCTCTCACCTCCTG, in 
which bold letters denote a NdeI cleavage site and the backward primer 
AGCGCGGGATCCTCAGTGATGGTGATGGTGATGCTTGCAGAGGGTCTCTC
CAAA, in which bold letters denote a BamHI cleavage site, italic letters the stop 
codon and underlined letters the 6xHis tag, were used to amplify the gene encoding 
N-TM1-TM2 from the cDNA of the Y4 receptor (University of Missouri-Rolla, 
USA). The amplified gene was ligated into the plasmid pLC01 after both were 
cleaved with NdeI and BamHI and purified from agarose gel. The correctness of the 
recombinant DNA was confirmed by dideoxy sequencing (Synergene Biotech, 
Switzerland). 
 
4.5.2 Protein Expression and Purification 
The plasmid encoding the target protein was transformed into BL21-AI cells for 
expression, which were previously shown to result in higher expression levels 
compared to other strains 36. A freshly transformed colony was used to inoculate 10 
ml LB containing 100 mg/ml ampicillin. This preculture was grown over night at 37 
°C and was then used to inoculate 1L LB (for the unlabeled sample) or M9 (with 
15NH4Cl and 13C glucose as sole nitrogen and carbon sources) media containing 100 
mg/ml ampicillin and cultured at 37 °C until the OD600 reached 0.45-0.5. For 
induction the temperature was lowered to 20 °C and 0.2% L-arabinose was added. 
Cells were harvested after 12 hours and stored at –20 °C until further use. To allow 
expression in deuterated water transformed BL21-AI cells were plated on a D2O M9 
agar plate, and one colony was used to inoculate a LB preculture in 100% D2O 
containing 100 mg/ml ampicillin. The preculture was grown at 37 °C overnight and 
was then used to inoculate 1L 95% D2O M9 containing 75 mg/ml ampicillin. After 
incubation at 37°C overexpression was induced when the OD600 had reached 0.45 by 
adding 0.2% L-arabinose at 20 °C, and cells were harvested after 24 hours. 
The cell pellet from 1 L culture was resuspended in GdHCl-containing buffer and the 
target protein purified from inclusion bodies under denaturing conditions using Ni-
affinity chromatography.  The protein was incubated together with 100 mM DTT, 250 
mM mercaptoethanol, 10 mM EDTA at 4 °C over night to reduce any disulfide bonds. 
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The reduced eluant was purified by C4 reverse-phase HPLC using a H2O/acetonitrile 
solvent system containing 0.1% TFA. The correctness of the target peptide was 
confirmed by MALDI-TOF (in case of unlabeled sample: 13645, theoretical mass: 
13647.9) as well as western blotting with anti-His antibody and N-terminal amino 
acid sequencing. The level of deuteration for the sample that was used for the 
backbone assignment was approx. 65% according to MS. Incomplete deuteration is 
solely due to back-exchange from labile protons and protons picked up from the non-
deuterated glucose. 
 
4.5.3 NMR Sample Preparation 
1.7 mg 15N or 2H,13C,15N uniformly labeled protein was dissolved in 200 µl 
90%H2O/ D2O containing 2.5 mg DPC by thorough sonication and shaking at 37 °C 
for 30 min. 15 mg LPPG were dissolved in 50 µl 0.2 mM phosphate buffer (pH 6.0), 
after which the two detergent solutions were mixed. The final concentration for each 
component in the final solution was as follows: 0.5 mM protein, 1% (28 mM) DPC, 
6% (118 mM) LPPG, 10% D2O and 40 mM phosphate buffer (pH 6.0). The sample 
was stable for more than 2 months at 4 °C and more than 2 weeks at 47 °C.  
 
4.5.4 NMR Spectroscopy and Backbone Assignment  
All data were recorded on Avance 600 and 700 MHz Bruker spectrometers using 
triple-resonance cryoprobes at 47 °C. Chemical shifts of protons were calibrated 
according to the water line at 4.53 ppm at 47 °C, from which the carbon and nitrogen 
chemical shifts were referenced indirectly using the conversions factors published on 
the BMRB database. Sample optimization was conducted using solely 15N-labeled 
samples and [15N,1H]-TROSY spectroscopy 77. For backbone assignments standard 
Bruker experiments for the TROSY versions 78 of the 3D HNCACB 79; 80, 
HN(CO)CACB 79, HNCO 81 and HN(CA)CO 81 and a 200 ms 15N-NOESY were used. 
For the HNCACB or HN(CO)CACB experiments 1024(1H)*20(15N)*80(13C), for the 
HNCO or HN(CA)CO experiments 1024(1H)*20(15N)*32(13C), and for the 3D 15N-
resolved NOESY 1024(1H)*20(15N)*125(1H) complex data points were acquired. 
Spectral widths (and carrier positions) were 26 ppm (118.0 ppm) for 15N, 60 ppm for 
13C in the experiments that label Ca and Cb resonances with the carbon carrier at 39 
ppm for Cab and 54 ppm for Ca. In the HNCO-type experiments 20 ppm were used 
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for carbon, with the carrier set to 176 ppm. All experiments used pulsed field 
gradients for water suppression 82, and the Kay-Palmer sensitivity enhancement trick 
83 as incorporated into the TROSY sequences by Weigelt 84. A proton-detected 
version of the steady-state 15N{1H} heteronuclear Overhauser effect sequence was 
used for measurement of the heteronuclear NOE using a train of 120 degree proton 
pulses separated by 5 ms over a period of 3 seconds to achieve saturation of amide 
protons 85. 15N{1H}-NOEs were computed from the ratio of integrals from signals in 
the presence to those in the absence of amide proton irradiation. 
Spectra were processed within the Bruker spectrometer software Topspin 2.0. 
Backbone assignment was accomplished within the software CARA 86. Preferences 
for secondary structure based on 13Ca, 13Cb, 13CO and 15N chemical shifts were 
computed with the program TALOS 60. 
 
4.5.5 Circular Dichroism Spectroscopy 
CD spectra were recorded on Jasco model J-810 using 50 mM protein in 40 mM 
phosphate buffer (pH 6.0) in a mixture of 1% DPC and 6% LPPG in a quartz cuvette 
with a path length of 1 mm. All spectra were averaged from 3 consecutive 
measurements in the range between 190 and 250 nm at 47 °C with a slit width of 1nm 
and a scanning rate of 5 nm/min. The blank sample was recorded under identical 
conditions and subtracted from the sample spectra. The final CD intensity is 
expressed as the mean residue ellipticity (deg cm2 dmol-1). 
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4.8 Supplementary Materials 
 
 
Figures: S1: Aggregation for TM1-TM2 
 
 
 
 
 
 
 
Figure S2: Presaturation experiment: 
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Table S3 Chemical shift of N-TM1-TM2-Y4 
 
No. Residue H N CA CB CO 
3 THR 8.502 116.704 64.639 68.049 175.956 
4 SER 8.297 117.174 61.182 62.11  
6 LEU 7.541 118.651 57.169 40.818 178.007 
7 LEU 7.824 116.372 57.203 40.259 178.092 
8 ALA 7.431 118.379 53.659 17.352 179.231 
9 LEU 7.319 116.245 56.134 41.323 177.463 
10 LEU 7.352 115.795 55.042 42.384 175.882 
11 LEU 7.336 116.954 52.441 40.46 174.681 
13 LYS 8.211 120.489 55.169 32.156 176.35 
14 SER 8.163 117.305 55.913 63.147 173.046 
16 GLN 8.235 119.338 55.489 28.446 176.399 
17 GLY 8.14 109.486 44.86  174.064 
18 GLU 8.118 120.26 56.033 29.231 176.105 
19 ASN 8.292 118.881 52.891 38.159 174.891 
20 ARG 8.087 121.063 55.578 29.724 175.979 
21 SER 8.158 116.689 57.852 63.693 173.757 
22 LYS 7.993 123.056 53.762 31.71 174.26 
24 LEU 8.099 120.823 54.763 41.43 177.019 
25 GLY 8.042 108.218 44.654  173.293 
26 THR 7.822 114.31 59.277 68.975 173.156 
28 TYR 7.73 118.795 57.613 38.16 174.899 
29 ASN 8.086 119.892 52.539 37.743 175.384 
30 PHE 8.113 121.307 59.609 38.722 176.702 
31 SER 8.225 114.721 60.226 62.833 175.609 
32 GLU 7.85 120.867 57.44 28.538 177.125 
33 HIS 7.831 115.255 55.926 28.369 175.614 
34 CYS 7.956 118.697 60.705 27.006 175.257 
35 GLN 8.248 120.432 57.827 27.72 176.773 
36 ASP 8.113 118.158 55.651 39.767 177.393 
37 SER 7.797 114.924 61.304 63.068 175.333 
38 VAL 7.798 121.908 65.628 30.682 176.829 
39 ASP 8.08 119.262 56.611 39.228 178.94 
40 VAL 7.717 119.968 65.61 30.696 177.133 
41 MET 7.834 118.844 58.492 31.117 177.828 
42 VAL 8.409 118.005 66.193 30.847 178.527 
43 PHE 7.972 121.986 60.701 37.947 177.557 
44 ILE 8.253 119.943 64.547 36.878 177.638 
45 VAL 8.1 114.911 64.891 30.67 176.856 
46 THR 7.736 107.996 63.125 69.177 175.815 
47 SER 7.486 116.533 60.129 63.251 173.66 
48 TYR 7.513 119.947 57.3 38.891 174.547 
49 SER 7.996 114.635 57.196 64.313 175.532 
50 ILE 8.668 123.423 63.026 36.645 176.94 
51 GLU 8.527 119.58 59.329 27.728 179.185 
52 THR 7.736 116.742 65.512 68.076 176.22 
53 VAL 7.675 120.84 66.226 30.679 177.119 
54 VAL 8.366 117.993 66.304 30.539 178.266 
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55 GLY 7.853 107.714 46.592  176.326 
56 VAL 7.824 121.858 65.569 30.632 178.171 
57 LEU 8.181 119.129 57.552 40.384 179.287 
58 GLY 8.615 106.718 47.107  175.71 
59 ASN 7.753 120.101 55.856 37.98 177.852 
60 LEU 8.223 120.884 57.618 40.632 178.803 
61 CYS 8.253 117.607 63.741 26.203 176.421 
62 LEU 7.779 118.724 57.244 40.254 179.732 
63 MET 8.021 119.473 58.33 31.962 177.828 
64 CYS 7.88 116.525 62.913 26.804 175.883 
65 VAL 7.788 116.707 65.039 30.796 177.477 
66 THR 7.812 114.599 65.039 68.594 176.237 
67 VAL 7.85 120.146 64.688 30.548 176.854 
68 ARG 7.831 119.629 57.561 28.783 177.026 
69 GLN 7.846 117.188 57.086 27.852 177.34 
70 LYS 7.903 119.125 57.185 31.888 177.399 
71 GLU 8.139 117.887 56.43 28.092 176.762 
72 LYS 7.951 120.119 57.557 31.378 176.943 
73 ALA 8.009 122.21 52.929 17.831 177.742 
74 ASN 8.017 116.734 53.932 38.031 176.59 
75 VAL 8.101 119.059 64.495 30.794 176.585 
76 THR 7.937 114.408 65.352 67.953 175.438 
77 ASN 7.933 118.552 55.01 37.823 176.631 
78 LEU 7.664 120.124 56.61 41.235 177.914 
79 LEU 7.748 118.737 56.825 40.967 177.916 
80 ILE 7.748 115.977 62.554 37.006 176.982 
81 ALA 7.726 121.253 53.177 17.982 178.009 
82 ASN 7.648 114.432 53.546 39.12 174.909 
83 LEU 7.713 121.071 55.624 41.242 177.014 
84 ALA 8.026 122.608 52.829 17.628 178.085 
85 PHE 7.832 116.965 58.715 38.221 176.416 
86 SER 8.013 114.77 60.676 62.804 175.522 
87 ASP 8.107 121.944 56.714 39.495 178.197 
88 PHE 7.93 120.164 60.276 38.171 176.854 
89 LEU 7.876 118.322 57.193 40.554 178.23 
90 MET 7.946 115.666 57.389 30.773 178.358 
91 CYS 7.678 117.566 61.858 26.084 176.489 
92 LEU 7.523 119.597 57.08 40.879 176.955 
93 LEU 7.541 113.374 55.777 41.017 177.303 
94 CYS 7.463 113.246 60.09 27.666 175.267 
97 LEU 8.131 117.315 56.787 39.982 178.197 
98 THR 7.656 112.816 65.312 68.215  
99 ALA 7.805 124.299 54.592 17.593 178.848 
100 VAL 7.664 116.162 65.607 30.546 177.032 
101 TYR 7.939 118.513 59.883 36.748 177.758 
102 THR 7.909 114.942 65.878 68.552 176.027 
103 ILE 7.801 120.128 64.101 36.779 177.296 
104 MET 8.011 117.727 58.19 31.58 177.495 
105 ASP 7.978 118.206 56.131 39.54 177.742 
106 TYR 7.862 118.423 59.975 37.529 177.029 
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107 TRP 8.19 120.39 59.408 28.847 176.828 
108 ILE 7.786 117.441 62.928 36.541 177.551 
109 PHE 7.666 119.482 59.212 38.067 177.289 
110 GLY 8.122 107.674 46.379  174.728 
111 GLU 8.246 120.011 57.799 27.902 177.57 
112 THR 7.774 113.838 64.716 68.348 175.617 
113 LEU 7.848 121.518 56.756 40.886 178.085 
114 CYS 7.807 115.664 60.692 26.926 175.433 
115 LYS 7.8 119.058 57.202 31.471 176.86 
116 HIS 7.882 116.16 55.42 28.445 174.38 
117 HIS 7.943 117.91   173.812 
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Chapter 5 
  
Recognition of neurohormones of NPY family by 
their receptors 
 
5.1 Introduction 
G protein-coupled receptors (GPCRs) play a pivotal role in biology by 
transmitting signals from outside the cell into the cell, thereby bypassing the cellular 
membrane that is impermeable for most of the signaling molecules. So far only a 
single high-resolution structure of an intact GPCR, namely from bovine rhodopsin, 
has been published1. Therein, the polypeptide chain crosses the membrane seven 
times, and these segments are comprised of α-helices, which pack against each other. 
The transmembrane-helices are connected via three extracellular and three 
intracellular loops. In addition, all GPCRs possess N- and C-terminal domains of 
varying size and may in addition be glycosylated or further modified.  
Whereas at least some information on the structure of GPCRs is available, and 
modeling using structural information derived from rhodopsin is frequently done2, 
little is known on the exact binding mode of ligands to the GPCRs. To some extent 
such information is available from receptor mutagenesis studies (e.g. for the case of 
rhodopsin see references in Rader et al.3), from photoaffinity labeling4; 5 or spin 
labelling6 experiments. Interestingly, the results from these techniques are not always 
fully consistent, which may be due to the fact that mutants with reduced affinity 
potentially suffer from significant distortions in their architecture even if the mutated 
residues are not directly involved in binding. Nevertheless, all these techniques have 
dramatically improved our understanding of ligand binding to GPCRs.  
An interesting question related to this subject is whether the ligands to GPCRs are 
directly recognized from solution or whether they associate with the membrane prior 
to receptor binding (see Fig. 1). Kaiser and Kezdy in their seminal paper have noticed 
that many features of the ligands seem to be optimized for membrane binding7. 
Moreover, they realized that the ligands are often far too large for the few contacts 
they probably make with their receptors8. Accordingly, they suspected that the 
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hormones were evolutionarily optimized for membrane binding. This view was then 
further developed by Schwyzer, who established the membrane compartment model9; 
10; 11. His theory states that the membrane also helps to sort the ligands into the correct 
compartments, e.g. the aqueous phase, the water-membrane interface or the 
membrane interior, and that it could in addition pre-organize the molecules to adopt a 
conformation similar to the bioactive (receptor-bound) one. 
 
 
Fig.1: Pathway for recognition of hormones from the NPY family by their receptors via direct 
recognition from solution (path II) or via a series of events, in which association with the 
membrane (Ia) followed by lateral diffusion along the membrane precedes receptor binding (Ib). 
 
The ideas of Kaiser, Kezdy and Schwyzer have been heavily debated during the 
last 20 years or so. Moroder in an elegant approach has added lipid chains to the 
peptides in order to increase their affinity for the membrane12. The membrane 
compartment model was originally formulated very generally in such that it may be 
applicable to all kinds of ligands to GPCRs, but in the meantime many cases have 
been reported in which such a pathway is unlikely. We have decided to take a 
structural approach to this question and look at non-modified hormones13. In our 
studies we have structurally characterized peptides from the neuropeptide Y family 
both in solution and in the membrane-bound states13; 14; 15; 16; 17; 18. We have 
subsequently investigated whether structural differences of a series of peptides with 
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known pharmacology can be better related to the solution structures or to the 
structures of the membrane-bound state. This view requires that molecules with 
highly similar pharmacology at different receptor subtypes should possess similar 
conformations in the state from which they are recognized. If this would not be the 
case the associated changes of entropic terms would result in differences in the free 
energies of binding, which in turn would translate into differences in binding affinities 
or signal transduction efficiencies. 
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5.2 Structural Features of Peptides from the Neuropeptide Y Family 
in Solution 
 
The neuropeptide Y family comprises three different members: The neuropeptide 
Y (NPY), the peptide YY (PYY) and the pancreatic peptide (PP) 19. These C-
terminally amidated peptides contain 36 amino acids. Moreover, the N-terminal 
segment contains a Pro-rich segment, and in addition many aromatic residues, in 
particular Tyr residues, are found in the sequence, which is also the reason for the 
name (NPY). The peptides target a heterologous population of G protein-coupled 
receptors, the so-called Y receptors20; 21. These are approx. 375 to 450 amino acid 
long polypeptides coupled to proteins of the Gi subtype. So far, four Y receptor 
subtypes have been identified, sequenced and pharmacologically characterized. They 
occur in the central or peripheral nervous system and in the gastrointestinal tract. 
Activation of these receptors by one of the peptides triggers pharmacologically highly 
important functions22 such as vasoconstriction, memory retention and food uptake, 
which recently moved into focus of research23; 24. 
The pancreatic polypeptide was one of the first smaller peptides that is devoid of 
disulfide bonds or any other rigidifying modifications, for which a crystal structure 
became available. In their work Blundell et al. could demonstrate that the C-terminal 
half of the molecule, comprising residues 14-29, forms an amphiphatic α-helix, which 
via a turn encompassing residues 10 to 13 is connected to an N-terminal type II 
polyproline helix25. The latter forms a hydrophobic contact by back-folding onto the 
amphiphatic α-helix resulting in a structural motif that became known as the PP fold. 
The crystal structure of avian PP (aPP) also revealed the presence of a dimer. Therein, 
aromatic residues form a hydrophobic core, in which the π-systems of Tyr and Phe 
residues stack onto each other thereby mutually stabilizing both the back-fold as well 
as the dimeric nature of the peptides. Later on, it could be demonstrated by NMR that 
in case of bovine PP (bPP) the PP-fold also exists in solution26. The neuropeptide Y 
was originally also proposed to display a PP-fold type structure27. However, a later, 
better resolved structure revealed that the N terminus is flexible28, and this view was 
then supported by our data on backbone dynamics18 and from spin-labeling studies29. 
PYY is again back-folded and in its structure highly similar to PP16; 30 (see Fig. 2), 
although PYY is believed to largely exists in monomeric form31. Common to all 
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molecules of the NPY family is the C-terminal α-helix, but differences exist in the 
structure of the C-terminal pentapeptide.  
 
 
 
Fig.2: Backbone representation of the 20 lowest-energy conformers of PYY as determined by 
NMR spectroscopy in solution (left) or when bound to DPC micelles (right). 
 
Most of the peptides from the NPY family are dimeric in nature with dissociation 
constants in the low µM range for NPY and PP, with the exact values very much 
depending on the pH. PYY in contrast is proposed to largely exist in monomeric 
form. We have introduced a particular amino acid derived from the spin label 
TEMPO in combination with 15N labeling to establish spatial proximity of residues of 
NPY in the dimer18. From these data we concluded that in the NPY dimer both 
parallel and anti-parallel association of the helices occurs. However, it is presently 
unclear whether contacts are present simultaneously by forming a three-helix bundle, 
or whether the two association modes interconvert via a partially unfolded state. 
It is somewhat surprising that NPY and PYY differ so much in their solution 
structure considering that their sequence homology is larger than 80%. In particular, 
the distribution of hydrophobic, polar or charged residues along the sequence is 
almost identical. In an attempt to better understand the molecular features that favor 
one conformation over the other we have expressed all single Pro-to-Ala mutants as 
well as certain mutants, in which Tyr was replaced by Ala. One of the most obvious 
differences between sequences of NPY and PYY is that Pro in NPY occurs at position 
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13 whereas it is found at position 14 in PYY. Replacing Pro-14 in PYY by Ala did 
not disrupt the back-fold. In contrast, when Pro-14 was shifted to position 13, where it 
is found in NPY, the back-fold is no longer present, and hence a single amino acid 
shift by one position seems to be sufficient to transform the molecule from the PP-
fold conformation into the non back-folded species. Replacement of Pro residues 2, 5 
and 8, which are part of the polyproline type II helix, by Ala always destabilized the 
back-fold dramatically (unpublished results), and we believe that this is due to an 
increase of the entropy of the non back-folded species.  In addition, Tyr7 in bPP is 
involved in the π-stacking interactions, but no such Tyr residue is found in position 7 
in PYY, although the structure of PYY is highly similar to the one of bPP. We have 
introduced Tyr into position 7 in PYY, and noticed formation of a stable dimer, in 
which ring-stacking interactions almost identical to the ones observed in PP occur.  
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5.3 Structural Features of Peptides from the Neuropeptide Y Family 
in the Membrane-bound State 
Biophysical properties of the membrane interior or the water-membrane interface 
are substantially different from those in bulk aqueous solution, and partitioning of 
peptides into these compartments may result in structural changes. Accordingly, we 
have determined structures of the NPY peptides in the presence of membrane-
mimicking dodecylphosphocholine (DPC) micelles32. These readily assemble into 
spherical aggregates, the size of which is still compatible with high-resolution NMR 
studies.  
Fig. 2 displays a comparison of the structure of procine PYY (pPYY) in aqueous 
solution and in the presence of DPC micelles. Clearly, a remarkable conformational 
transition has occurred: Whereas the C-terminal α-helix has been retained, the contact 
between the N- and C-terminal segments has been disrupted16. The hydrophobic side 
of the α-helix now forms the membrane-binding interface. The membrane also serves 
to stabilize the C-terminal α-helix in NPY and in particular the C-terminal 
pentapeptide, which is rather flexible in solution but very rigid in the micelle-bound 
state18. We have mainly used a micelle-integrating spin-label, 5-doxylstearate, which 
in a distance-dependent manner broadens signals from protons close to the 
phospholipid head-groups, in order to establish the membrane-binding topology. All 
peptides from the NPY family are anchored onto the micelle through insertion of side-
chains from hydrophobic residues into the hydrophobic interior. More polar or 
charged residues are oriented towards the aqueous phase. The N-terminal segment, 
which is rather rigid in the back-folded peptides, always becomes flexible in the 
micelle-bound state and mainly diffuses freely in solution.  
The structural transition can be well explained using thermodynamic arguments: 
Wimley and White have determined free energies of transferring whole amino acids 
from bulk solution into the membrane-water interface or into the membrane interior 
33. Their data confirm our intuitive understanding of how polarity and hydrophobicity 
should influence partitioning. In particular, their work, which has been recently 
verified based on a biological read-out of partitioning34, attributes a particular role to 
aromatic amino acids, and in particular to Tyr and Trp residues35.  Predicting the 
membrane-anchoring mode of the NPY peptides based on their thermodynamic data 
accurately reproduces our experimental findings13. For example, the N-terminus of 
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NPY or PYY makes no contacts with the micelle surface, whereas such contacts are 
observed in the case of bPP, an observation that can be readily attributed to the 
presence of Tyr7 in bPP. The energies of transferring whole amino acids into the 
water-membrane interface are also systematically lower in the C-terminal part of the 
molecules (the α-helix) compared to the N-terminal part, and therefore one would 
predict that it is the hydrophobic side of the C-terminal helix that binds to the 
micelles. We like to emphasize that this supports the view that these molecules have 
been evolutionarily optimized for membrane binding.  
I like to summarize our structural studies of peptides from the NPY family in the 
micelle-bound state as follows:  
i) all peptides that adopt the PP fold in solution do not display the association of the 
N- and C-terminal segments in the micelle-bound state. This hydrophobic contact is 
replaced by binding of the helix to the membrane.  
ii) the peptides are oriented such that the hydrophobic side of the amphiphatic helix 
constitutes the membrane-binding interface. Side-chains of hydrophobic residues 
penetrate into the membrane interior. A particular role is found for the Tyr residues, 
which always partition into the water-membrane interface and probably contribute to 
overall membrane-binding substantially. The N terminus is generally unstructured but 
associates with the micelle surface when it contains aromatic residues.  
iii) the C-terminal pentapeptide containing Arg33 and Arg35, for which a direct 
contact with the Y receptors has been postulated, becomes structurally better defined 
upon micelle binding. Peptides, for which large changes in pharmacology with respect 
to NPY are observed, often display a significantly different conformation in that 
region. 
iv) we find no indication that the peptides, which mostly exist in dimeric form in 
solution, still form aggregates in the micelle-bound state. 
 
NPY and PYY have very high sequence similarity. Moreover, their pharmacology 
is almost identical: Both peptides are ligands with nanomolar binding affinities at all 
receptor subtypes. Yet, the structure of the two peptides in solution is very different 
16: In NPY the N terminus is unstructured, whereas it is back-folded in PYY. We 
expect that peptides with very similar pharmacology at all receptor subtypes should 
also be conformationally similar, because the are likely to share a common binding 
mode. In the micelle-bound state the structural difference that exists between NPY 
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and PYY in solution is removed because the back-fold is disrupted, and the 
conformations of the two peptides in this environment become virtually 
indistinguishable. In addition, bPP, a peptide highly selective to the Y4 receptor 
subtype, which in solution shares much more similarity with PYY than NPY with 
PYY, differs significantly in the C-terminal pentapeptide in the micelle-bound state. 
A comparison of the conformations of PYY, NPY and PP in the two environments is 
depicted in Fig. 3. The differences in structure of NPY/PYY with PP are accompanied 
by differences in the mode by which these peptides bind to the micelles: In case of 
NPY and PYY no association of the N terminus with the micelle is observed, whereas 
binding of the N-terminal segment of PP (basically via partitioning of Tyr-7 into the 
interface) to the micelle is detected. To conclude, similarities and differences of 
pharmacology of NPY, PYY and PP are much better correlated in the micelle-bound 
state.  
 
 
Fig.3: Comparison of the structures ob pPYY (left), pNPY (middle) and bPP (right) in solution 
(top panel) and in the micelle-bound state (bottom panel). The C-terminal pentapeptide is color-
coded in red. Figure reproduced from Lerch et. al.16. 
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5.4 A Series of Events for Receptor Binding  
The experimental results described in the previous section indicate that hormones 
from the neuropeptide Y family are not directly recognized from solution, but rather 
from the membrane-bound state. Unfortunately, no structural data of the complex 
formed between the peptides and any of the Y receptor subtypes are presently 
available. Some mutagenesis data have been published for hNPY at the human Y1 
receptor. Walker et al. have postulated a prominent role for Asp residues for 
binding36. In particular, an Asp residue at the interface between the 6th TM domain 
and the third extracellular loop is conserved in all known Y receptor sequences. 
Moreover, interacting partners were proposed to reside in the N-terminal domain as 
well as in the first extracellular loop37. Beck-Sickinger et al. have conducted a full 
Ala scan of hNPY at the human Y1 receptor 38. Most significant reductions in affinity 
were observed for Arg33 and Arg35. Moreover, binding was almost completely 
abolished when the C-terminal amide was replaced with a free C terminus. From 
these results direct interactions involving hormone residues Arg33 and/or Arg35 and 
an Asp receptor residue (Asp289 in case of the hY1 receptor) have been postulated. 
Nevertheless, Dougherty has also proposed that π-cation interactions involving one of 
the Arg residues and aromatic receptor residues contribute to binding39. Even if the 
exact nature of the ligand-receptor complex is presently unknown, partitioning of the 
hormones into binding pockets located deeper in the membrane is unlikely 
considering the presence of a larger number of polar or charged residues in the 
hormones and the absence of corresponding polar residues in the membrane interior 
of the Y receptors. Hence, it is most likely that NPY is binding to the extracellular 
loops and/or to the N-terminal domain40. 
We are proposing the following series of events during binding of hormones from 
the NPY family to the Y receptors 13; 16 as described in Fig. 4: i) initially, association 
of the peptides with the membrane occurs. This event is driven by electrostatic 
attraction involving cationic residues of the peptides and the negative charges of the 
phospholipids. Such electrostatic interactions have also been observed in case of the 
membrane-active peptides, e.g. cell-penetrating or antimicrobial peptides, and were 
characterized in more detail using surface plasmon resonance (SPR)41 or calorimetric 
techniques. Once the peptides have approached the membrane-surface closely enough 
they reorient such that the side-chains of the hydrophobic residues penetrate into the 
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membrane interior. The peptides then diffuse laterally along the membrane surface 
towards the receptors, and there may also be an electrostatic component involved in 
the latter. It is important in that respect that the biophysics in such an environment are 
different from those encountered in bulk solution42: There is a steep gradient in charge 
density along the membrane normal. Depending on its exact location the dielectric 
constant may vary considerably, from about 78 in bulk solution to about 2 in the 
membrane center, and hence solvation of polar groups could be very different. A 
consequence of this is the often-observed partitioning-folding by which peptides that 
are unstructured in solution adopt a unique conformation when partitioning into the 
interface42. The lowered dielectric constant also results in an increase of the range for 
which electrostatic interactions are relevant due to the diminished Debye-Hückel 
screening. It is therefore reasonable to assume that electrostatics will be more 
important in an environment of reduced permittivity. Again, considering the steep 
gradient of charges along the membrane normal, the importance of the mentioned 
arguments depends very much on where the peptide is exactly located in the 
membrane (interface).  
 
Fig.4: Detailed mechanism of receptor binding including membrane association (1), lateral 
diffusion towards the receptor (2), dissociation from the membrane (3) possibly linked to 
(transient) binding to the N-terminal domain of the receptor (4) followed by diffusion into the 
binding pocket (5). 
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Another aspect of receptor binding is concerned with how these peptides can 
possibly diffuse into the binding pocket from the membrane-associated state. It is 
unlikely that they can directly enter the binding site, because the receptor-surrounding 
lipids and the loop regions are separated in space and most likely do not mutually 
penetrate. Moreover, at least in the case of rhodopsin the scaffold built by the 7 TM 
bundle is fairly rigid1, and any pathway that requires the scaffold to re-organize in 
order to allow entry of the ligands is unlikely. It is therefore conceivable that the 
hormones must come off the membrane in order to diffuse into the binding pockets. In 
order to be able to do so, the affinity for binding to the membrane should not be too 
high. We have determined affinities of NPY, PYY and PP to neutral and negatively 
charged phospholipids surfaces using surface-plasmon resonance (SPR, BiaCore)14. 
The measured association constants to zwitterionic phospholipids were in the range 
between 4.6•104 for PP and 6.8•104 for NPY, and hence the peptides will be in 
dynamic equilibrium between the membrane-bound form and a dissociated state, 
which, however, remains close to the membrane surface. These values are 
significantly lower than those observed for membrane-active peptides such as 
melittin.  
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5.5 Investigating the Structural Transition between Bulk Solution 
and the Membrane Environment 
 
Since we have emphasized the importance of the membrane-bound state for 
receptor recognition it is of much interest to know whether the peptides, once they 
come off the membrane, immediately adopt the conformation observed in bulk 
solution, or whether the conformation of the membrane-bound species is retained to 
some extent. We have recently realized that the conformation of PYY in methanol 
almost perfectly superimposes with the structure of the micelle-bound state. Fig. 5 
displays a comparison of the structures of PYY in methanol and in its DPC-micelle 
bound state. We have recently made extensive use of the heteronuclear NOE to 
characterize backbone dynamics and to quantify the extent of back-folding. Both, 
structural data and backbone dynamics indicate that water-methanol mixtures may be 
very useful to simulate the transition occurring in the solvent environment when the 
peptides diffuse from the aqueous phase to the water-membrane interface. We 
therefore recorded spectra of a variant of PYY, Y7-PYY, in various water-methanol 
mixtures. As a result we noticed a smooth transition between the two forms, e.g. the 
state in solution and in the micelle-bound form. Moreover, we have seen that the 
population of the non back-folded form is still high, even when the water content is as 
high as 60%. From these data we conclude that the conformation of the membrane-
bound species is retained as long as the peptides don’t diffuse back into bulk solution 
but remain in vicinity of the interface where solvent properties, in particular the 
dielectric constant, have not been changed too dramatically. We believe that the 
binding constants for the membrane are sufficiently high, so that re-binding occurs 
quickly preventing the peptides from diffusing back into bulk solution.  
Following the arguments presented above we conclude that the conformation of 
the membrane-bound hormone is important, even when the peptides need to detach 
from the membrane in order to diffuse into the binding pocket. 
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Fig.5: Values of the 15N{1H}-NOE of pPYY in various water-methanol mixtures. The structures 
of pPYY in methanol and in the micelle-bound state are depicted as small insets in blue and red, 
respectively. 
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5.6 Removal of the Back-fold When Diffusing towards the Membrane 
Occurs Cooperatively 
In the previous section the structural transition occurring in PYY when it diffuses 
from bulk solution into the water-membrane interface was described and data were 
presented to demonstrate that water-methanol mixtures are useful to simulate that 
event. One remaining interesting question is whether unfolding occurs in a non-
concerted manner like unzipping, e.g. by removing individual contacts of proline 
residues with the C-terminal helix from one end onwards, or whether all these 
contacts are disrupted simultaneously. Replacement of Pro residues at positions 2, 5 
and 8 has resulted in removal of the PP fold, and hence it is likely that each of these 
residues contributes to the back-fold. However, each of these interactions on its own 
is too weak to stabilize the PP fold. If this is the case then only cooperative folding 
can result in a stable structure, because the latter would require all contacts to be 
formed simultaneously.  
Fig. 6 displays the chemical shifts changes of selected amide protons, and the data 
have been grouped into residues being part of the interface formed by the PP-fold, and 
those residing on the side of the helix that is opposite to the interface. Clearly, 
chemical shifts of amide protons located at the interface display a sigmoidal shape, 
and the point of inflection occurs at about 40% methanol. Given that the shapes of the 
curves from all amide protons located at the interface are similar, and considering the 
fact that the point of inflection is roughly the same in all cases, these data clearly 
confirm the view that formation of the PP fold is cooperative. Amide protons pointing 
to the opposite side will only experience a change in solvent properties. In this case, 
increasing methanol concentrations leads to a stabilization of the internal hydrogen 
bonds resulting in low-field shifts of these protons. 
Moreover, we have noticed that changes in backbone dynamics do not seem to be 
well correlated to changes in chemical shift in these solvent mixtures (data not 
shown). While this is an issue of present investigations, it indicates that a smoother 
transition between a fully flexible N terminus and one that is tightly fixed by back-
folding, occurs. It is of particular interest that these experiments can be performed 
using the same molecule and hence do not require the preparation of a series of 
mutant peptides.  
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Moreover, in comparison to methods in which changes in fluorescence are 
observed, it does not require introducing aromatic residues into specific (non-native) 
positions, which themselves will influence membrane partitioning and, possibly also 
to some extent, folding. 
 
 
Fig.6: Chemical shifts of amide protons of selected residues of Tyr7-PYY in dependence of the 
methanol content in water-methanol mixtures depicted for residues part of the back-fold 
interface (top row) and for residues placed at other positions (bottom row). Side-chains of these 
residues have been drawn in the structures depicted on the left. 
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5.7 Weak Interactions between the Hormones and the N-terminal 
Domains Are Observed 
It was already known from mutagenesis experiments that residues of the N 
terminal domains of the Y receptors might be involved in binding40. All of the Y 
receptor subtypes contain such domains which comprise between 42 and 53 amino 
acids, and which are placed on the extracellular side. It is therefore conceivable that 
the hormones may actually in their initial encounter with the receptors, at least 
transiently, bind to these domains. Such an event may also help to shift the 
equilibrium between membrane-associated hormomes and those that have come off 
the membrane towards the latter. In that way, the N-terminal domains may help to 
transfer the peptides from the micelle-bound state into the binding pockets. We have 
synthesized or expressed the N-terminal domains from all Y receptor subtypes and 
tested binding of NPY, PYY and PP to them. In all cases we could detect such an 
interaction by chemical shift mapping. The changes in peak positions in the 15N,1H-
correlation experiment for all peptides when interacting with the human Y2 receptor 
are depicted in Fig. 7. Clearly, specific changes are observed for resonances of the 
hormones. In contrast, there are many more changes detected for the Y2 receptor 
fragment. Dynamics data indicate that the isolated Y2 N-terminal fragment is largely 
unfolded, and we believe that the changes in chemical shift observed for resonances 
of the Y2 fragment more likely indicate that it becomes at least partially structured 
upon interaction with the hormones. The profiles of a particular peptide, as 
demonstrated for bPP in Fig. 7, are also different at the various receptor subtypes. We 
are currently in the process of characterizing these interactions in much more detail, 
both structurally as well as with respect to binding affinities or residues involved in 
forming the contacts. 
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Fig.7: Results from chemical shift mapping of pNPY, pPYY and bPP at the N-terminal domain 
of the Y2 receptor (left) or for bPP at all Y receptor subtypes (right). 
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5.8 Outlook 
Structural biology of receptor-ligand interactions is still a field in which much 
more information is desperately needed. In particular, larger quantities of purified and 
successfully reconstituted receptors are required for structural studies, and much 
progress in that area is presently made 43; 44. Crystallization of membrane proteins for 
use in crystallography is still difficult but again the numbers of published structures is 
rapidly expanding. NMR methodology has witnessed a number of recent 
improvements such as TROSY techniques45 or the use of residual dipolar couplings46 
that have dramatically increased the maximum molecular weight at which structures 
of such molecules may still be elucidated. In addition, rapid progress is made in the 
solid-state NMR field47. It is therefore conceivable that structures of recombinantly 
expressed GPCRs will be solved in near future by one of these techniques, provided 
that enough (labeled) protein can be expressed.  
However, even when such structures (or even those of GPCR-ligand complexes) 
become available the pathway of binding may still not be easily deduced. We have 
previously proposed that all events during receptor recognition are important, and that 
highly effective ligands need to be optimized for all steps occurring during 
recognition13. I like to emphasize here that this does not imply that all ligands follow 
the same path, e.g. the small molecule drugs certainly do not contain all the 
functionality for such a pathway. Nevertheless, it is of much importance for our 
understanding of the basic biology behind receptor function how these naturally 
occurring systems operate. It has been known for some time that biological 
membranes are chemically inhomogeneous entities. Much attention has been recently 
paid to lipid rafts48, and it has been proposed that ligands binding to GPCRs may 
actually be influenced by the presence of the latter. Moreover, the morphology of the 
membrane may depend on the state of the cell. A pathway that includes membrane 
association may therefore be influenced by changes in membrane morphology, and 
the question whether hormones associate with the membrane prior to receptor binding 
could therefore have more implications than those that are immediately obvious. 
Clearly, there is still a need for clever cell-biological experiments to investigate this 
question from a different point of view in the future. 
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